學術研究成果/Publication
基本資料/Profiles
姓名/Name: 夏德椿 性別/Gender:
英文姓名/
English Name:
Te-Chun Hsia 英文縮寫/
Abbreviation:
任職單位/
Affiliation:
1.健康照護學院健康科技產業博士學位學程(教授) / The Ph.D Program for Health Science and Industry (Professor)
2.中國附醫內科部胸腔科(副主任) / Division of Pulmonary Medicine (Deputy Director)
Email: derrick.hsia@msa.hinet.net
研究專長/Fields of Specialty
1﹒ 肺癌
2﹒ 高壓氧
3﹒ 中醫輔助療法及營養補充
 
期刊論文/Journal Paper
(作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄)
SCI論文 陳偉峻(Wei-Chun chen)、鄭文建(Wen-Chien Cheng)*、陳傑龍(Chen Chieh-Lung)、廖偉志(Liao, Wei-Chih)、陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)、林季千(Chi-Chien Lin)*、夏德椿(Te-Chun Hsia),Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy,Cancer Medicine,2024 Apr,13(7):
SCI論文 林延淞(Yen-Sung Lin)、沈德群(Shen, Te-Chun)*、林橙莉(Cheng-Li Lin)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、徐武輝(Wu-Huei Hsu)、周德陽(Der-Yang Cho),Risk of sleep disorders in patients with pneumoconiosis: a retrospective cohort study,Journal of Epidemiology and Global Health,2024 Apr,2024():s44197-024-00225-5
SCI論文 (Pei-Shin Hu)、夏寧憶(Ning-Yi Hsia)、(Zhi-Hong Wang)、(Hung-Chih Chen)、夏德椿(Te-Chun Hsia)、林孟亮(Lin, Meng-Liang)、王韻琪(Wang, Yun-Chi)、張文馨*、包大靝(Da-Tian Bau)*、蔡佳紋(Chia-Wen Tsai)*,Contribution of Matrix Metalloproteinase-2 Genotypes to Taiwan Pterygium Risk,IN VIVO,2024 Mar,38(2):539-545
SCI論文 涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、林膺峻(Lin,Ying-Chun)、梁基安(Ji-An Liang)、李佳瑾、簡君儒(Chien, Chun-Ru)*,Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors,Canadian Respiratory Journal,2024 Mar,2024():8889536-8889536
SCI論文 吳秉錡(WU BING-QI)、劉得誼(LIU DE-YI)、沈德群(Shen, Te-Chun)*、賴昱汝(Lai, Yu-Ru)、余采岭(Yu, Cai-Ling)、徐祥立(HSU HSIANG-LI)、李修銘(LEE HSIU-MING)、廖偉志(Liao, Wei-Chih)、夏德椿(Te-Chun Hsia),Effects of Hyperbaric Oxygen Therapy on Long COVID: A Systematic Review,Life-Basel,2024 Mar,14(4):438
SCI論文 鄭文建(Wen-Chien Cheng)、(Chi-Chien Lin)*、廖偉志(Liao, Wei-Chih)、林裕超(Yu-Chao Lin)、陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)*,The diference between dacomitinib and afatinib in efectiveness and safety in frst-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study,BMC CANCER,2024 Feb,24(228):
SCI論文 (Chun-Kai Fu)、(Mei-Chin Mong)、(Huey-En Tzeng)、楊美都(Mei-Due Yang)、(Jaw-Chyun Chen)、夏德椿(Te-Chun Hsia)、夏寧憶(Ning-Yi Hsia)、蔡佳紋(Chia-Wen Tsai)、張文馨、(Chou-Pin Chen)*、包大?(Da-Tian Bau)*,The Significant Contribution of Interleukin-16 Genotypes, Smoking, Alcohol Drinking, and Helicobacter Pylori Infection to Gastric Cancer,IN VIVO,2024 Jan,38(1):90-97
SCI論文 (Li-Hsiou Chen)、李嘉翔(Chia-Hsiang Li)、(Shou-Cheng Wang)、(Kuo-Liang Chiu)、(Meng-Feng Wu)、楊家欣(Jai-Sing Yang)、蔡佳紋(Chia-Wen Tsai)、張文馨、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*,Association of Matrix Metalloproteinase-1 Promoter Polymorphisms With Asthma Risk,IN VIVO,2024 Jan,38(1):365-371
SCI論文 王英哲(WANG YING-TSO)、沈德群(Shen, Te-Chun)*、林橙莉(Cheng-Li Lin)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、徐武輝(Wu-Huei Hsu),Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort,Open Medicine,2023 Nov,18(1):20230852
SCI論文 (Tzu-Shun Lin)、(Wan-Nei Huang)、(Jiun-Long Yang)、彭淑芬(Shu-Fen Peng)、劉國慶(Liu, Kuo-Ching)、(Jaw-Chyun Chen)、夏德椿(Te-Chun Hsia)*、(An-Cheng Huang)*,Allyl isothiocyanate inhibits cell migration and invasion in human gastric cancer AGS cells via affecting PI3K/AKT and MAPK signaling pathway in vitro,ENVIRONMENTAL TOXICOLOGY,2023 Oct,38(10):2287-2297
SCI論文 陳傑龍(Chen Chieh-Lung)、王幸婷(SING TING, WANG)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、鄭文建(Wen-Chien Cheng)*、陳鴻仁(Hung-Jen Chen)*,A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma,BMC CANCER,2023 Sep,23():
SCI論文 (Yen-Hsien Lee)、(Shou-Cheng Wang)、李嘉翔(Chia-Hsiang Li)、(Li-Hsiou Chen)、沈德群(Shen, Te-Chun)、劉彥芳(Yen-Fang Liu)、王韻琪(Wang, Yun-Chi)、蔡佳紋(Chia-Wen Tsai)、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*、張文馨(Chang, Wen-Shin)*,The Contribution of DNA Ligase 4 Genetic Variations to Taiwanese Lung Cancer,ANTICANCER RESEARCH,2023 Aug,43(8):3447-3453
SCI論文 (Shang-Miao Chang)、(Ya-Chen Yang)、(Guan-Liang Chen)、(Li-Hsiou Chen)、沈德群(Shen, Te-Chun)、劉彥芳(Yen-Fang Liu)、王韻琪(Wang, Yun-Chi)、蔡佳紋(Chia-Wen Tsai)、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*、張文馨(Wen-Shin Chang)*,The Association of DNA Ligase 1 Rs20579 Polymorphism With Lung Cancer Risk Among Taiwanese,IN VIVO,2023 Jul,37(4):1504-1510
SCI論文 李佳瑾(Chia-Chin Li)、林膺峻(Lin,Ying-Chun)、梁基安(Ji-An Liang)、趙坤山(Kun-San Clifford Chao)、夏德椿(Te-Chun Hsia)、簡君儒(Chien, Chun-Ru)*,Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review,International Journal of Environmental Research and Public Health,2023 Mar,20():4727
SCI論文 黄怡萍(Huang, Yi-Ping)、夏德椿(Te-Chun Hsia)、葉俊安(Chun-An Yeh)、(Yi-Shih Ma)、徐聖曜(Sheng-Yao Hsu)、劉益忠(YiChung Liu)、呂平江(Ping-Chiang Lyu)、賴光啟(Kuang-Chi Lai)、彭淑芬(Shu-Fen Peng)、連金城(Lien, Jin-Cherng)*、謝文聰(Wen-Tsong Hsieh)*,PW06 triggered Fas-FADD to induce apoptotic cell death in human pancreatic carcinoma MIA PaCa-2 cells through the activation of the caspases-mediated pathway,Oxidative Medicine and Cellular Longevity,2023 Feb,2023(2023):3479688
SCI論文 (Kuo-Liang Chiu)、張文馨(Wen-Shin Chang)、蔡佳紋(Chia-Wen Tsai)、(Mei-Chin Mong)、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*,Novel genetic variants in long non-coding RNA MEG3 are associated with the risk of asthma,PeerJ,2023 Feb,11():e14760
SCI論文 李柏翰(Po Han, Li)、(Cheng-Hsi Liao)、黃文欽(Huang,Wen-Chin)、張文馨(Wen-Shin Chang)、吳錫金(Hsi-Chin Wu)、(Shih-Wei Hsu)、(Kai-Yuan Chen)、(Zhi-Hong Wang)、夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau)*、蔡佳紋(Chia-Wen Tsai)*,Association of Matrix Metalloproteinase-2 Genotypes With Prostate Cancer Risk,ANTICANCER RESEARCH,2023 Jan,43(1):343-349
SCI論文 (Cheng-Hsi Liao)、張文馨(Wen-Shin Chang)、許瑋麟(Wei-Lin Hsu)、(Pei-Shin Hu)、吳錫金(Hsi-Chin Wu)、(Shih-Wei Hsu)、(Bo-Ren Wang)、(Te-Cheng Yueh)、陳肇烜(Chao-Hsuan Chen)、夏德椿(Te-Chun Hsia)、黃文欽(Huang,Wen-Chin)*、包大靝(Da-Tian Bau)*、蔡佳紋(Chia-Wen Tsai)*,Association of Matrix Metalloproteinase-7 Genotypes With Prostate Cancer Risk,ANTICANCER RESEARCH,2023 Jan,43(1):381-387
SCI論文 鄭文建(Wen-Chien Cheng)、沈宜成(Yi-Cheng Shen)、陳傑龍(Chen Chieh-Lung)、廖偉志(Wei-Chih Liao)、陳鴻仁(Hung-Jen Chen)、夏德椿(Te-Chun Hsia)、陳家弘(Chia-Hung Chen)*、涂智彥(Chih-Yen Tu)*,The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or 
Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer,Diagnostics,2023 Jan,13(1):129
SCI論文 鄭文建(Wen-Chien Cheng)、沈宜成(Yi-Cheng Shen)、陳傑龍(Chen Chieh-Lung)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)*,Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study,Cancers,2023 Jan,15(3):642
SCI論文 魏照軒(Chao-Hsuan Wei)、李嘉翔(Chia-Hsiang Li)、沈德群(Shen, Te-Chun)*、洪羽彤(Hung, Yu-Tung)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、徐武輝(Wu-Huei Hsu)、許重義(Chung Y. Hsu),Risk of Chronic Kidney Disease in Pneumoconiosis: Results from a Retrospective Cohort Study (2008–2019),Biomedicines,2023 Jan,11(1):150
Other論文 陳昫元(CHEN HSU-YUAN)、沈宜成(Yi-Cheng Shen)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)、林裕超(Yu-Chao Lin)*、夏德椿(Te-Chun Hsia)*,Real-World Experience with Immunotherapy for Lung Cancer in a Tertiary Hospital in Central Taiwan,胸腔醫學,2023 Jan,38(3):177-186
SCI論文 (Yi-Shih Ma)、彭淑芬(Shu-Fen Peng)、吳世銓(Rick Sai-Chuen Wu)、(Fu-Shin Chueh)、(Wen-Wen Huang)、(Po-Yuan Chen)、郭昭麟(Kuo, Chao-Lin)、(AN?CHENG HUANG)、廖慶龍(Liao, Ching-Lung)*、夏德椿(Te-Chun Hsia)*,Bisdemethoxycurcumin suppresses human osteosarcoma U‑2 OS cell migration and invasion via affecting the PI3K/Akt/NF‑κB, PI3K/Akt/GSK3β and MAPK signaling pathways in vitro,ONCOLOGY REPORTS,2022 Dec,48(6):3892-3901
SCI論文 施亮均(Liang-Chun Shih)、蔡佳紋(Chia-Wen Tsai)、(Tzu-Chieh Lin)、王韻琪(Wang, Yun-Chi)、(Jie-Long He)、(Che-Lun Hsu)、夏德椿(Te-Chun Hsia)、蔡輔仁(Fuu-Jen Tsai)、楊家欣(Jai-Sing Yang)、徐媛曼(Yuan-Man Hsu)、包大靝(Da-Tian Bau)*、張文馨(Wen-Shin Chang)*,Association of EZH2 Genotypes With Oral Cancer Risk,IN VIVO,2022 Nov,36(6):2669-2677
SCI論文 潘師涵(SHIH HAN, PAN)、(Wei-Ching Chien)、(Jie-Long He)、施亮均(Liang-Chun Shih)、(Che-Lun Hsu)、夏德椿(Te-Chun Hsia)、王韻琪(Wang, Yun-Chi)、(Hao-Yuan Tsao)、蔡佳紋(Chia-Wen Tsai)、包大靝(Da-Tian Bau)*、張文馨(Wen-Shin Chang)*,The Contribution of Flap Endonuclease 1 Genotypes to Oral Cancer Risk,ANTICANCER RESEARCH,2022 Sep,42(9):4329-4335
SCI論文 (Shou-Cheng Wang)、蔡佳紋(Chia-Wen Tsai)、張文馨(Wen-Shin Chang)、夏寧憶(Ning-Yi Hsia)、(Mei-Chin Mong)、王韻琪(Wang, Yun-Chi)、夏德椿(Te-Chun Hsia)*、(Jian Gu)*、包大靝(Da-Tian Bau)*,Genetic variants in miR‑145 gene are associated with the risk of asthma in Taiwan,Scientific Reports,2022 Sep,12(1):15155
SCI論文 呂孔文(Kung-Wen Lu)、呂岱融(LU, TAI-JUNG)、(Fu-Shin Chueh)、賴光啟(Lai Kuang-Chi)、夏德椿(Te-Chun Hsia)、彭淑芬(Shu-Fen Peng)、程景章(CHENG,CHING-CHANG)、(Yu-Cheng Chou)*、許斐婷(Hsu, Fei-Ting)*,Allyl Isothiocyanate (AITC) Induces Apoptotic Cell Death In Vitro and Exhibits Anti-Tumor Activity in a Human Glioblastoma GBM8401/luc2 Model,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2022 Sep,23(18):10411
SCI論文 施亮均(Liang-Chun Shih)、(Jie-Long He)、張文馨(Wen-Shin Chang)、(Che-Lun Hsu)、夏德椿(Te-Chun Hsia)、王韻琪(Wang, Yun-Chi)、楊家欣(Jai-Sing Yang)、(Mei-Chin Mong)、蔡佳紋(Chia-Wen Tsai)*、包大靝(Da-Tian Bau)*,The Contribution of PDCD6 Polymorphisms to Oral Cancer Risk,Cancer Genomics & Proteomics,2022 Jul,19(4):456-463
SCI論文 (Pei-Shin Hu)、夏寧憶(Ning-Yi Hsia)、(Wei-Ching Chien)、(Mei-Chin Mong)、夏德椿(Te-Chun Hsia)、(Heng-Ming Chang)、王韻琪(Wang, Yun-Chi)、張文馨(Wen-Shin Chang)、包大靝(Da-Tian Bau)*、蔡佳紋(Chia-Wen Tsai)*,Protective Effects of Gamma-mangostin on Hydrogen Peroxideinduced Cytotoxicity in Human Retinal Pigment Epithelial Cells,IN VIVO,2022 Jul,36(4):1676-1683
SCI論文 (Meng-Feng Wu)、(Li-Hsiou Chen)、夏寧憶(Ning-Yi Hsia)、沈宜成(Yi-Cheng Shen)、沈德群(Shen, Te-Chun)、(Zhi-Hong Wang)、(Ya-Chen Yang)、王韻琪(Wang, Yun-Chi)、張文馨(Wen-Shin Chang)、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*、蔡佳紋(Chia-Wen Tsai)*,Significant Contribution of Interleukin-18 Genotypes to Lung Cancer Risk in Taiwanese,ANTICANCER RESEARCH,2022 Jul,42(7):3381-3387
SCI論文 (Shang-Gin Wu)、(Chi-Lu Chiang)、(Chin-Chou Wang)、(Jen-Yu Hung)、夏德椿(Te-Chun Hsia)、(Chih-Hsi Kuo)、(Jin-Yuan Shih)*,Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan,Journal of Cancer,2022 Jul,13(9):2922-2932
SCI論文 涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、夏德椿(Te-Chun Hsia)、方信元(Hsin-Yuan Fang)、李佳瑾、簡君儒(Chien, Chun-Ru)*,Adjuvant Concurrent Chemoradiotherapy Versus Adjuvant Chemotherapy Only in Locally Advanced Non-small-cell Lung Cancer With Involved Microscopic Resection Margin: A Population-based Cohort Study,ANTICANCER RESEARCH,2022 Jun,42(6):3195-3201
SCI論文 (Chiung-Ju Chen)、(Hung-Sheng Shang)、(Yuan-Li Huang)、田霓(Ni Tien)、(Yung-Liang Chen)、(Sheng-Yao Hsu)、吳世銓(Rick Sai-Chuen Wu)、(Chien-Lun Tang)、連金城(Lien, Jin-Cherng)、(Mei-Hui Lee)、呂旭(Hsu-Feng Lu)*、夏德椿(Te-Chun Hsia)*,Bisdemethoxycurcumin suppresses human brain glioblastoma multiforme GBM 8401 cell migration and invasion via affecting NF-κB and MMP-2 and MMP-9 signaling pathway in vitro,ENVIRONMENTAL TOXICOLOGY,2022 Jun,():1-10
SCI論文 陳傑龍(Chen Chieh-Lung)、王幸婷(SING TING, WANG)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、夏德椿(Te-Chun Hsia)*、鄭文建(Wen-Chien Cheng)*,When to Add Anti-Angiogenesis Drugs to EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Patients: A Real-World Study from Taiwan,BMC CANCER,2022 May,22():571
SCI論文 (Che-Jui Yang)、(Meng-Hsuan Wu)、(Jai-Jen Tsai)、許斐婷(Hsu, Fei-Ting)、夏德椿(Te-Chun Hsia)、劉國慶(Liu, Kuo-Ching)、郭于誠(Yu-Cheng Kuo)*,Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib,ANTICANCER RESEARCH,2022 May,42(5):2495-2505
SCI論文 廖偉志(Wei-Chih Liao)、林橙莉(Cheng-Li Lin)、沈德群(Shen, Te-Chun)*、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、徐武輝(Wu-Huei Hsu),Risk of Pleural Empyema in Adult Patients With Asthma: A Nationwide Retrospective Cohort Study,Frontiers in Medicine,2022 Apr,9():851573
SCI論文 (Sanjay Popat)*、夏德椿(Te-Chun Hsia)、(Jen-Yu Hung)、(Hyun Ae Jung)、(Jin-Yuan Shih)、(Cheol Kyu Park)、(Seung Hyeun Lee)、(Tatsuro Okamoto)、(Hee Kyung Ahn)、(Yong Chul Lee)、(Yuki Sato)、(Sung Sook Lee)、(Celine Mascaux)、(Hasan Daoud)、(Angela Marten)、(Satoru Miura),Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG),ONCOLOGIST,2022 Apr,27(4):255-265
SCI論文 李嘉翔(Chia-Hsiang Li)、(Ya-Chen Yang)、夏德椿(Te-Chun Hsia)、沈德群(Shen, Te-Chun)、沈宜成(Yi-Cheng Shen)、張文馨(Wen-Shin Chang)、王韻琪(Wang, Yun-Chi)、蔡佳紋(Chia-Wen Tsai)、包大靝(Da-Tian Bau)*,Association of Interleukin-8 Promoter Genotypes With Taiwan Lung Cancer Risk,ANTICANCER RESEARCH,2022 Mar,42(3):1229-1236
SCI論文 鄭文建(Wen-Chien Cheng)、沈宜成(Yi-Cheng Shen)、簡君儒(Chien, Chun-Ru)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)*,The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan,Thoracic Cancer,2022 Mar,2022():
SCI論文 李嘉菱(Chia-Ling Li)、夏德椿(Te-Chun Hsia)*、楊仕哲(Su-Tso Yang)*、趙坤山(Kun-San Clifford Chao)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、李嘉翔(Chia-Hsiang Li),Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial,INTEGRATIVE CANCER THERAPIES,2022 Mar,21():1-17
SCI論文 (Shun Lu)*、(Qiming Wang)、(Guojun Zhang)、(Xiaorong Dong)、(Cheng-Ta Yang)、(Yong Song)、(Gee-Chen Chang)、(You Lu)、(Hongming Pan)、(Chao-Hua Chiu)、夏德椿(Te-Chun Hsia)、(Yang, James Chih-Hsin),Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790Mþ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial,Journal of Thoracic Oncology,2022 Mar,17(3):411-422
SCI論文 夏德椿(Te-Chun Hsia)、彭淑芬(Shu-Fen Peng)、(Fu-Shin Chueh)、呂孔文(Kung-Wen Lu)、(Jiun-Long Yang)、(An-Cheng Huang)、許斐婷(Hsu, Fei-Ting)*、吳世銓(Rick Sai-Chuen Wu)*,Bisdemethoxycurcumin Induces Cell Apoptosis and Inhibits Human Brain Glioblastoma GBM 8401/Luc2 Cell Xenograft Tumor in Subcutaneous Nude Mice In Vivo,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2022 Jan,23(1):538
SCI論文 廖偉志(Wei-Chih Liao)、(Chien-Wen Huang)、夏德椿(Te-Chun Hsia)、沈宜成(Yi-Cheng Shen)、張文馨(Wen-Shin Chang)、蔡佳紋(Chia-Wen Tsai)、王韻琪(Wang, Yun-Chi)、殷湄晶(Mei-chin Yin)*、包大靝(Da-Tian Bau)*,Association of TIMP-2 Rs8179090 Genotypes With Lung Cancer Risk in Taiwan,ANTICANCER RESEARCH,2021 Nov,41(11):5425-5430
SCI論文 廖慶龍(Liao, Ching-Lung)、馬易世(Yi-Shih Ma)、夏德椿(Te-Chun Hsia)、周育誠(Yu-Cheng Chou)、連金城(Lien, Jin-Cherng)、彭淑芬(Shu-Fen Peng)、郭昭麟(Kuo, Chao-Lin)*、許斐婷(Hsu, Fei-Ting)*,Tetrandrine Suppresses Human Brain Glioblastoma GBM 8401/luc2 Cell-Xenografted Subcutaneous Tumors in Nude Mice In Vivo,MOLECULES,2021 Nov,26(23):7105
SCI論文 黄怡萍(Huang, Yi-Ping)、陳達人(Dar-Ren Chen)、林文仁(Lin, Wun-Ren)、林昱秈(Yu-Hsien Lin)、陳建宇(Jiann-Yeu Chen)、郭悅雄(Yueh-Hsiung Kuo)、鍾景光(Jing-Gung Chung)、夏德椿(Te-Chun Hsia)*、謝文聰*,Ergosta-7,9(11),22-trien-3β-ol Attenuates Inflammatory Responses via Inhibiting MAPK/AP-1 Induced IL-6/JAK/STAT Pathways and Activating Nrf2/HO-1 Signaling in LPS-Stimulated Macrophage-Like Cells,Antioxidants,2021 Sep,10(9):1430
SCI論文 陳鴻儀(Hung-Yi Chen)、楊美都(Mei-Due Yang)、(Yu-Cheng Chou)、(Yi-Shih Ma)、彭淑芬(Shu-Fen Peng)、廖慶龍(Liao, Ching-Lung)、陳柏源(Chen, Po-Yuan)、夏德椿(Te-Chun Hsia)、連金城(Lien, Jin-Cherng)*、(Chung-Hung Chen)*,Ouabain Suppresses Cell Migration and Invasion in Human Gastric Cancer AGS Cells Through the Inhibition of MMP Signaling Pathways,ANTICANCER RESEARCH,2021 Sep,41(9):4365-4375
SCI論文 李嘉翔(Chia-Hsiang Li)、陳鴻仁(Hung-Jen Chen)、陳偉峻(Wei-Chun chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、徐武輝(Wu-Huei Hsu)、張志宗(Chiz-Tzung Chang)、黃秋錦(Chiu-Ching Huang)、包大靝(Da-Tian Bau)*、周哲毅(Che-Yi Chou)*,The risk of Tuberculosis infection in non-dialysis chronic kidney disease patients,Frontiers in Medicine,2021 Aug,0(0):
SCI論文 沈宜成(Yi-Cheng Shen)、夏德椿(Te-Chun Hsia)、許慶賢(HSU CHING-HSIEN)*,Software Optimization in Ultrasound Imaging Technique Using Improved Deep Belief Learning Network on the Internet of Medical Things Platform,WIRELESS PERSONAL COMMUNICATIONS,2021 Aug,():
SCI論文 陳家弘(Chia-Hung Chen)、王柏幃(Wang, Bo-Wei)、蕭宇君(Hsiao, Yu-Chun)、(Chun-Yi Wu)、鄭方茹(Cheng, Fang-Ju)、夏德椿(Te-Chun Hsia)、(Chih-Yi Chen)、(Yihua Wang)、(Zhang Weihua)、鄒瑞煌(Ruey-Hwang Chou)、湯智昕(Chih-Hsin Tang)、(Yun-Ju Chen)、魏雅鈴(Ya-Ling Wei)、(Jennifer L. Hsu)、涂智彥(Chih-Yen Tu)*、洪明奇(Mien-Chie Hung)*、黃偉謙(Huang, Wei-Chien)*,PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs,ONCOGENE,2021 Jul,0():
SCI論文 李嘉翔(Chia-Hsiang Li)、(Kuo-Liang Chiu)、夏德椿(Te-Chun Hsia)、沈德群(Shen, Te-Chun)、(Li-Hsiou Chen)、余建志、(Mei-Chin Mong)、(Wen-Shin Chang)、蔡佳紋(Chia-Wen Tsai)、包大靝(Da-Tian Bau)*,Significant Association of Cyclin D1 Promoter Genotypes With Asthma Susceptibility in Taiwan,IN VIVO,2021 Jul,35(4):2041-2046
SCI論文 (Jason C. Hsu)*、(Phung-Anh Nguyen)、(Yen-Tzu Chen)、(Szu-Chun Yang)、(Chien-Chung Lin)、(Yi-Hsin Yang)、(Yu-Chao Lin)、夏德椿(Te-Chun Hsia)、(Hsing-Chun Hsieh)、(Jia-Syuan Wu)、(Chi-Pei Chang)、(Yin-Hsun Feng)、(Peng-Chan Lin)、(Ping-Chih Hsu)、(Huey-En Tzeng)、(Shu-Chen Chien)、(Wei-Chiao Chang)、(Chih-Cheng Chang)、(Hsuan-Chia Yang)、(Chueh Ming Lee)、(Christine Y. Lu),The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study,Frontiers in Oncology,2021 Jul,11():671127
SCI論文 (Michael Boyer)*、(Mehmet A. N. Sendur)、(Delvys Rodriguez-Abreu)、(Keunchil Park)、(Irfan Cicin)、(Perran Fulden Yumuk)、(Francisco J Orlandi)、(Ticiana A Leal)、(Olivier Molinier)、(Nopadol Soparattanapaisarn)、夏德椿(Te-Chun Hsia)、(Reck, Martin),Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study,JOURNAL OF CLINICAL ONCOLOGY,2021 Jul,39(21):2327-2338
SCI論文 (Cheng-Nan Wu)、(Wen-Shin Chang)、施亮均(Liang-Chun Shih)、王韻琪(Wang, Yun-Chi)、(Hsu-Tung Lee)、余建志、(Zhi-Hong Wang)、(Mei-Chin Mong)、夏德椿(Te-Chun Hsia)、蔡佳紋(Chia-Wen Tsai)*、包大靝(Da-Tian Bau)*,Interaction of DNA Repair Gene XPC With Smoking and Betel Quid Chewing Behaviors of Oral Cancer,Cancer Genomics & Proteomics,2021 May,18(3 Suppl):441-449
SCI論文 (Yen-Hsiang Huang)、(Jen-Yu Hung)、(How-Wen Ko)、(Po-Lan Su)、(Chun-Liang Lai)、(Huang-Chih Chang)、夏德椿(Te-Chun Hsia)、(Sheng-Hao Lin)、(Kuan-Li Wu)、(Cheng-Ta Yang)、(Wu-Chou Su)、(Yi-Chun Chu)、(Chin-Chou Wang)、(Wei-Yu Liao)、(Yen-Ting Lin)、(Ching-Hsiung Lin)、(Meng-Chih Lin)、(Kuo-Hsuan Hsu)、(Jeng-Sen Tseng)、(Tsung-Ying Yang)、(Kun-Chieh Chen)、(Mei-Hsuan Lee)、(Sung-Liang Yu)、(Chao-Chi Ho)、(Gee-Chen Chang)*,The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study,Therapeutic Advances in Medical Oncology,2021 May,13():1758835921
SCI論文 沈宜成(Yi-Cheng Shen)、夏德椿(Te-Chun Hsia)、許慶賢(HSU CHING-HSIEN)*,Analysis of Electronic Health Records Based on Deep Learning with Natural Language Processing,ARABIAN JOURNAL FOR SCIENCE AND ENGINEERING,2021 Apr,():
SCI論文 (Yung-Hung Luo)、(Chao-Hua Chiu)、(Chih-Hsi Scott Kuo)、(Teh-Ying Chou)、(Yi-Chen Yeh)、(Han-Shui Hsu)、(Sang-Hue Yen)、(Yuan-Hung Wu)、(James Chih-Hsin Yang)、(Bin-Chi Liao)、夏德椿(Te-Chun Hsia)、(Yuh-Min Chen)*,Editorial Material: Lung Cancer in Republic of China,Journal of Thoracic Oncology,2021 Apr,16(4):519-527
SCI論文 (Guan-Liang Chen)、(Shou-Cheng Wang)、沈德群(Shen, Te-Chun)、(Wen-Shin Chang)、林靜茹(Chingju Lin)、夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau)*、蔡佳紋(Chia-Wen Tsai)*,Significant Association of Chitinase 3-like 1 Genotypes to Asthma Risk in Taiwan,IN VIVO,2021 Mar,35(2):799-803
SCI論文 鄭益慶(Cheng, Yi-Ching)、陳柏源(Chen, Po-Yuan)、魏宗德(Tzong-Der Way)、(CHING-LING CHENG)、黃怡萍(Yi-Ping Huang)、夏德椿(Te-Chun Hsia)、(YU-CHENG CHOU)*、彭淑芬(Shu-Fen Peng)*,Pre-Treatment of Pterostilbene Enhances H2O2-induced Cell Apoptosis Through Caspase-dependent Pathway in Human Keratinocyte Cells,IN VIVO,2021 Mar,35(2):833-843
SCI論文 鄭方茹(Cheng, Fang-Ju)、陳家弘(Chia-Hung Chen)、蔡文正(Tsai, Wen-Chen)、王柏幃(Wang, Bo-Wei)、游孟潔(Meng-Chieh Yu)、夏德椿(Te-Chun Hsia)、魏雅鈴(Ya-Ling Wei)、蕭宇君(Hsiao, Yu-Chun)、胡玳瑋、何建宜(Chien-Yi Ho)、(Tzong-Shiun Li)、(Chun-Yi Wu)、(Wen-Yu Chou)、余永倫(Yung-Luen Yu)、湯智昕(Chih-Hsin Tang)、(Chih-Yi Chen)、(Chuan-Mu Chen)、(Jennifer L. Hsu)、(Hsiao-Fan Chen)、陳曄(Chen,Yeh)、涂智彥(Chih-Yen Tu)*、洪明奇(Mien-Chie Hung)*、黃偉謙(Wei-Chien Huang)*,Cigarette Smoke-induced LKB1/AMPK Pathway Deficiency Reduces EGFR TKI Sensitivity in NSCLC,ONCOGENE,2021 Feb,40(6):1162-1175
SCI論文 (Chung-Lin Tsai)、蔡佳紋(Chia-Wen Tsai)、(Wen-Shin Chang)、(Jiunn-Cherng Lin)、夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau)*,Protective Effects of Baicalin on Arsenic Trioxide-induced Oxidative Damage and Apoptosis in Human Umbilical Vein Endothelial Cells,IN VIVO,2021 Jan,35(1):155-162
SCI論文 黃正吉(Cheng-Chi Huang)、莫之欣(Chih-Hsin Muo)、吳天方(Tain-Fung Wu)、紀東昀(Tung-Yun Chi)、沈德群(Shen, Te-Chun)*、夏德椿(Te-Chun Hsia)*、施純明(Chuen-Ming Shih),The Application of Non-invasive and Invasive Mechanical Ventilation in the First Episode of Acute Respiratory Failure,Internal and Emergency Medicine,2021 Jan,16(1):83-91
SCI論文 (Li-Hsiou Chen)、(Kuo-Liang Chiu)、夏德椿(Te-Chun Hsia)、(Yen-Hsien Lee)、沈德群(Shen, Te-Chun)、李嘉翔(Chia-Hsiang Li)、沈宜成(Yi-Cheng Shen)、(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)、包大靝(Da-Tian Bau)*,Significant Association of MMP2 Promoter Genotypes to Asthma Susceptibility in Taiwan,IN VIVO,2020 Dec,34(6):3181-3186
SCI論文 鄭文建(Wen-Chien Cheng)、吳秉儒(Bing-Ru Wu)、廖偉志(Wei-Chih Liao)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、徐武輝(Wu-Huei Hsu),When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment,International Journal of Chronic Obstructive Pulmonary Disease,2020 Dec,2020(15):3375-3384
SCI論文 陳鴻仁(Hung-Jen Chen)*、涂智彥(Chih-Yen Tu)、黃國揚(Kuo-Yang Huang)、簡君儒(Chun-Ru Chien)、夏德椿(Te-Chun Hsia),Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma,PLoS One,2020 Dec,15(12):e0240736
SCI論文 鄭文建(Wen-Chien Cheng)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)*,The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy,OncoTargets and Therapy,2020 Dec,2020(13):13425-13435
Other論文 夏德椿(Te-Chun Hsia)、(Kai-Cheng Chan)、黃岱琳(Huang, Tai-Lin)、秦宇廷(Chin, Yu-Ting)、林郁欣(Lin, Yu-Hsin)、黃宜茹(Huang, Yi-Ru)、沈德群(Shen, Te-Chun)、李嘉翔(Chia-Hsiang Li)、(Yu-Chen Hsiau)、王韻琪(Wang, Yun-Chi)、(Wen-Shin Chang)、蔡佳紋(Chia-Wen Tsai)、楊家欣(Jai-Sing Yang)、蔡輔仁(Fuu-Jen Tsai)、包大靝(Da-Tian Bau)*,傳統中醫藥於對抗新冠病毒之角色與重要性,中西整合醫學雜誌,2020 Dec,22(2):1-10
SCI論文 (James Chih-Hsin Yang)*、(Ross Camidge)、(Cheng-Ta Yang)、(Jianying Zhou)、(Renhua Guo)、(Chao-Hua Chiu)、(Gee-Chen Chang)、(Her-Shyong Shiah)、(Yuan Chen)、(Chin-Chou Wang)、(David Berz)、(Wu-Chou Su)、(Nong Yang)、(Ziping Wang)、(Jian Fang)、(Jianhua Chen)、(Petros Nikolinakos)、(You Lu)、(Hongming Pan)、(Ajit Maniam)、(Lyudmila Bazhenova)、(Keisuke Shirai)、(Mohammad Jahanzeb)、(Maurice Willis)、(Nehal Masood)、(Naveed Chowhan)、夏德椿(Te-Chun Hsia)、(Hong Jian)、(Shun Lu),Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial,Journal of Thoracic Oncology,2020 Dec,15(12):1907-1918
SCI論文 (Yuh-Min Chen)、(James Chih-Hsin Yang)、(Wu-Chou Su)、(Inn-Wen Chong)、夏德椿(Te-Chun Hsia)、(Meng-Chih Lin)、(Gee-Chen Chang)、(Chao-Hua Chiu)、(Chao-Chi Ho)、(Shang-Yin Wu)、(Jen-Yu Hung)、(Chin-Chou Wang)、(Tsung-Ying Yang)、(Chong-Jen Yu)*,Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2020 Dec,119(12):1817-1826
SCI論文 蕭楹澄(Yin-Chen Hsiao)、(Fu-Shin Chueh)、(Yi-Shih Ma)、連金城(Lien, Jin-Cherng)、夏德椿(Te-Chun Hsia)、黃雯雯(Huang, Wen-Wen)、(Yu-Cheng Chou)、陳柏源(Chen, Po-Yuan)、鍾景光(Jing-Gung Chung)、陳鴻儀(Hung-Yi Chen)*、劉國慶(Liu, Kuo-Ching)*,Genistein enhances the effects of L-asparaginase on inducing cell apoptosis in human leukemia cancer HL-60 cells,ENVIRONMENTAL TOXICOLOGY,2020 Nov,():
SCI論文 陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、方信元(Hsin-Yuan Fang)、陳家弘(Chia-Hung Chen)、陳碩爵(Shuo-Chueh Chen)、李嘉翔(Chia-Hsiang Li)、廖裕民(Yu-Min Liao)、謝清昀(Ching-Yun Hsieh)、連銘渝(Ming-Yu Lien)、梁基安(Ji-An Liang)、簡君儒(Chun-Ru Chien)*,Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy,ANTICANCER RESEARCH,2020 Oct,40(10):5895-5899
SCI論文 (Li-Hsiou Chen)、沈德群(Te-Chun Shen)、李嘉翔(Chia-Hsiang Li)、(Kuo-Liang Chiu)、(Yu-Chen Hsiau)、王韻琪(Wang, Yun-Chi)、龔志力(Gong Chi-Li)、(Zhi-Hong Wang)、(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)、夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau)*,The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk,Cancer Genomics & Proteomics,2020 Sep,17(5):571-577
SCI論文 林裕超(Yu-Chao Lin)、(CHING?CHIEH YANG)、(CHING?HSIUNG LIN)、夏德椿(Te-Chun Hsia)、(WEN?CHENG CHAO)、林季千(Chi-Chien Lin)*,Atractylodin ameliorates ovalbumin‑induced asthma in a mouse model and exerts immunomodulatory effects on Th2 immunity and dendritic cell function,Molecular Medicine Reports,2020 Sep,2020():
SCI論文 沈宜成(Yi-Cheng Shen)、廖光明(Kuang-Ming Liao)、林延淞(Yen-Sung Lin)、黃于真(Yu-Jhen Huang)、林橙莉(Cheng-Li Lin)、蔡佳紋(Chia-Wen, Tsai)、張文馨(Wen-Shin Chang)、沈德群(Shen, Te-Chun)*、包大靝(Da-Tian Bau)、夏德椿(Te-Chun Hsia),Depression is Associated with Subsequent Risk of Pleural Empyema,Therapeutic Advances in Respiratory Disease,2020 Sep,14():1-9
SCI論文 陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、陳碩爵(Shuo-Chueh Chen)、林宏霖(Hung-Lin Lin)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、杭良文(Liang-Wen Hang)、鄭文建(Wen-Chien Cheng)、李佳瑾、簡君儒(Chun-Ru Chien)*,Focal conformal fractionated radiotherapy vs. radiosurgery for lung cancer patients with limited brain metastases,Annals of Palliative Medicine,2020 Sep,9(5):2600-2605
SCI論文 (Shang-Gin Wu)、(Chi-Lu Chiang)、(Chien-Ying Liu)、(Chin-Chou Wang)、(Po-Lan Su)、夏德椿(Te-Chun Hsia)、(Jin-Yuan Shih)、(Gee-Chen Chang)*,An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan,Frontiers in Oncology,2020 Sep,10():1481
SCI論文 (Shin-Hwar Wu)、(Fu-Shin Chueh)、(Yu-Cheng Chou)、(Yi-Shih Ma)、彭淑芬(Shu-Fen Peng)、(Chin-Chung Lin)、(Ching-Lung Liao)、陳柏源(Chen, Po-Yuan)、夏德椿(Te-Chun Hsia)、連金城(Lien, Jin-Cherng)*,Tetrandrine inhibits cell migration and invasion in human nasopharyngeal carcinoma NPC-TW 039 cells through inhibiting MAPK and RhoA signaling pathways,JOURNAL OF FOOD BIOCHEMISTRY,2020 Jul,0(0):0-0
SCI論文 梁基安(Ji-An Liang)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、方信元(Hsin-Yuan Fang)、李佳瑾(Chia-Chin Li)、簡君儒(Chun-Ru Chien)*,Effectiveness of image-guided radiotherapy for locally advanced lung cancer patients treated with definitive concurrent chemoradiotherapy,Thoracic Cancer,2020 Jul,11(9):2639-2649
SCI論文 陳致宇(Chih-Yu Chen)、吳秉儒(Bing-Ru Wu)、陳家弘(Chia-Hung Chen)、鄭文建(Wen-Chien Cheng)、陳偉峻(Wei-Chun chen)、廖偉志(Wei-Chih Liao)*、陳志毅、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu),Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer,Journal of Clinical Medicine,2020 May,9():
SCI論文 林裕超(Yu-Chao Lin)、張文馨(Wen-Shin Chang)、沈德群(Te-Chun Shen)、李欣庭(Li, Hsin-Ting)、李嘉翔(Chia-Hsiang Li)、(Yu-Chen Hsiau)、王韻琪(Wang, Yun-Chi)、(Cheng-Nan Wu)、龔志力(Gong Chi-Li)、(Zhi-Hong Wang)、蔡佳紋(Chia-Wen, Tsai)*、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*,Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk,IN VIVO,2020 May,34(3):1047-1052
SCI論文 (Meng-Feng Wu)、王韻琪(Wang, Yun-Chi)、沈德群(Te-Chun Shen)、張文馨(Wen-Shin Chang)、李欣庭(Li, Hsin-Ting)、(Cheng-Hsi Liao)、龔志力(Gong Chi-Li)、(Zhi-Hong Wang)、蔡佳紋(Chia-Wen, Tsai)*、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*,Significant Association of Interleukin-16 Genetic Variations to Taiwanese Lung Cancer,IN VIVO,2020 May,34(3):1117-1123
SCI論文 (Chun-Liang Lai)、(Yu-Fen Wei)、夏德椿(Te-Chun Hsia)、(Gee-Chen Chang)、(Jiun-Ting Wu)、(Jung-Yueh Chen)、(Yuh-Min Chen)*,S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan,Asia-Pacific Journal of Clinical Oncology,2020 Apr,16(2):e88-e73
SCI論文 張文馨(Wen-Shin Chang)、沈德群(Te-Chun Shen)、(Jiuan-Miaw Liao)、蔡岳廷(Tsai, Yueh-Ting)、夏德椿(Te-Chun Hsia)、吳錫金(Hsi-Chin Wu)、蔡佳紋(Chia-Wen, Tsai)*、包大靝(Da-Tian Bau)*,Significant Contribution of DNA Repair Human 8-Oxoguanine DNA N-Glycosylase 1 Genotypes to Renal Cell Carcinoma,OncoTargets and Therapy,2020 Feb,13():1583-1591
SCI論文 程證羽(Cheng, Zheng-Yu)、(蕭詠庭)、黄怡萍(Huang, Yi-Ping)、彭淑芬(Shu-Fen Peng)、黃雯雯(Huang, Wen-Wen)、劉國慶、夏德椿(Te-Chun Hsia)、魏宗德(Tzong-Der Way)*、鍾景光(Jing-Gung Chung)*,Casticin Induces DNA Damage and Affects DNA Repair Associated Protein Expression in Human Lung Cancer A549 Cells(Running Title: Casticin Induces DNA Damage in Lung Cancer Cells),MOLECULES,2020 Jan,25(2):341
SCI論文 (Giorgio Scagliotti)*、(Denis Moro-Sibilot)、(Jens Kollmeier)、(Adolfo Favaretto)、(Eun Kyung Cho)、(Heidrun Grosch)、(Martin Kimmich)、(Nicolas Girard)、(Chun-Ming Tsai)、夏德椿(Te-Chun Hsia)、(Matteo Brighenti)、(Christian Schumann)、(Xuejing Aimee Wang)、(Sameera R. Wijayawardana)、(Aaron M. Gruver)、(Johan Wallin)、(Kambiz Mansouri)、(Volker Wacheck)、(Gee-Chen Chang),A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients,Journal of Thoracic Oncology,2020 Jan,15(1):80-90
SCI論文 (Vassiliki A. Papadimitrakopoulou)*、(Ji-Youn Han)、(Myung-Ju Ahn)、(Suresh S. Ramalingam)、(Angelo Delmonte)、夏德椿(Te-Chun Hsia)、(Janessa Laskin)、(Sang-We Kim)、(Yong He)、(Chun-Ming Tsai)、(Toyoaki Hida)、(Makoto Maemondo)、(Terufumi Kato)、(Suzanne Jenkins)、(Sabina Patel)、(Xiangning Huang)、(Gianluca Laus)、(Aleksandra Markovets)、(Kenneth S. Thress)、(Yi-Long Wu)、(Tony Mok),Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer,CANCER,2020 Jan,126(2):373-380
Other論文 夏德椿(Te-Chun Hsia)、吳芩紋(Wu, Cin-Wun)、李欣庭(Li, Hsin-Ting)、程綮萱(CHENG,CHI-HSUAN)、潘佳宜(PAN,CHIA-YI)、施子卿(TZU-CHING SHIH)、沈德群(Te-Chun Shen)、(Wen-Shin Chang)*、蔡佳紋(Chia-Wen, Tsai)*,The Role of Matrix Metalloproteinases 8 Genotypes in Gastric Cancer Risk in Taiwan,J Int Chin west Med,2019 Dec,21(2):1-12
SCI論文 陳冠良(Chen, Guang-Liang)、(SHOU-CHENG WANG)、黃偉謙(Wei-Chien Huang)、張文馨(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)、李欣庭(Li, Hsin-Ting)、沈德群(Te-Chun Shen)、夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau)*,The Association of MMP-11 Promoter Polymorphisms with Susceptibility to Lung Cancer in Taiwan,ANTICANCER RESEARCH,2019 Oct,39(10):5375-5380
SCI論文 (Guan-Liang Chen)、(Shou-Cheng Wang)、沈德群(Te-Chun Shen)、(Chia-Wen Tsai)、張文馨(Wen-Shin Chang)、李欣庭(Li, Hsin-Ting)、(Cheng-Nan Wu)、趙哲毅(Che-Yi Chao)、夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau)*,TheAssociation of Matrix Metalloproteinas‑2 Promoter Polymorphisms with Lung Cancer Susceptibility in Taiwan,CHINESE JOURNAL OF PHYSIOLOGY,2019 Oct,62(5):210-216
SCI論文 鄭文建(Wen-Chien Cheng)、廖偉志(Wei-Chih Liao)、吳秉儒(Bing-Ru Wu)、陳致宇(Chih-Yu Chen)、沈孟芳(Meng-Fang Shen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、徐武輝(Wu-Huei Hsu),Clinical predictors of asthmatics in identifying subgroup requiring long-term tiotropium add-on therapy: a real-world study,Journal of Thoracic Disease,2019 Sep,11(9):3785-3793
SCI論文 沈德群(Te-Chun Shen)、張文馨(Wen-Shin Chang)、夏德椿(Te-Chun Hsia)、李欣庭(Li, Hsin-Ting)、陳偉峻(Wei-Chun chen)、蔡佳紋(Chia-Wen, Tsai)*、包大靝(Da-Tian Bau)*,Contribution of programmed cell death 6 genetic variations, gender, and smoking status to lung cancer,OncoTargets and Therapy,2019 Aug,12():6237-6244
SCI論文 (Yu-Feng Wei)、(Wen-Tsung Huang)、(Tu-Chen Liu)、(Jiunn-Min Shieh)、(Chih-Feng Chian)、(Ming-Fang Wu)、(Chih-Cheng Chang)、(Ching-Hsiung Lin)、(Jen-Chung Ko)、(Jen-Chung Ko)、(Chia-Mo Lin)、夏德椿(Te-Chun Hsia)*,Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study,Journal of Cancer,2019 Jul,10(17):4151
SCI論文 夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、李佳瑾、簡君儒(Chun-Ru Chien)*,In response to Komiya T et al. ‘‘Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database”,RADIOTHERAPY AND ONCOLOGY,2019 Apr,135(2019):199-199
SCI論文 李嘉菱(Chia-Ling Li)、夏德椿(Te-Chun Hsia)、李嘉翔(Chia-Hsiang Li)、(Ko-Jung Chen)、(Yao-Hsu Yang)*、楊仕哲(Su-Tso Yang)*,Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study,INTEGRATIVE CANCER THERAPIES,2019 Mar,18(1):1-13
SCI論文 (Balazs Halmos)*、(Eng-Huat Tan)、(Ross A. Soo)、(Jacques Cadranel)、(Min Ki Lee)、(Pascal Foucher)、夏德椿(Te-Chun Hsia)、(Maximilian Hochmair)、(Frank Griesinger)、(Toyoaki Hida)、(Edward Kim)、(Barbara Melosky)、(Angela Marten)、(Enric Carcereny),Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo),LUNG CANCER,2019 Jan,127():103-111
SCI論文 涂智彥(Chih-Yen Tu)、王柏幃(Wang, Bo-Wei)、(Chuan-Mu Chen)、鄭方茹(Cheng, Fang-Ju)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、魏雅鈴(Ya-Ling Wei)、(Chih-Yi Chen)、謝宜珊(I-Shan Hsieh)、葉屹倫(Yeh, Yi-Lun)、王立昀(Wang, Li-Yun)、張為超(Wei-Chao Chang)*、黃偉謙(Wei-Chien Huang)*,Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression,American Journal of Cancer Research,2018 Dec,8(12):2575-2589
SCI論文 夏德椿(Te-Chun Hsia)、梁基安(Ji-An Liang)、李佳瑾、簡君儒(Chun-Ru Chien)*,Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR,Thoracic Cancer,2018 Nov,9(11):1398-1405
SCI論文 (Meng-Feng Wu)、(Yun-Chi Wang)、(Hsin-Ting Li)、陳偉峻(Wei-Chun chen)、(Cheng-Hsi Liao)、施子卿(Tzu-Ching Shih)、張文馨(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)*、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*,The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer,ANTICANCER RESEARCH,2018 Nov,38(11):6321-6327
SCI論文 楊仕哲(Su-Tso Yang)*、林邑蓉(Yi-Rong Lin)、吳美瑤(Mei-Yao Wu)、(Jen-Huai Chiang)、楊佩珊(Yang pei shan)、夏德椿(Te-Chun Hsia)、顏宏融(Hung-Rong Yen)*,Utilization of Chinese Medicine for Respiratory Discomforts by Patients with a Medical History of Tuberculosis in Taiwan,BMC Complementary and Alternative Medicine,2018 Nov,18(1):313
SCI論文 林裕超(Yu-Chao Lin)、(Su JH)、(Lin SC)、張嘉哲(Chia-Che Chang)、夏德椿(Te-Chun Hsia)、(Tung YT)*、林季千(Chi-Chien Lin)*,A Soft Coral-Derived Compound, 11-Dehydrosinulariolide, Induces G2/M Cell Cycle Arrest and Apoptosis in Small Cell Lung Cancer,Marine Drugs,2018 Nov,16(12):E479
SCI論文 王禎佑(Chen-Yu Wang)、黃紘森(Huang Hung-Sen)、(Yuan-Chih Su)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、黃升騰(Sheng-Teng Huang)*,Conventional treatment integrated with Chinese herbal medicine improves the survival rate of patients with advanced non-small cell lung cancer,COMPLEMENTARY THERAPIES IN MEDICINE,2018 Oct,40():29-36
SCI論文 (Guan-Liang Chen)、沈德群(Te-Chun Shen)、(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)、(Hsin-Ting Li)、(Chih-Liang Chuang)、(Yi-Liang Lai)、(Te-Cheng Yueh)、夏德椿(Te-Chun Hsia)*、(Shou-Cheng Wang)*、包大靝(Da-Tian Bau)*,The Contribution of MMP-7 Promoter Polymorphisms to Taiwan Lung Cancer Susceptibility,ANTICANCER RESEARCH,2018 Oct,38(10):5671-5677
SCI論文 (Chung-Yu Huang)、(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)、夏德椿(Te-Chun Hsia)、沈德群(Te-Chun Shen)*、包大靝(Da-Tian Bau)*、(Hao-Ai Shui)*,Interleukin-18 promoter genotype is associated with the risk of nasopharyngeal carcinoma in Taiwan,Cancer Management and Research,2018 Oct,2018(10):5199-5207
SCI論文 (Cheng-Hsi Liao)、(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)、(Pei-Shin Hu)、(Hsi-Chin Wu)、(Shih-Wei Hsu)、(Guan-Liang Chen)、(Te-Cheng Yueh)、沈德群(Te-Chun Shen)、夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau)*,Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer,IN VIVO,2018 Oct,32(5):1045-1050
SCI論文 廖偉志(Wei-Chih Liao)、鄭文建(Wen-Chien Cheng)、吳秉儒(Bing-Ru Wu)、陳偉峻(Wei-Chun chen)、陳致宇(Chih-Yu Chen)、陳家弘(Chia-Hung Chen)*、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia),Outcome and prognostic factors of patients treated in the intensive care unit for carbon monoxide poisoning,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2018 Oct,117():
SCI論文 蕭琬云(Wan-Yun Hsiao)、蔡佳紋(Chia-Wen, Tsai)、(Wen-Shin Chang)、(Shengyu Wang)、(Che-Yi Chao)、陳偉峻(Wei-Chun chen)、沈德群(Te-Chun Shen)*、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*,Association of Polymorphisms in DNA Repair Gene XRCC3 with Asthma in Taiwan,IN VIVO,2018 Sep,32(5):1039-1043
SCI論文 (Chung-Yu Huang)、(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)、夏德椿(Te-Chun Hsia)、沈德群(Te-Chun Shen)*、包大靝(Da-Tian Bau)*、(Hao-Ai Shui)*,The contribution of interleukin-8 genotypes and expression to nasopharyngeal cancer susceptibility in Taiwan,MEDICINE,2018 Sep,97(36):e12135
SCI論文 黄怡萍、江以文(Jiang Yi-Wen)、陳心于、蕭詠庭(Hsiao, Yung-Ting)、彭淑芬(Shu-Fen Peng)、(YU-CHENG CHOU)、(JIUN-LONG YANG)、夏德椿(Te-Chun Hsia)、鍾景光(Jing-Gung Chung)*,Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro,ANTICANCER RESEARCH,2018 Sep,38(9):5165-5176
SCI論文 沈德群(Te-Chun Shen)、陳家弘(Chen, Chia-Hung)、黃于真(Yu-Jhen Huang)、林橙莉、張庭彰(Ting-Chang Chang)、涂智彥(Tu, Chih-Yen)、夏德椿(Hsia, Te-Chun)、施純明(Shih, Chuen-Ming)*、徐武輝(Hsu, Wu-Huei)、宋鴻樟(Sung, Fung-Chang)*,Risk of Pleural Empyema in Patients with Schizophrenia: A Nationwide Propensity-matched Cohort Study in Taiwan,BMJ Open,2018 Jul,8(7):e021187
SCI論文 (CHENG-HSI LIAO)、吳錫金(Wu, Hsi-Chin)、(PEI-SHIN HU)、(SHIH-WEI HSU)、沈德群(Te-Chun Shen)、夏德椿(Hsia, Te-Chun)、(WEN-SHIN CHANG)*、蔡佳紋(Tsai, Chia-Wen)*、包大靝(Bau, Da-Tian)*,The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Prostate Cancer in Taiwanese Patients,ANTICANCER RESEARCH,2018 Jul,38(7):3907-3912
SCI論文 鄭文建(Wen-Chien Cheng)、吳秉儒(Bing-Ru Wu)、廖偉志(Wei-Chih Liao)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、徐武輝(Wu-Huei Hsu),Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: a real-life study,Journal of Thoracic Disease,2018 Jun,10(6):3661-3669
SCI論文 涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、方信元(Hsin-Yuan Fang)、梁基安(Ji-An Liang)、楊仕哲(Su-Tso Yang)、李佳瑾(Chia-Chin Li)、簡君儒(Chun-Ru Chien)*,A population-based study of the effectiveness of stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical stage I non-small cell lung cancer patients,Radiology and Oncology,2018 Jun,52(2):181-188
SCI論文 涂智彥(Tu, Chih-Yen)、鄭方茹(Cheng, Fang-Ju)*、(Chuan-Mu Chen)*、(Shu-Ling Wang)*、(Yu-Chun Hsiao)、陳家弘(Chen, Chia-Hung)、夏德椿(Hsia, Te-Chun)、何宥豪(He, Yu-Hao)、王柏幃、謝宜珊(Hsieh, I-Shan)、葉屹倫(Yeh, Yi-Lun)、(Chih-Hsin Tang)、(Yun-Ju Chen)、黃偉謙(Huang, Wei-Chien)*,Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs,Molecular Oncology,2018 May,12(5):705-723
SCI論文 沈德群(Te-Chun Shen)*、張佩穎(Chang, Pei-Ying)、林橙莉(Cheng-Li Lin)、魏長菁(Chang-Ching Wei)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chung J Sung)、高嘉鴻(Chia-Hung Kao),Reply from authors: RE: Risk of periodontal disease in patients with asthma: A nationwide population-based retrospective cohort study,JOURNAL OF PERIODONTOLOGY,2018 May,89(5):518-518
SCI論文 施亮均(Liang-Chun Shih)、(CHING-HAO LI)、孫國丁(Sun, Kuo-Ting)、陳亮宇(Liang-Yu Chen)、許哲綸(Che-Lun Hsu)、(YI-WEN HUNG)、(CHENG-NAN WU)、夏德椿(Hsia, Te-Chun)、沈德群(Te-Chun Shen)、張文馨(Chang, Wen-Shin)、施子卿(Shih, Tzu-Ching)*、蔡佳紋(Tsai, Chia-Wen)*、包大靝(Bau, Da-Tian)*,Association of Matrix Metalloproteinase-7 Genotypes to the Risk of Oral Cancer in Taiwan,ANTICANCER RESEARCH,2018 Apr,38(4):2087-2092
SCI論文 夏德椿(Te-Chun Hsia)、黄怡萍(Huang, Yi-Ping)、江以文(Jiang Yi-Wen)、陳心于、程證羽(Cheng, Zheng-Yu)、蕭詠庭(Hsiao, Yung-Ting)、陳政彥(CHENG-YEN CHEN)、彭淑芬(Shu-Fen Peng)、闕甫伈(Fu-Shin Chueh)、周育誠(YU-CHENG CHOU)、鍾景光(教授,研)*,Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro,ANTICANCER RESEARCH,2018 Apr,38(4):2137-2147
Other論文 涂智彥(Tu, Chih-Yen)、陳全木(Chuan-Mu Chen)、廖偉志(Liao, Wei-Chih)*、吳秉儒(Biing-Ru Wu)、陳致宇(Chih-Yu Chen)、陳偉峻(Chen, Wei-Chun)、夏德椿(Hsia, Te-Chun)、鄭文建(Wen-Chien Cheng)、陳家弘(Chen, Chia-Hung)*,Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations,Oncotarget,2018 Feb,():1-8
SCI論文 沈德群(Te-Chun Shen)、張文馨(Chang, Wen-Shin)、蔡佳紋(Tsai, Chia-Wen)、趙哲毅(Che-Yi Chao)、林怡廷(Yi-Ting Lin)、蕭捷倫(Chieh-Lun Hsiao)、許哲綸(Che-Lun Hsu)、陳偉峻(Chen, Wei-Chun)、夏德椿(Hsia, Te-Chun)*、包大靝(Bau, Da-Tian)*,The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk,ANTICANCER RESEARCH,2018 Jan,38(1):253-257
SCI論文 蕭詠庭(Hsiao, Yung-Ting)、范宗宸(Fan, Ming-Jen)、黃安正(An-Cheng Huang)、連金城(Lien, Jin-Cherng)、林楨智(Lin, Jen-Jyn)、陳兆群(Jaw-Chyun Chen)、夏德椿(Hsia, Te-Chun)、吳世銓(Wu, Rick Sai-Chuen)*、鍾景光(Chung, Jing-Gung)*,Deguelin Impairs Cell Adhesion, Migration and Invasion of Human Lung Cancer Cells through the NF-κB Signaling Pathways,AMERICAN JOURNAL OF CHINESE MEDICINE,2018 Jan,46(1):209-229
SCI論文 沈德群(Te-Chun Shen)、張佩穎(Pei-ying Chang)、林橙莉、魏長菁(Chang-Ching Wei)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*、高嘉鴻(Chia-Hung Kao)*,Impact of Periodontal Treatment on Hospitalization for Adverse Respiratory Events in Asthmatic Adults: A Propensity-matched Cohort Study,European Journal of Internal Medicine,2017 Dec,46():56-60
SCI論文 沈德群(Te-Chun Shen)、林圻域(Chi-Yu Lin)*、林橙莉、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*,Risk of Developing Pleural Empyema in Patients with Stroke: A Propensity-matched Cohort Study,Internal and Emergency Medicine,2017 Dec,12(8):1131-1138
SCI論文 (JEN-SHENG PEI)、周安國(Chou, An-Kuo)、(PEI-CHEN HSU)、蔡佳紋(Tsai, Chia-Wen)、張文馨(Chang, Wen-Shin)、(MENG-FENG WU)、(MING-HSIEN WU)、夏德椿(Hsia, Te-Chun)、(SHUN-PING CHENG)、包大靝(Bau, Da-Tian)*,Contribution of Matrix Metalloproteinase-7 Genotypes to the Risk of Non-solid Tumor, Childhood Leukemia,ANTICANCER RESEARCH,2017 Dec,37(12):6679-6684
SCI論文 彭逸豪(Peng, Yi-Hao)、陳政國(Cheng-Kuo Chen)、(Ching-Hua Su)、廖偉志(Liao, Wei-Chih)、(Chih-Hsin Muo)、夏德椿(Hsia, Te-Chun)、宋鴻樟(Sung, Fung-Chang)、賴志河(Lai, Chih-Ho)*、高嘉鴻(Kao, Chia-Hung)*,Increased risk of chronic obstructive pulmonary disease among patients with Helicobacter pylori infection: a population-based cohort study,Clinical Respiratory Journal,2017 Sep,11(5):558-565
SCI論文 陳家弘(Chen, Chia-Hung)、夏德椿(Hsia, Te-Chun)、葉名焮(Yeh, Ming-Hsin)、陳宗偉(Tsung-Wei Chen)、陳韻如(Chen, Yun-Ju)、(Chen, Jung-Tsu)、魏雅鈴(Ya-Ling Wei)、涂智彥(Tu, Chih-Yen)*、黃偉謙(Huang, Wei-Chien)*,MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701,Molecular Oncology,2017 Sep,11(9):1273-1281
Other論文 沈德群(Te-Chun Shen)、夏德椿(Hsia, Te-Chun)*,Case Report: Neuroinvasive Listeriosis,台灣急重症醫學雜誌,2017 Sep,2(3):171-174
SCI論文 沈德群(Te-Chun Shen)、張佩穎(Pei-ying Chang)、林橙莉、魏長菁(Chang-Ching Wei)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*、高嘉鴻(Chia-Hung Kao)*,Risk of Periodontal Disease in Patients with Asthma: A Nationwide Population-based Retrospective Cohort Study,JOURNAL OF PERIODONTOLOGY,2017 Aug,88(8):723-730
SCI論文 沈宜成(Yi-Cheng Shen)、曾冠欽(Guan-Chin Teseng)、涂智彥(Tu, Chih-Yen)、陳偉峻(Chen, Wei-Chun)、廖偉志(Liao, Wei-Chih)、陳韋成(Chen Wei-cheng)、李嘉翔(Li, Chia-Hsiang)、陳鴻仁(Chen, Hung-Jen)*、夏德椿(Hsia, Te-Chun)*,Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations,LUNG CANCER,2017 Aug,110():56-62
SCI論文 沈德群(Te-Chun Shen)、陳家弘(Chia-Hung Chen)、王怡寬(I-Kuan Wang)、林橙莉、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*,Risk of Empyema in Patients with End-Stage Renal Disease: A Nationwide Propensity-Matched Cohort Study,QJM-AN INTERNATIONAL JOURNAL OF MEDICINE,2017 Jul,110(7):425-430
SCI論文 沈德群(Te-Chun Shen)、夏德椿(Te-Chun Hsia)、趙哲毅、陳韋成(Chen Wei-cheng)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、林怡廷(YI-TING LIN)、蕭捷倫(CHIEH-LUN HSIAO)、張文馨(Chang, Wen-Shin)、蔡佳紋(Tsai, Chia-Wen)*、包大靝(Da-Tian Bau)*,The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer,ANTICANCER RESEARCH,2017 Jul,37(7):3563-3567
SCI論文 沈德群(Te-Chun Shen)、陳家弘(Chia-Hung Chen)、賴學洲(Hsueh-Chou Lai)、林橙莉、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*,Risk of Empyema in Patients with Chronic Liver Disease and Cirrhosis: A Nationwide, Population-based Cohort Study,LIVER INTERNATIONAL,2017 Jun,37(6):862-870-2016接受
SCI論文 沈德群(Te-Chun Shen)、蔡佳紋(Tsai, Chia-Wen)、張文馨(Chang, Wen-Shin)、(Shengyu Wang)、(Che-Yi Chao)、(Chieh-Lun Hsiao)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)*、包大靝(Da-Tian Bau)*,Association of Interleukin-12A rs568408 with Susceptibility to Asthma in Taiwan,Scientific Reports,2017 Jun,7(1):3199-3199
SCI論文 沈德群(Te-Chun Shen)、夏德椿(Te-Chun Hsia)、蕭捷倫(Chieh-Lun Hsiao)、林橙莉、楊稚怡(Chih-Yi Yang)、蘇啟成(Khay-Seng Soh)、劉良智(Liu, Liang-Chih)、張文馨(Wen-Shin Chang)、蔡佳紋(Tsai, Chia-Wen)、包大靝(Da-Tian Bau)*,Patients with Uterine Leiomyoma Exhibit a High Incidence but Low Mortality Rate for Breast Cancer,Oncotarget,2017 May,8(20):33014-33023
SCI論文 吳莘華(Shin-Hwar Wu)、包大靝(Da-Tian Bau)、蕭詠庭(Hsiao, Yung-Ting)、呂孔文(KUNG-WEN LU)、夏德椿(Te-Chun Hsia)、連金城(Lien Jin Cherng)、(Yang-Ching Ko)、徐武輝(Wu-Huei Hsu)、楊仕哲(Su-Tso Yang or YANG Shi-zhe)、黄怡萍(Huang, Yi-Ping)*、鍾景光(Jing-Gung Chung)*,Bufalin Induces Apoptosis In Vitro and has Antitumor Activity Against Human Lung Cancer Xenografts In Vivo,ENVIRONMENTAL TOXICOLOGY,2017 Apr,32(4):1305-1317
SCI論文 彭逸豪(Yi-Hao Peng)、陳冠妃(Kuan-Fei Chen)、廖偉志(Wei-Chih Liao)、夏德椿(Te-Chun Hsia)、陳宣如(Chen, Hsuan-Ju)、尹明謙(Ming-Chien Yin)、何文照(Wen-Chao Ho)*,Association of migraine with asthma risk: A retrospective population-based cohort study,Clinical Respiratory Journal,2017 Mar,():
SCI論文 蔡佳紋(Tsai, Chia-Wen)、楊美都(Mei-Due Yang)、夏德椿(Te-Chun Hsia)、(Wen-Shin Chang)、(Chin-Mu Hsu)、(Yi-Hsien Hsieh)、鍾景光(Jing-Gung Chung)*、包大靝(Da-Tian Bau)*,Dithiothreitol enhanced arsenic-trioxide-induced cell apoptosis in cultured oral cancer cells via mitochondrial dysfunction and endoplasmic reticulum stress,ENVIRONMENTAL TOXICOLOGY,2017 Jan,32(1):17-27
SCI論文 徐于絜(Yu-Chieh Hsu)、江若華(Jo-Hua Chiang)、(Chun-Shu Yu)、夏德椿(Te-Chun Hsia)、吳世銓(Rick Sai-Chuen Wu)、連金城(Lien Jin Cherng)、賴光啟(Kuang-Chi Lai)、游富順、鍾景光(Jing-Gung Chung)*,Antitumor effects of deguelin on H460 human lung cancer cells in vitro and in vivo: Roles of apoptotic cell death and H460 tumor xenografts model,ENVIRONMENTAL TOXICOLOGY,2017 Jan,32(1):84-98
SCI論文 彭逸豪(Yi-Hao Peng)、方心禹(Hsin-Yu Fang)、吳秉儒(Biing-Ru Wu)、高嘉鴻(Chia-Hung Kao)、陳宣如(Chen, Hsuan-Ju)、夏德椿(Te-Chun Hsia)、廖偉志(Wei-Chih Liao)*,Adult asthma is associated with an increased risk of herpes zoster: A population-based cohort study,JOURNAL OF ASTHMA,2017 Jan,54(3):250-257
SCI論文 陳家弘(Chia-Hung Chen)、吳秉儒(Biing-Ru Wu)、鄭文建(Wen-Chien Cheng)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、廖偉志(Wei-Chih Liao)、涂智彥(Chih-Yen Tu)*、徐武輝(Wu-Huei Hsu),Interventional pulmonology for patients with central airway obstruction: An 8-year institutional experience,MEDICINE,2017 Jan,():
SCI論文 黃安正(An-Cheng Huang)、楊美都(Mei-Due Yang)、蕭詠庭(Yung-Ting Hsiao)、林子舜(Tzu-Shun Lin)、馬易世(Yi-Shih Ma)、彭淑芬(Shu-Fen Peng)、夏德椿(Te-Chun Hsia)、鄭奕帝(Yih-Dih Cheng)、郭昭麟(Kuo Chao-Lin)*、鍾景光(Jing-Gung Chung)*,Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro,JOURNAL OF ETHNOPHARMACOLOGY,2016 Dec,194():1043-1050
SCI論文 夏德椿(Te-Chun Hsia)、余建志(Chien-Chih Yu)、蕭詠庭(Hsiao, Yung-Ting)、吳莘華(SHIN-HWAR WU)、包大靝(Da-Tian Bau)、呂旭峰(HSU-FENG LU)、黄怡萍(Huang, Yi-Ping)、林昭庚(Jaung-Geng Lin)、張淑貞(Shu-Jen Chang)*、鍾景光(Jing-Gung Chung)*,Cantharidin Impairs Cell Migration and Invasion of Human Lung Cancer NCI-H460 Cells via UPA and MAPK Signaling Pathways.,ANTICANCER RESEARCH,2016 Nov,36(11):5989-5997
SCI論文 沈德群(Te-Chun Shen)、陳宣如(Chen, Hsuan-Ju)、魏長菁(Chang-Ching Wei)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*、包大靝(Da-Tian Bau)*,Risk of asthma in patients with primary Sjögren's syndrome: a retrospective cohort study,BMC Pulmonary Medicine,2016 Nov,16(1):152-152
SCI論文 沈德群(Te-Chun Shen)、杭良文(Liang-Wen Hang)*、梁信杰(Shinn-Jye Liang)、黃建中(Chien-Chung Huang)、林橙莉、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*,Risk of Obstructive Sleep Apnoea in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Study,BMJ Open,2016 Nov,6(11):e013151-e013151
SCI論文 (Pierre Chabot)、夏德椿(Te-Chun Hsia)、(Jeong-Seon Ryu)、(Vera Gorbunova)、(Cristobal Belda-Iniesta)、(David Ball)、(Ebenezer Kio)、(Minesh Mehta)、(Katherine Papp)、(Qin Qin)、(Jane Qian)、(Kyle D. Holen)、(Vince Giranda)、(John H. Suh)*,Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study,JOURNAL OF NEURO-ONCOLOGY,2016 Sep,():
SCI論文 夏德椿(Te-Chun Hsia)、殷梅津(YIN, MEI-CHIN)*、(Mei-chin Mong),Advanced glycation end-products enhance lung cancer cell invasion and migration,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2016 Aug,17(-):1289
SCI論文 夏德椿(Te-Chun Hsia)、殷梅津(YIN, MEI-CHIN)*,Post-intake of s-Ethyl Cysteine and s-Methyl Cysteine Improved LPS-induced Acute Lung Injury in Mice,Nutrients,2016 Aug,8(-):507
SCI論文 蘇振賢(CHEN-HSIEN SU)、藍先元(Hsien-Yuan Lane)、蕭捷倫(CHIEH-LUN HSIAO)、劉良智(Liu, Liang-Chih)、紀宏學(HONG-XUE JI)、李欣庭(HSIN-TING LI)、顏秀婷(SHIOU-TING YEN)、蘇崇皓(CHUNG-HAO SU)、夏德椿(Te-Chun Hsia)、張文馨(WEN-SHIN CHANG)*、蔡佳紋(Tsai, Chia-Wen)*、包大靝(Da-Tian Bau)*,Matrix Metalloproteinase-1 Genetic Polymorphism in Breast Cancer in Taiwanese,ANTICANCER RESEARCH,2016 Jul,36(7):3341-3346
SCI論文 (Kuo-Hsuan Hsu)、(Jeng-Sen Tseng)、(Chih-Liang Wang)、(Tsung-Ying Yang)、(Chien-Hua Tseng)、(Hsuan-Yu Chen)、(Kun-Chieh Chen)、(Chi-Ren Tsai)、(Cheng-Ta Yang)、(Sung-Liang Yu)、(Kang-Yi Su)、(Chong-Jen Yu)、(Chao-Chi Ho)、夏德椿(Te-Chun Hsia)、(Ming-Fang Wu)、(Kuo-Liang Chiu)、(Chien-Ming Liu)、(Pan-Chyr Yang)、(Jeremy J.W. Chen)*、(Gee-Chen Chang)*,Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients,Oncotarget,2016 Jul,7(33):53299-53308
SCI論文 沈德群(Te-Chun Shen)、張佩穎(Pei-ying Chang)、林橙莉、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*、高嘉鴻(Chia-Hung Kao)*,Periodontal Treatment Reduces Risk of Adverse Respiratory Events in Patients with Chronic Obstructive Pulmonary Disease: A Propensity-Matched Cohort Study,MEDICINE,2016 May,95(20):e3735
Other論文 沈德群(Te-Chun Shen)、梁信杰(Shinn-Jye Liang)*、林橙莉、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu),Ankylosing Spondylitis and the Subsequent Risk of Sleep Disorders: A Retrospective Population-Based Cohort Study in Taiwan,內科學誌,2016 Apr,27(2):79-88
SCI論文 唐娜櫻(Nou-Ying Tang)、(Fu-Shin Chueh)、余建志(Chien-Chih Yu)、廖慶龍(Liao, Ching-Lung)、林楨智(Jen-Jyn Lin)、夏德椿(Te-Chun Hsia)、吳憬全(King-Chuen Wu)、劉馨中(Hsin-Chung Liu)、呂孔文(KUNG-WEN LU)、鍾景光(Jing-Gung Chung)*,Benzyl isothiocyanate alters the gene expression with cell cycle regulation and cell death in human brain glioblastoma GBM 8401 cells.,ONCOLOGY REPORTS,2016 Apr,35(4):2089-2096
SCI論文 沈德群(Te-Chun Shen)、林橙莉、魏長菁(Chang-Ching Wei)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*、高嘉鴻(Chia-Hung Kao)*,Bidirectional Association between Asthma and Irritable Bowel Syndrome: Two Population-Based Retrospective Cohort Studies,PLoS One,2016 Apr,11(4):e0153911
SCI論文 陳致宇(Chih-Yu Chen)、陳家弘(Chia-Hung Chen)、沈德群(Te-Chun Shen)、鄭文建(Wen-Chien Cheng)、許正男(Cheng-Nan Hsu)、廖春函(Chun-Han Liao)、陳志毅(Chih-Yi Chen)、夏德椿(Te-Chun Hsia)、廖偉志(Wei-Chih Liao)*、涂智彥(Chih-Yen Tu)*、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu),Lung Cancer Screening with Low-Dose Computed Tomography:Experiences from a Tertiary Hospital in Taiwan,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2016 Mar,115(3):163-170
SCI論文 彭逸豪(Yi-Hao Peng)、陳冠妃(Kuan-Fei Chen)、高嘉鴻(Chia-Hung Kao)、陳宣如(Chen, Hsuan-Ju)、夏德椿(Te-Chun Hsia)、陳家弘(Chia-Hung Chen)*、廖偉志(Wei-Chih Liao)*,Risk of migraine in pateints with asthma: A nationwide cohort study,MEDICINE,2016 Mar,95(9):e2911
SCI論文 沈德群(Te-Chun Shen)、吳秉儒(Biing-Ru Wu)、陳宣如(Chen, Hsuan-Ju)、林橙莉、魏長菁(Chang-Ching Wei)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*、高嘉鴻(Chia-Hung Kao)*,Risk of Chronic Obstructive Pulmonary Disease in Female Adults with Primary Sjögren's Syndrome: A Nationwide Population-Based Cohort Study,MEDICINE,2016 Mar,95(10):e3066
SCI論文 姚智偉(Chih-Wei Yao)、沈德群(Te-Chun Shen)*、盧炯睿(Chiung-Ray Lu)、王昱喬(Wang Yu Chiao)、林橙莉、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*,Asthma Is Associated with a Subsequent Risk of Peripheral Artery Disease: A Longitudinal Population-Based Study,MEDICINE,2016 Jan,95(3):e2546
SCI論文 陳家弘(Chia-Hung Chen)、鄭文建(Wen-Chien Cheng)、吳秉儒(Biing-Ru Wu)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、廖偉志(Wei-Chih Liao)*、涂智彥(Chih-Yen Tu)*、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、王國本(Ko-Pen Wang),Improved Diagnostic Yield of Bronchoscopy in Peripheral Pulmonary Lesions: Combination of Radial Probe EBUS and Rapid On-site Evaluation,Journal of Thoracic Disease,2015 Dec,7(S4):418-425
SCI論文 沈德群(Te-Chun Shen)、林橙莉、魏長菁(Chang-Ching Wei)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、鍾季容(Chi-Jung Chung)*、宋鴻樟(Fung-Chang Sung)*、高嘉鴻(Chia-Hung Kao)*,Previous History of Tuberculosis Is Associated with Rheumatoid Arthritis,INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE,2015 Nov,19(11):1401-1405
SCI論文 沈德群(Te-Chun Shen)、張佩穎(Pei-ying Chang)、林橙莉、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*、高嘉鴻(Chia-Hung Kao)*,Risk of Periodontal Diseases in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study,MEDICINE,2015 Nov,94(46):e2047
SCI論文 夏德椿(Te-Chun Hsia)、張文馨(Wen-Shin Chang)、(Shengyu Wang)、沈德群(Te-Chun Shen)、蕭琬云(Wan-Yun Hsiao)、劉金蓉(Chin-Jung Liu)、梁信杰(Shinn-Jye Liang)、陳偉峻(Wei-Chun chen)、涂智彥(Chih-Yen Tu)、(CHIA-WEN TSAI)、(CHIN-MU HSU)、包大靝(Da-Tian Bau)*,The Contribution of Interleukin-10 Promoter Genotypes to Susceptibility to Asthma in Adults,IN VIVO,2015 Nov,29(5):695-700
SCI論文 陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao)、吳秉儒(Biing-Ru Wu)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、鄭文建(Wen-Chien Cheng)*、涂智彥(Chih-Yen Tu)*、徐武輝(Wu-Huei Hsu),Endobronchial ultrasound changed the world of lung cancer patients: A 11-year institutional experience,PLoS One,2015 Nov,10(11):e0142336
SCI論文 夏德椿(Te-Chun Hsia)、林如華(JU-HWA, LIN)、徐素琴、唐娜櫻(Nou-Ying Tang)、(Hsu-Feng Lu)、(Shin-Hwar Wu)、林昭庚(Jaung-Geng Lin)*、鍾景光(Jing-Gung Chung)*,Cantharidin Induces DNA Damage and Inhibits DNA Repair-Associated Protein Levels in NCI-H460 Human Lung Cancer Cells,ENVIRONMENTAL TOXICOLOGY,2015 Sep,30(10):1135-1143
SCI論文 彭逸豪(Yi-Hao Peng)、廖偉志(Wei-Chih Liao)、(Ching-Hua Su)、陳宣如、夏德椿(Te-Chun Hsia)、朱家成(Chia-Chen Chu)、劉金蓉(Chin-Jung Liu)、高嘉鴻(Chia-Hung Kao)*,Association of inflammatory bowel disease with asthma risk: A nationwide cohort study.,ALLERGY AND ASTHMA PROCEEDINGS,2015 Sep,36(5):92-98
SCI論文 夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、方信元(Hsin-Yuan Fang)、梁基安(Ji-An Liang)、李佳瑾(Chia-Chin Li)、簡君儒(Chun-Ru Chien)*,Cost and effectiveness of image-guided radiotherapy for nonoperated localized lung cancer: a population-based propensity score-matched analysis,Journal of Thoracic Disease,2015 Sep,7(9):1643-1649
SCI論文 夏德椿(Te-Chun Hsia)、殷梅津(YIN, MEI-CHIN)*,S-Ethyl cysteine and s-methyl cysteine protect human bronchial epithelial cells against hydrogen peroxide induced injury,JOURNAL OF FOOD SCIENCE,2015 Sep,80(9):2094-2101
SCI論文 沈德群(Te-Chun Shen)、王怡寬(I-Kuan Wang)、魏長菁(Chang-Ching Wei)、林橙莉、蔡佳達(Chia-Ta Tsai)、夏德椿(Te-Chun Hsia)、宋鴻樟(Fung-Chang Sung)*、高嘉鴻(Chia-Hung Kao)*,The Risk of Septicemia in End Stage Renal Disease with and without Renal Transplantation: A Propensity-Matched Cohort Study,MEDICINE,2015 Aug,94(34):e1437
SCI論文 夏德椿(Te-Chun Hsia)、余建志(Chien-Chih Yu)、徐素琴(Shu-Chun Hsu)、唐娜櫻(Nou-Ying Tang)、呂旭峰(Hsu-Feng Lu)、游春淑(chun shu yu)、吳莘華(Shin-Hwar Wu)、林昭庚(Jaung-Geng Lin)*、鍾景光(Jing-Gung Chung)*,cDNA microarray analysis of the effect of cantharidin on DNA damage, cell cycle and apoptosis-associated gene expression in NCI-H460 human lung cancer cells in vitro,Molecular Medicine Reports,2015 Jul,12():1030-1042
SCI論文 陳鴻仁(Hung-Jen Chen)、張文馨(WEN-SHIN CHANG)、夏德椿(Te-Chun Hsia)、繆佳恩(CHIA-EN MIAO)、陳偉峻(Wei-Chun chen)、梁信杰(Shinn-Jye Liang)、陳安琪(An-Chyi Chen)、張建國(Jan-Gowth Chang)、蔡佳紋(CHIA-WEN TSAI)、許欽木(CHIN-MU HSU)、蔡長海(Chang-Hai Tsai)、包大靝(Da-Tian Bau)*,Contribution of Genotype of DNA Double-Strand Break Repair Gene XRCC3, Gender, and Smoking Behavior to Lung Cancer Risk in Taiwan,ANTICANCER RESEARCH,2015 Jul,35(7):3893-3900
SCI論文 沈德群(Te-Chun Shen)、林橙莉、魏長菁(Chang-Ching Wei)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)、高嘉鴻(Chia-Hung Kao)*,Risk of Obstructive Sleep Apnea in Adult Patients with Asthma: A Population-based Cohort Study in Taiwan,PLoS One,2015 Jun,10(6):e0128461
SCI論文 沈德群(Te-Chun Shen)、黃國揚(Kuo-Yang Huang)、趙志浩(Chih-Hao Chao)、王昱喬、莫之欣、魏長菁(Chang-Ching Wei)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)、高嘉鴻(Chia-Hung Kao)*,The Risk of Chronic Kidney Disease in Tuberculosis: A Population-based Cohort Study,QJM-AN INTERNATIONAL JOURNAL OF MEDICINE,2015 May,108(5):397-403
SCI論文 (Chiu CH)*、(Yang CT)、(Shih JY)、(Huang MS)、(Su WC)、(Lai RS)、(Wang CC)、(Hsiao SH)、(Lin YC)、(Ho CL)、夏德椿(Te-Chun Hsia)、(Wu MF),Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations,Journal of Thoracic Oncology,2015 May,10(5):793-799
SCI論文 陳偉峻(Wei-Chun chen)、陳韋成(Chen Wei-cheng)、陳致宇(Chih-Yu Chen)、吳秉儒(Biing-Ru Wu)、鄭文建(Wen-Chien Cheng)、林?宏(Kuo-Hung Lin)、夏德椿(Te-Chun Hsia)、陳煒(Wei Chen)、陳家弘(Chia-Hung Chen)、莫之欣、李嘉翔(Chia-Hsiang Li)*、廖偉志(Wei-Chih Liao)*,Amiodarone Use Is Associated With Increased Risk of Stroke in Patients With Nonvalvular Atrial Fibrillation A Nationwide Population-Based Cohort Study,MEDICINE,2015 May,19(6):
SCI論文 沈德群(Te-Chun Shen)、陳汶吉(Chen, Wen-Chi)*、林橙莉、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*,The Risk of Erectile Dysfunction in Chronic Obstructive Pulmonary Disease: A Population-based Cohort Study in Taiwan,MEDICINE,2015 Apr,94(14):e448-e448
SCI論文 (Kuo-Hsuan Hsu)、(Chao-Chi Ho)、夏德椿(Te-Chun Hsia)、(Jeng-Sen Tseng)、(Kang-Yi Su)、(Ming-Fang Wu)、(Kuo-Liang Chiu)、(Tsung-Ying Yang)、(Kun-Chieh Chen)、(Hean Ooi)*,Identification of Five Driver Gene Mutationsin Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan,PLoS One,2015 Mar,10(3):1-14
SCI論文 (G. V. Scagliotti)*、(I. Bondarenko)、(F. Blackhall)、(F. Barlesi)、夏德椿(Te-Chun Hsia)、(J. Jassem)、(J. Milanowski)、(S. Popat)、(J. M. Sanchez-Torres)、(S. Novello)、(R. J. Benner)、(S. Green)、(K. Molpus),Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.,ANNALS OF ONCOLOGY,2015 Mar,26(3):497-504
SSCI論文 彭逸豪(Yi-Hao Peng)、吳秉儒(Biing-Ru Wu)、(Ching-Hua Su)、廖偉志(Wei-Chih Liao)、莫之欣、夏德椿(Te-Chun Hsia)、高嘉鴻(Chia-Hung Kao)*,Adult asthma increases dementia risk: a nationwide cohort study.,JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH,2015 Feb,69(2):123-128
SCI論文 沈德群(Te-Chun Shen)、林橙莉、魏長菁(Chang-Ching Wei)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、宋鴻樟(Fung-Chang Sung)*,The Risk of Asthma in Patients with Ankylosing Spondylitis: A Population-based Cohort Study,PLoS One,2015 Feb,10(2):
SCI論文 柯仰謦、SHU-CHUN HSU、(HSIN-CHUNG LIU)、(YUNG-TING HSIAO)、夏德椿(Te-Chun Hsia)、楊仕哲(Su-Tso Yang or YANG Shi-zhe)、徐武輝(Wu-Huei Hsu)*、鍾景光(Jing-Gung Chung)*,Demethoxycurcumin Alters Gene Expression Associated with DNA Damage, Cell Cycle and Apoptosis in Human Lung Cancer NCI-H460 Cells In Vitro,IN VIVO,2015 Feb,29(1):83-94
SCI論文 吳莘華(Shin-Hwar Wu)、蕭詠庭(Hsiao, Yung-Ting)、郭昭麟(Kuo Chao-Lin)、游富順、徐素琴(Shu-Chun Hsu)、吳玢玢(Wu Ping-Ping)、陳兆群(Jaw-Chyun Chen)、夏德椿(Te-Chun Hsia)、劉馨中(Hsin-Chung Liu)、徐武輝(Wu-Huei Hsu)*、鍾景光(Jing-Gung Chung)*,Bufalin Inhibits NCI-H460 Human Lung Cancer Cell Metastasis In Vitro by Inhibiting MAPKs, MMPs, and NF-κB Pathways.,AMERICAN JOURNAL OF CHINESE MEDICINE,2015 ,43(6):1247-1264
SCI論文 沈德群(Te-Chun Shen)、林橙莉、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)*、宋鴻樟(Fung-Chang Sung)*,Reply: Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis,QJM-AN INTERNATIONAL JOURNAL OF MEDICINE,2014 Dec,107(12):1055-1056
SCI論文 夏德椿(Te-Chun Hsia)、(Wen-hu Liu)、(Wen-wei Qiu)、(Jian Luo)、殷梅津(YIN, MEI-CHIN)*,Maslinic Acid Induces Mitochondrial Apoptosis and Suppresses HIF-1 Expression in A549 Lung Cancer Cells under Normoxic and Hypoxic Conditions,MOLECULES,2014 Dec,2(19):19892-19906
SCI論文 沈德群(Te-Chun Shen)、王健宇(Chien-Yu Wang)、林橙莉、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、鍾季容(Chi-Jung Chung)*,People with Tuberculosis Are Associated with a Subsequent Risk of Depression,European Journal of Internal Medicine,2014 Dec,25(10):936-940
SCI論文 夏德椿(Te-Chun Hsia)、張文馨(WEN-SHIN CHANG)、陳偉峻(Wei-Chun chen)、梁信杰(Shinn-Jye Liang)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、梁基安(Ji-An Liang)、蔡佳紋(CHIA-WEN TSAI)、許欽木(CHIN-MU HSU)、蔡長海(Chang-Hai Tsai)、包大靝(Da-Tian Bau)*,Genotype of DNA Double-strand Break Repair Gene XRCC7 Is Associated with Lung Cancer Risk in Taiwan Males and Smokers,ANTICANCER RESEARCH,2014 Dec,34(12):7001-7006
SCI論文 夏德椿(Te-Chun Hsia)、張文馨(WEN-SHIN CHANG)、梁信杰(Shinn-Jye Liang)、陳偉峻(Wei-Chun chen)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、楊美都(Mei-Due Yang)、蔡佳紋(CHIA-WEN TSAI)、許欽木(CHIN-MU HSU)、蔡長海(Chang-Hai Tsai)、包大靝(Da-Tian Bau)*,Interleukin-10 (IL-10) Promoter Genotypes Are Associated with Lung Cancer Risk in Taiwan Males and Smokers,ANTICANCER RESEARCH,2014 Dec,34(12):7039-7044
SCI論文 簡君儒(Chun-Ru Chien)*、夏德椿(Te-Chun Hsia)、陳志毅(Chih-Yi Chen),Cost-effectiveness of chemotherapy combined with thoracic radiotherapy versus chemotherapy alone for limited stage small cell lung cancer: A population-based propensity-score matched analysis,Thoracic Cancer,2014 Nov,5(6):530-536
SCI論文 (Shih-ming Tsao)、夏德椿(Te-Chun Hsia)、殷梅津(YIN, MEI-CHIN)*,Protocatechuic Acid Inhibits Lung Cancer Cells by Modulating FAK, MAPK, and NF-κB Pathways,NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL,2014 Nov,66(8):1331-1341
SCI論文 (Lee DH)、(Lee JS)、(Wang J)、夏德椿(Te-Chun Hsia)、(Wang X)、(Kim J)、(Orlando M)*,Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-LineTreatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Tria,Cancer Research and Treatment,2014 Nov,0(0):0-0
SCI論文 林裕超(Yu-Chao Lin)、(Chen WC)、(Liao WC)、夏德椿(Te-Chun Hsia)*,Central retinal artery occlusion and brain infarctions after nasal filler injection.,QJM-AN INTERNATIONAL JOURNAL OF MEDICINE,2014 Nov,():
SCI論文 沈德群(Te-Chun Shen)、林橙莉、魏長菁(Chang-Ching Wei)、廖偉志(Wei-Chih Liao)、陳偉峻(Wei-Chun chen)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、李嘉翔(Chia-Hsiang Li)*、宋鴻樟(Fung-Chang Sung)*,Increased risk of tuberculosis in patients with type 1 diabetes mellitus: Results from a population-based cohort study in Taiwan,MEDICINE,2014 Oct,93(16):e96
SCI論文 夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳碩爵(Shuo-Chueh Chen)、梁基安(Ji-An Liang)、陳志毅(Chih-Yi Chen)、王耀慶(Yao-Ching Wang)*、簡君儒(Chun-Ru Chien)*,A Population-based Study of Primary Chemoradiotherapy in Clinical Stage III Non-small Cell Lung Cancer: Intensity-modulated Radiotherapy Versus 3D Conformal Radiotherapy,ANTICANCER RESEARCH,2014 Sep,34():5175-5180
Other論文 沈德群(Te-Chun Shen)、陳煒(Wei- Chen)、林橙莉、黃國揚(Kuo-Yang Huang)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、張晏蓉(Yen-Jung Chang)*,Chronic Obstructive Pulmonary Disease is Associated with an Increased Risk of Peripheral Arterial Disease,內科學誌,2014 Aug,25(4):272-280
SCI論文 沈德群(Te-Chun Shen)、林橙莉、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)*、宋鴻樟(Fung-Chang Sung)*,Increased Risk of Chronic Obstructive Pulmonary Disease in Patients with Rheumatoid Arthritis: A Population-based Cohort Study,QJM-AN INTERNATIONAL JOURNAL OF MEDICINE,2014 Jul,107(7):537-543
SCI論文 夏德椿(Te-Chun Hsia)、余建志(Chien-Chih Yu)、(Shu-Chun Hsu)、唐娜櫻(Nou-Ying Tang)、(Hsu-Feng Lu)、黄怡萍(Huang, Yi-Ping)、(Shin-Hwar Wu)、林昭庚(Jaung-Geng Lin)*、鍾景光(Jing-Gung Chung)*,Cantharidin induces apoptosis of H460 human lung cancer cells through mitochondria-dependent pathways.,INTERNATIONAL JOURNAL OF ONCOLOGY,2014 Jul,45(1):245-254
SCI論文 夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)*,The impact of rescue or maintenance therapy with EGFR TKIs for Stage IIIb-IV non-squamous non-small-cell lung cancer patients requiring mechanical ventilation,BMC Anesthesiology,2014 Jul,14(55):1-8
SCI論文 沈德群(Te-Chun Shen)、鐘威昇(Wei-Sheng Chung)、林橙莉、魏長菁(Chang-Ching Wei)、陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)*、徐武輝(Wu-Huei Hsu)、鍾季容(Chi-Jung Chung)*,Does Chronic Obstructive Pulmonary Disease with or without Type 2 Diabetes Mellitus Influence the Risk of Lung Cancer? Result from a Population-based Cohort Study,PLoS One,2014 May,9(5):e98290
SCI論文 劉俊麟(Chun-Lin Liu)、夏德椿(Te-Chun Hsia)、殷梅津(YIN, MEI-CHIN)*,S-Methyl cysteine enhanced survival of nerve growth factor differentiated PC12 cells under hypoxic conditions,Food & Function,2014 May,5(-):1125-1133
SCI論文 (Shin-Hwar Wu)、(Yung-Ting Hsiao)、(Jaw-Chyum Chen)、林如華(JU-HWA, LIN)、(Shu-Chun Hsu)、夏德椿(Te-Chun Hsia)、楊仕哲(Su-Tso Yang or YANG Shi-zhe)、徐武輝(Wu-Huei Hsu)*、鍾景光(Jing-Gung Chung)*,Bufalin alters gene expressions associated DNA damage, cell cycle, and apoptosis in human lung cancer NCI-H460 cells in vitro.,MOLECULES,2014 May,19(5):6047-6057
SCI論文 沈德群(Te-Chun Shen)、林橙莉、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、張晏蓉(Yen-Jung Chang)*,Increased Risk of Chronic Obstructive Pulmonary Disease in Patients with Systemic Lupus Erythematosus: A Population-based Cohort Study,PLoS One,2014 Mar,9(3):e91821-e91821
SCI論文 鄭文建(Wen-Chien Cheng)、夏德椿(Te-Chun Hsia)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、陳偉峻(Wei-Chun chen)*,Systemic intravascular and extravascular air bubbles in type I decompression sickness,EMERGENCY MEDICINE JOURNAL,2014 Mar,0(1):0-0
SCI論文 涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、(Min-Hsiang Hsu)、魏雅鈴(Ya-Ling Wei)、(Meng-Chie Yu)、(Wen-Shu Chen)、(Ke-Wei Hsu)、(Ming-Hsin Yeh)、劉良智(Liang-Chih Liu)、(Yun-Ju Chen)*、黃偉謙(Wei-Chien Huang)*,Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells,Biomed Research International,2014 Jan,2014():
SCI論文 (K. Kubota)、(Y. Ichinose)、(G. Scagliotti)、(D. Spigel)、(J. H. Kim)、(T. Shinkai)、(K. Takeda)、(S.-W. Kim)、夏德椿(Te-Chun Hsia)、(R. K. Li)、(B. J. Tiangco)、(S. Yau)、(W.-T. Lim)、(B. Yao)、(Y.-J. Hei)、(K. Park)*,Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.,ANNALS OF ONCOLOGY,2014 Jan,25(2):529-536
SCI論文 (Shin-Hwar Wu)、(Tzu-Yun Wu)、(Yung-Ting Hsiao)、林如華(JU-HWA, LIN)、(Shu-Chun Hsu)、夏德椿(Te-Chun Hsia)、楊仕哲(Su-Tso Yang or YANG Shi-zhe)、徐武輝(Wu-Huei Hsu)*、鍾景光(Jing-Gung Chung)*,Bufalin induces cell death in human lung cancer cells through disruption of DNA damage response pathways.,AMERICAN JOURNAL OF CHINESE MEDICINE,2014 ,42(3):729-742
SCI論文 吳憬全(Wu King-Chuen)、楊仕哲(Su-Tso Yang or YANG Shi-zhe)、(Shu-Chun Hsu)、(Jo-Hua Chiang)、夏德椿(Te-Chun Hsia)、(Jai-Sing Yang)、劉國慶(KUO-CHING LIU)、吳世銓(Rick Sai-Chuen Wu)*、鍾景光(Jing-Gung Chung)*,Propofol induces DNA damage in mouse leukemic monocyte macrophage RAW264.7 cells,ONCOLOGY REPORTS,2013 Nov,30():
SCI論文 (Yun-Ju Chen)、葉名焮(Ming-Hsin, Alex, Yeh)、游孟潔(Meng-Chieh Yu)、魏雅鈴(Ya-Ling Wei)、(Wen-Shu Chen)、(Jhen-Yu Chen)、(Chih-Yu Shih)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、(Pei-Hsuan Chien)、(Shu-Hui Liu)、余永倫(Yung-Luen Yu)、黃偉謙(Wei-Chien Huang)*,Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors,BREAST CANCER RESEARCH,2013 Nov,15(6):R108-R108
SCI論文 (Mei-chin Mong)、夏德椿(Te-Chun Hsia)、殷梅津(YIN, MEI-CHIN)*,Dietary trans fats enhance doxorubicin-induced cardiotoxicity in mice,JOURNAL OF FOOD SCIENCE,2013 Oct,78(10):1621-1628
SCI論文 賴光啟(Kuang-Chi Lai)、(Shu-Chun Hsu)、郭昭麟(Kuo Chao-Lin)、楊家欣(Yang Jai-Sing)、(Chia-Yu Ma)、(Hsu-Feng Lu)、唐娜櫻(Nou-Ying Tang)、夏德椿(Te-Chun Hsia)、何恒堅(Heng-Chien Ho)*、鍾景光(Jing-Gung Chung)*,Diallyl Sulfide, Diallyl Disulfide and Diallyl Trisulfide inhibit Migration and Invasion in Human Colon Cancer Colo 205 Cells through the Inhibition of Matrix Metalloproteinase-2, -7 and -9 Expressions,ENVIRONMENTAL TOXICOLOGY,2013 Sep,():
SCI論文 夏德椿(Te-Chun Hsia)、蔡佳紋(Chia-Wen Tsai)、梁信杰(Shinn-Jye Liang)、張文馨(Wen-Shin Chang)、林良怡(Liang-Yi Lin)、陳偉峻(Wei-Chun chen)、涂智彥(Chih-Yen Tu)、蔡長海(Chang-Hai Tsai)、包大靝(Da-Tian Bau)*,Effects of Ataxia Telangiectasia Mutated Genotypes and Smoking Habits on Lung Cancer Risk in Taiwan,ANTICANCER RESEARCH,2013 Sep,33(9):4067-4072
SCI論文 (Chang GC)、(Tsai CM)、夏德椿(Te-Chun Hsia)、(Yang CH)、(Abdulnabi R,)、(Blair JM)、(Linn C)*,Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2013 Sep,112(9):518-526
SCI論文 夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、簡君儒(Chun-Ru Chien)*,Effectiveness of Intensity-Modulated Radiotherapy for Lung Cancer,CLINICAL ONCOLOGY,2013 Jul,25(7):447-448
SCI論文 陳偉峻(Wei-Chun chen)、蔡佳紋(Chia-Wen Tsai)、夏德椿(Te-Chun Hsia)、張文馨(Wen-Shin Chang)、林良怡(Liang-Yi Lin)、梁信杰(Shinn-Jye Liang)、涂智彥(Chih-Yen Tu)、程味兒(Wei-Erh Cheng)、陳鴻仁(Hung-Jen Chen)、王舒民(Shu-Ming Wang)、包大靝(Da-Tian Bau)*,The Contribution of DNA Apurinic/apyrimidinic Endonuclease Genotype and Smoking Habit to Taiwan Lung Cancer Risk,ANTICANCER RESEARCH,2013 Jun,33(6):2775-2778
SCI論文 邱燦宏(Tsan-Hung Chiu)、(Kai-Ying Lan)、楊美都(Mei-Due Yang)、林楨智(Jen-Jyn Lin)、夏德椿(Te-Chun Hsia)、(Chin-Tung Wu)、楊家欣(Yang Jai-Sing)、(Fu-Shin Chueh)*、鍾景光(Jing-Gung Chung)*,Diallyl Sulfide Promotes Cell-Cycle Arrest Through the p53 Expression and Triggers Induction of Apoptosis Via Caspase- and Mitochondria-Dependent Signaling Pathways in Human Cervical Cancer Ca Ski Cells.,NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL,2013 Apr,65(1):165-174
SCI論文 夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、(Yun-Ju Chen)、魏雅鈴(Ya-Ling Wei)、(Meng-Chieh Yu)、(Sheng-Chie Hsu)、(Shing-Ling Tsai)、(Wen-Shu Chen)、葉名焮(Ming-Hsin, Alex, Yeh)、(Chia-Jui Yen)、余永倫(Yung-Luen Yu)、黃宗祺(Tzungchi Huang)、黃志揚(Chih-Yang Huang)、洪明奇(Mien-Chie Hung)、黃偉謙(Wei-Chien Huang)*,Lapatinib-mediated COX-2 expression via EGFR/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells,MOLECULAR PHARMACOLOGY,2013 ,20(3):2-13
SCI論文 曲陸彥(Lu-Yen Chu)、夏德椿(Te-Chun Hsia)、謝德鈞(Te-Chun Hsieh)、顏國揚(Kuo-Yang Yen)、高嘉鴻(Chia-Hung Kao)*,Rare cutaneous metastases from gastric cancer,AMERICAN JOURNAL OF THE MEDICAL SCIENCES,2012 Nov,344(5):406-406
SCI論文 李采娟(Tsai-Chung Li)、李佳霙(Chia-Ing Li)、(Chun-Hua Tseng)、(Chih-Yi Chen)、(Shing-Yu Yang)、陳志毅(Chih-Yi Chen)、夏德椿(Te-Chun Hsia)、(Yih-Dar Lee)、林正介(Cheng-Chieh Lin)*,Quality of life predicts survival in patients with non-small cell lung cancer,BMC PUBLIC HEALTH,2012 Sep,12():790-790
SCI論文 林昭庚(Jaung-Geng Lin)、范宗宸、唐娜櫻(Nou-Ying Tang)、楊家欣(Yang Jai-Sing)、夏德椿(Te-Chun Hsia)、林楨智(Jen-Jyn Lin)、賴光啟(Kuang-Chi Lai)、吳世銓(Rick Sai-Chuen Wu)、(Chia-Yu Ma)、(W. Gibson Wood)、鍾景光(Jing-Gung Chung)*,An Extract of Agaricus blazei Murill Administered Orally Promotes Immune Responses in Murine Leukemia BALB/c Mice In Vivo,INTEGRATIVE CANCER THERAPIES,2012 May,11(1):29-36
SCI論文 (BIN-CHUAN JI)、余建志(Chien-Chih Yu)、楊仕哲(Su-Tso Yang or YANG Shi-zhe)、夏德椿(Te-Chun Hsia)、楊家欣(Yang Jai-Sing)、賴光啟(Kuang-Chi Lai)、(YANG-CHING KO)、林楨智(Jen-Jyn Lin)、賴東淵(Tung-Yuan Lai)*、鍾景光(Jing-Gung Chung)*,Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells.,ONCOLOGY REPORTS,2012 Mar,27(4):959-964
SCI論文 夏德椿(Te-Chun Hsia)、劉金蓉(Chin-Jung Liu)、朱家成(Chia-Chen Chu)、杭良文(Liang-Wen Hang)、張文馨(Wen-Shin Chang)、蔡佳紋(Chia-Wen Tsai)、吳肇毅(Chao-I Wu)、連啟舜(Chi-Shun Lien)、廖文玲(Wen-Ling Liao)、何建宜(Chien-Yi Ho)、包大靝(Da-Tian Bau)*,Association of DNA double strand break gene XRCC6 Genotypes and lung cancer in Taiwan,ANTICANCER RESEARCH,2012 Mar,32(3):1015-1020
SCI論文 林精湛(Ching-Chan Lin)、夏德椿(Te-Chun Hsia)、簡君儒(Chun-Ru Chien)*,3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western woeld,LUNG CANCER,2012 Mar,():
SCI論文 (YUNG-LIANG CHEN)、(MING-YANG YEH)、(SHAU-YEN HUANG)、(CHI-MING LIU)、(CHI-CHEN SUN)、(HSU-FENG LU)*、邱燦宏(Tsan-Hung Chiu)、夏德椿(Te-Chun Hsia)、鍾景光(Jing-Gung Chung)*,Feasibility study for epidemic prevention and control in a regional hospital,Molecular Medicine Reports,2012 Mar,5(3):859-865
SCI論文 陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao)、劉奕亨(Yi-Heng Liu)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、徐武輝(Wu-Huei Hsu)、施純明(Chuen-Ming Shih)、涂智彥(Chih-Yen Tu)*,Secondary spontaneous pneumothorax: which associated condition is benefit for pigtail catheter treatment?,AMERICAN JOURNAL OF EMERGENCY MEDICINE,2012 Jan,30(1):45-50
SCI論文 (Hsu-Feng Lu)、(Yu-Jie Chie)、(Ming-Sung Yang)、呂孔文、(Jene-John Fu)、楊家欣(Yang Jai-Sing)、陳鴻儀(Hung-Yi Chen)、夏德椿(Te-Chun Hsia)、(Chia-Yu Ma)、葉兆雲(Ip Siu-Wan)、鍾景光(Jing-Gung Chung)*,Apigenin induces apoptosis in human lung cancer H460 cells through caspase-and mitochondria-dependent pathways.,HUMAN & EXPERIMENTAL TOXICOLOGY,2011 Dec,30():
SCI論文 夏德椿(Te-Chun Hsia)、劉金蓉(Chin-Jung Liu)、林志學(Chih-Hsueh Lin)、張文馨(Wen-Shin Chang)、朱家成(Chia-Chen Chu)、杭良文(Liang-Wen Hang)、李鳳琴(Hong-Zin Lee)、羅偉忠(Lo Woei Chung)*、包大靝(Da-Tian Bau)*,Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients,ANTICANCER RESEARCH,2011 Oct,31(10):3601-3606
Other論文 沈德群(Te-Chun Shen)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、劉奕亨(Yi-Heng Liu)*、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu),A Feasible Approach for Extraction of Dental Prostheses from the Airway by Flexible Bronchoscopy in Concert with Wire Loop Snares,胸腔醫學,2011 Oct,26(5):261-267
SCI論文 (Wu CL)、(Huang AC)、楊家欣(Yang Jai-Sing)、(Liao CL)、(Lu HF)、(Chou ST)、(Ma CY)、夏德椿(Te-Chun Hsia)、(Ko YC)、鍾景光(Jing-Gung Chung)*,Benzyl Isothiocyanate (BITC) and Phenethyl Isothiocyanate(PEITC)-Mediated Generation of Reactive Oxygen Species Causes Cell Cycle Arrest and Induces Apoptosis via Activation of Caspase-3, Mitochondria Dysfunction and Nitric Oxide (NO) in Human Osteogenic,JOURNAL OF ORTHOPAEDIC RESEARCH,2011 Aug,29(8):1199-1209
SCI論文 (Huang-Chi Chen)、陳汶吉(Chen, Wen-Chi)、(Kai-Huang Lin)、陳永祥(Yung-Hsiang Chen)、(Lun-Chien Lo)、(Tsung-Chieh Lee)、夏德椿(Te-Chun Hsia)、(Chu-Hsien Wang)、(Shin-Hwar Wu)、(Hsin-Whae Hsu)、(Yu-Jun Chang)、黃毓銓(Yu-Chuen Huang)、(Tien-Hsiung Ku)、(Ming-Hwarng Horng)*,Simultaneous use of traditional Chinese medicine (Si-Ni-Tang) to treat septic shock patients: study protocol for a randomized controlled trial,Trials,2011 Aug,12(1):199-203
SCI論文 吳玢玢(Wu Ping-Ping)、(HUI-WEN CHUNG)、劉國慶(KUO-CHING LIU)、吳世銓(Rick Sai-Chuen Wu)、楊家欣(Yang Jai-Sing)、唐娜櫻(Nou-Ying Tang)、羅琦(Lo, Chyi)、夏德椿(Te-Chun Hsia)、余建志(Chien-Chih Yu)、闕甫伈(FU-SHIN CHUEH)、(SONG-SHEI LIN)、鍾景光(Jing-Gung Chung)*,Diallyl sulfide induces cell cycle arrest and apoptosis in HeLa human cervical cancer cells through the p53, caspase- and mitochondria-dependent pathways,INTERNATIONAL JOURNAL OF ONCOLOGY,2011 Jun,38(6):1605-1613
SCI論文 (Mok TS)*、夏德椿(Te-Chun Hsia)、(Tsai CM),Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.,Asia-Pacific Journal of Clinical Oncology,2011 Jun,7(2):4-12
SCI論文 (Myung-Ju AHN)*、(Chun-Ming TS)、夏德椿(Te-Chun Hsia)、(Elaine WRIGHT)、(John Wen-Cheng CHANG)、(Heung Tae KIM),Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.,Asia-Pacific Journal of Clinical Oncology,2011 Jun,7(2):22-33
SCI論文 唐娜櫻(Nou-Ying Tang)、(Huang YT)、游春淑(chun shu yu)、(Ko YC)、(Wu SH)、(Ji BC)、楊家欣(Yang Jai-Sing)、(Yang JL)、夏德椿(Te-Chun Hsia)、(Chen YY)、鍾景光(Jing-Gung Chung)*,Phenethyl Isothiocyanate (PEITC) Promotes G2/M Phase Arrest via p53 Expression and Induces Apoptosis through Caspase- and Mitochondria-dependent Signaling Pathways in Human Prostate Cancer DU 145 Cells,ANTICANCER RESEARCH,2011 May,31(5):1691-1702
SCI論文 陳柏源(Po-Yuan Chen)、(Hsu WT)、(Jhuo MD)、(Ou CY)、鄭志鴻(CHENG, TZU-HURNG)、(Shih TC)、(Wu CH)、吳世銓(Rick Sai-Chuen Wu)、夏德椿(Te-Chun Hsia)、鍾景光(Jing-Gung Chung)*,Computational Analysis of De Novo Evolution of Hepatitis C Virus NS5B Polymerase Inhibitors.,IN VIVO,2011 Apr,25(2):219-228
SCI論文 (Myung-Ju AHN)*、(Chun-Ming TSAI)、夏德椿(Te-Chun Hsia)、(Elaine WRIGHT),Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwana,Asia-Pacific Journal of Chemical Engineering,2011 Apr,7(2):22-33
SCI論文 陳家弘(Chia-Hung Chen)、施純明(Chuen-Ming Shih)、周仁偉(Jen-Wei Chou)、劉奕亨(Yi-Heng Liu)、杭良文(Liang-Wen Hang)、夏德椿(Te-Chun Hsia)、徐武輝(Wu-Huei Hsu)、涂智彥(Chih-Yen Tu)*,Outcome predictors of cirrhotic patients with spontaneous bacterial empyema.,LIVER INTERNATIONAL,2011 Mar,31(3):417-424
SCI論文 林嘉德(Chia-Der Lin)、魏一華(Wei I Hua)、賴志河(Chih-Ho Lai)、夏德椿(Te-Chun Hsia)、高銘欽(Ming-Ching Kao)、蔡銘修(Ming-Hsui Tsai)、吳慶祥(Wu, Ching-Hsiang)、蔡孟宏(Mang Hung Tsai)*,Hyperbaric oxygen upregulates cochlear constitutive nitric oxide synthase,BMC NEUROSCIENCE,2011 Mar,12(21):1-10
SCI論文 江若華(Jo-Hua Chiang)、楊家欣(Yang Jai-Sing)、(Chia-Yu Ma)、楊美都(Mei-Due Yang)、黃惠煐(Huang Hui-Ying)、夏德椿(Te-Chun Hsia)、郭秀滿、吳玢玢(Wu Ping-Ping)、(Tsung-Han Lee)、鍾景光(Jing-Gung Chung)*,Danthron, an Anthraquinone Derivative, Induces DNA Damage and Caspase Cascades-Mediated Apoptosis in SNU-1 Human Gastric Cancer Cells through Mitochondrial Permeability Transition Pores and Bax-Triggered Pathways,CHEMICAL RESEARCH IN TOXICOLOGY,2011 Jan,24(1):20-29
SCI論文 (JEHN-HWA KUO)、朱永麟(YUNG-LIN CHU)、楊家欣(Yang Jai-Sing)、林景彬(Jing-Pin Lin)、賴光啟(Kuang-Chi Lai)、郭秀滿、夏德椿(Te-Chun Hsia)、鍾景光(Jing-Gung Chung)*,Cantharidin induces apoptosis in human bladder cancer TSGH8301 cells through mitochondria-dependent signal pathways,INTERNATIONAL JOURNAL OF ONCOLOGY,2010 Nov,37(5):1243-1250
SCI論文 陳偉峻(Wei-Chun chen)、陳煒(Wei- Chen)、曾冠欽(Guan-Chin Teseng)、賴學洲(Hsueh-Chou Lai)、施純明(Chuen-Ming Shih)、夏德椿(Te-Chun Hsia),Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?,LIVER INTERNATIONAL,2010 Nov,30(10):1548-1549
SCI論文 劉金蓉(Chin-Jung Liu)、夏德椿(Te-Chun Hsia)、蔡如愔(Ru-Yin Tsai)、孫盛生(Shung-Shung Sun)、王仲興(Chung-Hsing Wang)、林正介(Cheng-Chieh Lin)、蔡佳紋(Chia-Wen Tsai)、黃志揚(Chih-Yang Huang)、許欽木(Chin-Mu Hsu)、包大靝(Da-Tian Bau)*,The Joint Effect of hOGG1 Single Nucleotide Polymorphism and Smoking Habit on Lung Cancer in Taiwan,ANTICANCER RESEARCH,2010 Oct,30(10):4141-4145
SCI論文 林裕超(Yu-Chao Lin)、涂智彥(Chih-Yen Tu)、梁信杰(Shinn-Jye Liang)、陳鴻仁(Hung-Jen Chen)、陳煒(Wei- Chen)*、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu),Pigtail catheter for the management of pneumothorax in mechanically ventilated patients,AMERICAN JOURNAL OF EMERGENCY MEDICINE,2010 May,28(4):466-471
SCI論文 劉金蓉(Chin-Jung Liu)、夏德椿(Te-Chun Hsia)、王柔分(Rou-Fen Wang)、蔡佳紋(Chia-Wen Tsai)、朱家成(Chia-Chen Chu)、杭良文(Liang-Wen Hang)、王仲興(Chung-Hsing Wang)、李鳳琴(Hong-Zin Lee)*、蔡如愔(Ru-Yin Tsai)*、包大靝(Da-Tian Bau)*,Interaction of Cyclooxygenase 2 Genotype and Smoking Habit in Taiwanese Lung Cancer Patients,ANTICANCER RESEARCH,2010 Apr,30(4):1195-1199
SCI論文 簡君儒(Chun-Ru Chien)、楊仕哲(Su-Tso Yang or YANG Shi-zhe)、陳志毅(Chih-Yi Chen)、方信元(Hsin-Yuan Fang)、涂智彥(Chih-Yen Tu)、曾冠欽(Guan-Chin Teseng)、余養豪(Yang-Hao Yu)、陳鴻仁(Hung-Jen Chen)、何致德(Chih-Te Ho)、謝清昀(Ching-Yun Hsieh)、陳香霓(Shung-Ni CHen)、陳品儒(Pin-Ru Chen)、劉峻成(Juhn-Cherng Liu)、王耀慶(Yao-Ching Wang)、吳蕙樺(Hui-Hua Wu)、夏德椿(Te-Chun Hsia)*,Impact of the New Lung Cancer Staging System for a Predominantly Advanced-Disease Patient Population,Journal of Thoracic Oncology,2010 Mar,5(3):340-343
SCI論文 蘇進成(Chin-Cheng Su)、楊家欣(Yang Jai-Sing)、呂啟誠(Chi-Cheng Lu)、江若華(Jo-Hua Chiang)、吳長霖(Chang-Lin Wu)、林楨智(Jen-Jyn Lin)、賴光啟(Kuang-Chi Lai)、夏德椿(Te-Chun Hsia)、呂旭峰(Hsu-Feng Lu)、范宗宸(Ming-Jen Fan)、鍾景光(Jing-Gung Chung)*,Curcumin Inhibits Human Lung Large Cell Carcinoma Cancer Tumour Growth in a Murine Xenograft Model,PHYTOTHERAPY RESEARCH,2010 Feb,1(24):189-192
SCI論文 呂啟誠(Chi-Cheng Lu)、楊家欣(Yang Jai-Sing)、黃安正(An-Cheng Huang)、夏德椿(Te-Chun Hsia)、周淑姿(Su-Tze Chou)、郭昭麟(Kuo Chao-Lin)、呂旭峰(Hsu-Feng Lu)、李宗翰(Tsung-Han Lee)、(Wellington G. Wood)、鍾景光(Jing-Gung Chung)*,Chrysophanol induces necrosis through the production of ROS and alteration of ATP levels in J5 human liver cancer cells,MOLECULAR NUTRITION & FOOD RESEARCH,2010 Feb,54(1):967-976
Other論文 劉秋松(Chiu-Shong Liu)、蔡佳紋(CHia-Wen Tsai)、夏德椿(Te-Chun Hsia)、王柔分(Rou-Fen Wang)、劉金蓉(Chin-Jung Liu)、杭良文(Liang-Wen Hang)、江素瑛(Su-yin Chiang)、王仲興(Chung-Hsing Wang)、蔡如愔(Ru-Yin Tsai)*、林正介(Cheng-Chieh Lin)*、包大靝(Da-Tian Bau)*,Interaction of Methylenetetrahydrofolate Reductase Genotype and Smoking Habit in Taiwanese Lung Cancer Patients,CANCER GENOMICS & PROTEMICS,2009 Dec,6(1):325-330
SCI論文 唐娜櫻(Nou-Ying Tang)、楊家欣(Yang Jai-Sing)、林景彬(Jing-Pin Lin)、夏德椿(Te-Chun Hsia)、范宗宸(Fan MJ)、林楨智(Jen-Jyn Lin)、(Weng SW)、(yi-shih ma)、呂旭峰(Lu HF)、(Shen JJ)、林昭庚(Jaung-Geng Lin)、鍾景光(Jing-Gung Chung)*,Effects of Agaricus blazei Murill Extract on Immune Responses in Normal BALB/c Mice,IN VIVO,2009 Sep,23(5):761-766
SCI論文 邱燦宏(Tsan-Hung Chiu)、夏德椿(Te-Chun Hsia)、(JAI-SING YANG)、賴東淵(Tung-Yuan Lai)、吳玢玢(Wu Ping-Ping)、(CHIA-YU MA)、葉進仲(Yeh, Chin-Chung)、(CHIN-CHIN HO)、(HSU-FENG LU)、(W. GIBSON WOOD)、鍾景光(Jing-Gung Chung)*,Aloe-emodin Induces Cell Death through S-Phase Arrest and Caspase-dependent Pathways in Human Tongue Squamous Cancer SCC-4 Cells,ANTICANCER RESEARCH,2009 Sep,29(11):4503-4512
SCI論文 (BIN-CHUAN JI)、徐武輝(Wu-Huei Hsu)、楊家欣(Yang Jai-Sing)、夏德椿(Te-Chun Hsia)、呂啟誠(CHI-CHENG LU)、江若華(JO-HUA CHIANG)、楊鈞隆(JIUN-LONG YANG)、(CHING-HSIUNG LIN)、林楨智(Jen-Jyn Lin)、(LEE-JEN WU SUEN)、(WELLINGTON GIBSON WOOD)、鍾景光(Jing-Gung Chung)*,Gallic Acid Induces Apoptosis via Caspase-3 and Mitochondrion-Dependent Pathways in Vitro and Suppresses Lung Xenograft Tumor Growth in Vivo,JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY,2009 Aug,16(57):7596-7604
Other論文 黃浩堯(Wong-Ho Yiu)、陳家弘(Chia-Hung Chen)、劉奕亨(Yi-Heng Liu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、涂智彥(Chih-Yen Tu)*,Short-term Deployment of Self-expanding Metallic Stent for Healing of Tracheal Laceration after esophaectomy in an Esophageal Cancer Patient Requiring Mechanical Ventilation-Case Report,胸腔醫學,2009 Aug,24(4):218-222
SCI論文 何永鑚(YUNG-TSUAN HO)、呂啟誠(CHI-CHENG LU)、楊家欣(Yang Jai-Sing)、江若華(JO-HUA CHIANG)、(TSAI-CHUNG LI)、葉兆雲(Ip Siu-Wan)、夏德椿(Te-Chun Hsia)、廖慶隆(CHING-LUNG LIAO)、林昭庚(Jaung-Geng Lin)*、(W. GIBSON WOOD)、鍾景光(Jing-Gung Chung)*,Berberine Induced Apoptosis via Promoting the Expression of Caspase-8, -9 and -3, Apoptosis-inducing Factor and Endonuclease G in SCC-4 Human Tongue Squamous Carcinoma Cancer Cells,ANTICANCER RESEARCH,2009 Jul,29(1):4063-4070
SCI論文 陳鴻仁(Hung-Jen Chen)、余養豪(Yang-Hao Yu)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、蔡昆道、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)*,Ultrasound in Peripheral Pulmonary Air-Fluid Lesions color Doppler Imaging as an Aid in Differentiating Empyema and Abscsee,CHEST,2009 Jun,135(6):1426-1432
SCI論文 :徐素琴(Shu-Chun Hsu)、楊家欣(Yang Jai-Sing)、郭昭麟(Kuo Chao-Lin)、羅琦(Lo, Chyi)、林景彬(Jing-Pin Lin)、夏德椿(Te-Chun Hsia)、林楨智(Jen-Jyn Lin)、賴光啟(Kuang-Chi Lai)、郭秀滿、黃麗嬌(Li-Jiau Huang)、郭盛助(Sheng-Chu Kuo)、(W. Gibson Wood)、鍾景光(Jing-Gung Chung)*,Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line,JOURNAL OF ORTHOPAEDIC RESEARCH,2009 Jun,27(12):1637-1644
SCI論文 李玉菁(Yu-Ching Li)、林慧茹(Hui-Ju Lin)、楊仁宏(Jen-Hung Yang)、楊家欣(Yang Jai-Sing)、何恒堅(Heng-Chien Ho)、張淑貞(Shu-Jen Chang)、夏德椿(Te-Chun Hsia)、呂旭峰(Hsu-Feng Lu)、黃安正(An-Cheng Huang)、鍾景光(Jing-Gung Chung)*,Baicalein-Induced Apoptosis via Endoplasmic Reticulum Stress Through Elevations of Reactive Oxygen Species and Mitochondria Dependent Pathway in Mouse-Rat Hybrid Retina Ganglion Cells (N18).,NEUROCHEMICAL RESEARCH,2009 Mar,34(3):418-429
SCI論文 楊家欣(Yang Jai-Sing)、陳光偉(Guang-Wei Chen)、夏德椿(Te-Chun Hsia)、何恒堅(Heng-Chien Ho)、何蓁蓁(Chin-Chin Ho)、(Meng-Wei Lin)、林松水(Song-Shei Lin)、(Ru-Duan Yeh)、葉兆雲(Ip Siu-Wan)、(Hsu-Fung Lu)、鍾景光(Jing-Gung Chung)*,Diallyl disulfide induces apoptosis in human colon cancer cell line (COLO 205) through the induction of reactive oxygen species, endoplasmic reticulum stress, caspases casade and mitochondrial-dependent pathways.,FOOD AND CHEMICAL TOXICOLOGY,2009 Jan,47(1):171-179
SCI論文 夏德椿(Te-Chun Hsia)、楊家欣(Yang Jai-Sing)、陳光偉、邱燦宏(Tsan-Hung Chiu)、呂旭峰(HSU-FENG LU)、楊美都(Mei-Due Yang)、游富順、劉國慶(KUO-CHING LIU)、賴光啟(Kuang-Chi Lai)、林慶鐘(CHIN-CHUNG LIN)、鍾景光(Jing-Gung Chung)*,The Roles of Endoplasmic Reticulum Stress and Ca2+ on Rhein-induced Apoptosis in A-549 Human Lung Cancer Cells,ANTICANCER RESEARCH,2009 Jan,(29):309-318
SCI論文 陳榮洲(Jung-Chou Chen)、呂孔文(KUNG-WEN LU)、蔡明俐(Ming-Li Tsai)、(Shu-Chun Hsu)、郭昭麟(Kuo Chao-Lin)、楊家欣(Yang Jai-Sing)、夏德椿(Te-Chun Hsia)、(Chun-Shu Yu)、(Su-Tze Chou)、高銘欽(Ming-Ching Kao)、鍾景光(Jing-Gung Chung)*、(W. Gibson Wood),Gypenosides induced G0G1 arrest via CHk2 and apoptosis through endoplasmic reticulum stress and mitochondria-dependent pathways in human tongue cancer SCC-4 cells,ORAL ONCOLOGY,2009 ,45(0):273-283
Other論文 莊宏洋(Hung-Yang Chuang)、陳家弘(Chia-Hung Chen)、劉奕亨(Yi-Heng Liu)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)、涂智彥(Chih-Yen Tu)*,Real-time Endobronchial Ultrasound-guided Transbronchial Needle Aspiration is Useful for Diagnosing Recurrent Hypopharygeal Carcinoma Located in the Upper Paratracheal Space-A Case Report,胸腔醫學,2009 ,24(3):163-167
SCI論文 張永賢(Yung-Hsien Chang)、楊家欣(Yang Jai-Sing)、(JIUN-LONG YANG)、(CHANG-LIN WU)、張淑貞(Shu-Jen Chang)、呂孔文(KUNG-WEN LU)、郭昭麟(Kuo Chao-Lin)、夏德椿(Te-Chun Hsia)、鍾景光(Jing-Gung Chung)*,Gandoderma lucidum Extract Promotes Immune Responses in Normal BALB/c Mice In Vivo,IN VIVO,2009 ,23(0):755-760
SCI論文 張永賢(Yung-Hsien Chang)、楊家欣(Yang Jai-Sing)、(Jiun-Long YANG)、(Chang-Lin WU)、張淑貞(Shu-Jen Chang)、呂孔文(KUNG-WEN LU)、(Jen-Jyh LIN)、夏德椿(Te-Chun Hsia)、林意婷(Yi-Ting Lin)、(Chin-Chih HO)、(W. Gibson WOOD)、鍾景光(Jing-Gung Chung)*,Ganoderma lucidum Extracts Inhibited Leukemia WEHI-3 Cells in BALB/c Mice and Promoted an Immune Response in Vivo,BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY,2009 ,73(12):2589-2594
SCI論文 黃安正(AN-CHENG HUANG)、林淑媛(SHUW-YUAN LIN)、蘇進成(Chin-Cheng Su)、林松水(SONG-SHEI LIN)、何蓁蓁(CHIN-CHIN HO)、夏德椿(Te-Chun Hsia)、邱燦宏(Tsan-Hung Chiu)、游春淑(chun shu yu)、葉兆雲(Ip Siu-Wan)、林宗平、鍾景光(Jing-Gung Chung)*,Effeacts of curcumin on N-bis( 2-Hydroxypropyl )nitrosamine (DHPN)-induced lung and liver tumorigenesis in BALB/c mice in vivo,IN VIVO,2008 Dec,22(00):781-786
SCI論文 劉奕亨(Yi-Heng Liu)、夏德椿(Te-Chun Hsia)、劉峻成(Juhn-Cherng Liu)、陳煒(Wei- Chen)*,Fracture of the maxillary bone during hyperbaric oxygen therapy,CANADIAN MEDICAL ASSOCIATION JOURNAL,2008 Dec,179(12):1351-1351
SCI論文 徐武輝(Wu-Huei Hsu)*、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、李建德(Chien-Te Li)、余養豪(Yang-Hao Yu)、邱國樑(KUO-LIANG CHIU)、夏德椿(Te-Chun Hsia),Dynamic Flow US, Color Doppler US, and Power Doppler US in the Assessment of Vessel Signals of Thoracic Lesions Abutting Pulsatile Organs,ACADEMIC RADIOLOGY,2008 Aug,(15):350-360
SCI論文 林松水(LIN S-S)、黃宣榜(HUANG H-P)、楊家欣(Yang Jai-Sing)、吳政元(WU J-Y)、夏德椿(Te-Chun Hsia)、林慶鐘(LIN C-C)、林振文(Lin Cheng Wen)、郭昭麟(Kuo Chao-Lin)、(WOOD W-G)、鍾景光(Jing-Gung Chung)*,DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade- and mitochondrial-dependent pathway,CANCER LETTERS,2008 Jun,(272):77-90
Other論文 林育生(Yu-Sheng Lin)、夏德椿(Te-Chun Hsia)*、蔡育霖(Yu-Lin Tsai)、蔡文凱(Wen-Kai Tsai)、杭良文(Liang-Wen Hang)、吳肇毅(Chao-I Wu)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu),Experience with Non-survivors of Acute Carbon Monoxide Intoxication Who Received Hyperbaric Oxygen Therapy and Literature Review,胸腔醫學,2008 Jun,第二十三卷(第三期):187-194
Other論文 陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu),Lung Adenocarcinoma with Penile Metastasis– A Case Report,肺腺癌合併陰莖轉移─病例報告,胸腔醫學,2008 Jun,23(3):182-186
SCI論文 呂孔文(Kung-Wen Lu)、蔡明俐(Ming-Li Tsai)、陳榮洲(Jung-Chou Chen)、徐素琴(Shu-Chun)、夏德椿(Te-Chun Hsia)、林孟葳(Meng-Wei Lin)、黃安正(Huang AC)、張永賢(Yung-Hsien Chang)、葉兆雲(Ip Siu-Wan)、呂旭峰(Hsu-Feng Lu)、鍾景光(Jing-Gung Chung)*,Gypenosides inhibited invasion and migration of human tongue cancer SCC4 cells through down-regulation of NFkappaB and matrix metalloproteinase-9,ANTICANCER RESEARCH,2008 Mar,28(2A):1093-1100
Other論文 陳家銘(Chia-Ming Chen)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)*,An Unusual Form of Metastasis of Hepatocellular Carcinoma-Case Report,胸腔醫學,2008 Feb,23(1):8-13
SCI論文 陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)、梁信杰(Shinn-Jye Liang)、陳煒(Wei- Chen)、邱國樑(KUO-LIANG CHIU)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih)、徐武輝(Wu-Huei Hsu)*,Sonographic Appearances In Transudative Pleural Effusions: Not Always An Anechoic Pattern,ULTRASOUND IN MEDICINE AND BIOLOGY,2008 ,34(3):362-369
SCI論文 陳家弘(Chia-Hung Chen)、徐武輝(Wu-Huei Hsu)、陳鴻仁(Hung-Jen Chen)、陳煒(Wei- Chen)、施純明(Chuen-Ming Shih)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)*,Different bacteriology and prognosis of thoracic empyemas between patients with chronic and end-stage renal disease.,CHEST,2007 Aug,132(2):532-539
SCI論文 程味兒(Wei-Erh Cheng)、施純明(Chuen-Ming Shih)、杭良文(Liang-Wen Hang)、吳焜裕(Kuen-Yuh Wu)、楊新玲、徐武輝(Wu-Huei Hsu)、夏德椿(Te-Chun Hsia)*,Urinary biomarker of oxidative stress correlating with outcome in critically septic patients,INTENSIVE CARE MEDICINE,2007 Jul,(33):1187-1190
SCI論文 林慶鐘(Lin, Chin-Chung)、高尚德(Kao,Shung-Te)、(Ho, Chin-Chin)、何恒堅、夏德椿(Hsia,Te-Chun)、楊美都、葉進仲、(Liu, Po-Erh)、鍾景光*,Effects of oral administration of berberine on distribution and metabolism of 2-aminofluorene in Sprague-Dawley rats.,IN VIVO,2007 Mar,21(2):321-328
SCI論文 彭瑞鵬(Reury-Perng Perng)、陳志毅(Chih-Yi Chen)、張基晟(gee-Chen Chang)、夏德椿(Te-Chun Hsia)、許南榮(Nan-Yung Hsu)、Ying-Huang T(蔡熒煌)、蔡俊明(Chun-Ming Tsai)、楊志新(Chih-hsin Yang)、Yuh-Min Chen(陳育民)、余忠仁(Chong-Jen Yu),Revisit of 1997 TNM Staging System—Survival Analysis of 1112 Lung Cancer Patients in Taiwan,JAPANESE JOURNAL OF CLINICAL ONCOLOGY,2007 Jan,1(37):9-15
MT論文 陳建仲(Chen JJ)、梁文敏(Liang,Wen-Miin)、陳宏偉(Chen HW)、Lin CH(林慶雄)、杭良文(Liang-Wen Hang)、夏德椿(Te-Chun Hsia)、黃麗菁(Huang LJ),Association Between Clinical Variables and Health-related Quality of Life in Patients with A Chronic Obstructive Pulmonary Disease,Mid-Taiwan Journal of Medicine,2006 Sep,11(3):155-163
SCI論文 唐娜櫻(Nou-Ying Tang)、楊家欣(Yang Jai-Sing)、張永賢(Yung-Hsien Chang)、李德茂(Te-Mao Li)、夏德椿(Te-Chun Hsia)、林文川(Wen-Chuan Lin)、鍾景光*,Effects of Wogonin on in Levels of Cytokines and Function of Leukocytes Associated with NF-kappa B Expression in Sprague-Dawley Rats,IN VIVO,2006 Jul,20(4):527-532
SCI論文 陳鴻仁(Hung-Jen Chen)、徐武輝(Wu-Huei Hsu)*、涂智彥(Chih-Yen Tu)、余養豪(Yang-Hao Yu)、邱國樑(KUO-LIANG CHIU)、杭良文(Liang-Wen Hang)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih),Sonographic septation in lymphocyte-rich exudative pleural effusions: a useful diagnostic predictor for tuberculosis.,JOURNAL OF ULTRASOUND IN MEDICINE,2006 Jul,27(7):857-863
Other論文 陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)、梁信杰(Shinn-Jye Liang)、陳鴻仁(Hung-Jen Chen)、施純明(Chuen-Ming Shih),Ultraflex airway stent for the treatment of tracheobronchial stenosis due to lung cancer,胸腔醫學,2006 Jun,21(3):247-253
SCI論文 涂智彥(Chih-Yen Tu)、徐武輝(Wu-Huei Hsu)*、夏德椿(Te-Chun Hsia)、陳鴻仁(Hung-Jen Chen)、邱國樑(Kuo-Liang Chiu)、杭良文(Liang-Wen Hang)、施純明(Chuen-Ming Shih),The changing pathogens of complicated parapneumonic effusions or empyemas in a medical intensive care unit,INTENSIVE CARE MEDICINE,2006 Apr,32(4):570-576
SCI論文 (Yang JH)、夏德椿(Te-Chun Hsia)、郭秀滿、(Lee Chao PD)、(Chou CC)、(Wei YH)、鍾景光*,Inhibition of Lung Cancer Cell Growth by Quercetin Glucuronides via G2/M Arrest and Induction of Apoptosis.,DRUG METABOLISM AND DISPOSITION,2006 Feb,34(2):296-304
Other論文 陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、梁信杰(Shin-Jye Liang)、陳鴻仁(Hung-Jen Chen)、施純明(Chuen-Ming Shih),Kartagener syndrome: a case report and review of the literature,胸腔醫學,2006 ,21(3):247-254
SCI論文 (Lin SY)、(Yang JH)、夏德椿(Te-Chun Hsia)、(Lee JH)、邱燦宏(Tsan-Hung Chiu)、(Wei YH)、鍾景光*,Effect of inhibition of aloe-emodin on N-acetyltransferase activity and gene expression in human malignant melanoma cells (A375.S2).,MELANOMA RESEARCH,2005 Dec,15(6):489-494
SCI論文 (Lu KH)、(Lue KH)、夏德椿(Te-Chun Hsia)、(Chou MC)、(KL Lin)、鍾景光*,Oral administration of paclitaxel affects the distribution and metabolism of 2-aminofluorene in various tissues of Sprague-Dawley rats.,PHYTOMEDICINE,2005 Aug,12(8):577-587
Other論文 陳煒(Wei- Chen)、夏德椿(Te-Chun Hsia)、杭良文(Liang-Wen Hang),The Association Between Obstructive Sleep Apnea Hypopnea Syndrome and Obstructive Airway Disease,胸腔醫學,2005 Jun,20(3):198-205
SCI論文 林景彬(Jing-Pin Lin)、(Hsu-Feng Lu)、李昭宏(Jau-Hong Lee)、林昭庚(教授,研,董事)、夏德椿(Te-Chun Hsia)、吳禮字、鍾景光(教授,研)*,(-)-Menthol Inhibit DNA Topoisomerases I, IIαandβ and Promote NF-κB expression in Human Gastric Cancer SNU-5 Cells,ANTICANCER RESEARCH,2005 May,(25):2069-2074
SCI論文 (YU-CHING LI)、(YU-SHENG TYAN)、(YIH-MIN LEE)、(TANG-YI TSAO,)、莊淨媛、(HSIU-MAAN KUO)、夏德椿(Te-Chun Hsia)、(JEN-HUNG YANG)、鍾景光*,N-Acetyltransferase is Involed in Baicalein-induced N-Acetylation of 2-Aminofluorene and DNA-2-Aminofluorence Adduct Formation in Human Leukemia HL-60 Cells,IN VIVO,2005 Mar,19(2):399-405
SCI論文 (Lin SS)、(Yu CS)、(Wu JY)、(Tyan YS)、夏德椿(Te-Chun Hsia)、(Lin WC)、鍾景光*,Effects of aspirin on the in vitro and in vivo acetylation of 2-aminofluorene in Sprague-Dawley rats.,IN VIVO,2005 Mar,19(2):475-481
SCI論文 蔡輔仁(Fuu-Jen Tsai)、鄭雅靜(Ya-Chang Cheng)、陳昶仲(C C Chen)、夏德椿(Te-Chun Hsia)、陳慧毅(Huey-Yi Chen)、陳汶吉(Chen Wen-Chi),Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder.,BJU INTERNATIONAL,2005 Feb,95(3):432-435
Other論文 黃軒(Hean OOi)、夏德椿(Te-Chun Hsia)*,Clinical Outcomes of Community-Acquired Pneumonia in Young Adults: Analysis Using the Pneumonia Severity Index (PSI).,胸腔醫學,2005 ,20(1):17-24
SCI論文 涂智彥(Chih-Yen Tu)、徐武輝(Wu-Huei Hsu)*、夏德椿(Te-Chun Hsia)、陳鴻仁(Hung-Jen Chen)、蔡昆道、洪崇文(Chung-Wen Hung)、施純明(Chuen-Ming Shih),Pleural effusions in febrial medical ICU patients : chest US study,CHEST,2004 Oct,126(4):1274-1280
MT論文 夏德椿(Te-Chun Hsia)、林景彬(Jing-Pin Lin)、李德茂、(Shang-Wen Yuan)、鍾景光*,Diallyl Disulfide Inhibits N-acetytransferase Activity and gene Expression in Human Lung Cancer A549 Cells,Mid-Taiwan Journal of Medicine,2004 Sep,(9):161-168
SCI論文 余養豪、徐武輝(Hsu,Wu-Huei)、許南榮(Hsu,Nan-Yung)、林智一、夏德椿(Hsia,Te-Chun)、孫盛生(Shung-Shung Sun)、高嘉鴻(Kao,Chia-Hung),The use of dual phase 201Tl SPECT for differenting pulmonary malignancies from benign lesions,JAPANESE JOURNAL OF CLINICAL ONCOLOGY,2004 Aug,38(34):445-451
SCI論文 郭秀滿、夏德椿(Te-Chun Hsia)、(YC Chuang)、(HF Lu)、(SY Lin)、鍾景光*,Shikonin inhibits the growth and N-acetylation of 2-aminofluorene in Helicobacter pylori from ulcer patients.,ANTICANCER RESEARCH,2004 May,24(3a):1587-1592
MT論文 陳建仲(Chen-Chung Chen)、張郁瑩(Chang YY)、梁文敏(Wen-Miin Liang)*、夏德椿(Te-Chun Hsia)、杭良文(Liang-Wen Hang)、顏至慶(Chih-Ching Yen)、郭憲文(Hsien-Wen Kuo),Factor construct and health profile which define quality of life in patients with chronic obstructive pulmonary disease,Mid-Taiwan Journal of Medicine,2004 ,9(2):103-112
Other論文 夏德椿(Te-Chun Hsia)、(Jen-Hung Yang)、(Hui-Ju Lin)、(Chun-Shu Yu)、(Fu-Shun Yu)、鍾景光(Jing-Gung Chung)*,Paclitaxel inhibits N-Acetyltransferase activity and gene expression in human stomach tumor cells(SC-M1),Research Communications in Molecular Pathology and Pharmacology,2004 ,115, 116(115,116):21-37
SSCI論文 涂智彥(Chih-Yen Tu)、徐武輝(Wu-Huei Hsu)*、夏德椿(Te-Chun Hsia)、陳鴻仁(Hung-Jen Chen)、蔡昆道(Kuen-Daw Tsai)、洪崇文、施純明(Chuen-Ming Shih),Pleural effusions in febrile medical ICU patients- chese ultrasound study,MANCHESTER SCHOOL,2004 ,126():1274-1280
Other論文 蔡昆道(Kuen-Daw Tsai)、涂智彥(Chih-Yen Tu)、余養豪(Yang-Hao Yu)*、林智一(Tze-Yi Lin)、杭良文(Liang-Wen Hang)、夏德椿(Te-Chun Hsia),Amniotic fluid embolism- a case report and review of the literature,胸腔醫學,2003 Aug,18(4):368-372
SCI論文 陳榮洲(Jung-Chou Chen)*、(Jiunn-Ming Hwang)、郭秀滿、夏德椿(Te-Chun Hsia)、鍾景光,Curcumin decreases the DNA adduct formation, arylamines N-acetyltransferase activity and gene expression in human colon tumor cells (Colon 205). in vivo,IN VIVO,2003 May,17(1):301-310
SCI論文 劉建明(CHIEN-MING LIU,)、杭良文(Liang-Wen Hang)*、陳維恭(Wei-Kung Chen)、夏德椿(Te-Chun Hsia)、徐武輝(Wu-Huei Hsu),Pigtail tube drainage in the treatment of spontaneous pneumothorax.,AMERICAN JOURNAL OF EMERGENCY MEDICINE,2003 May,3(21):241-244
SCI論文 杭良文(Liang-Wen Hang)、夏德椿(Te-Chun Hsia)、陳汶吉(Chen Wen-Chi)、陳慧毅(Huey-Yi Chen)、蔡輔仁(Fuu-Jen Tsai),TAP1 gene ACC I polymorphism is associated with atopic bronchial asthma,JOURNAL OF CLINICAL LABORATORY ANALYSIS,2003 May,(17):57-60
SCI論文 杭良文(Liang-Wen Hang)、夏德椿(Te-Chun Hsia)、陳汶吉(Chen Wen-Chi)、陳慧毅(Huey-Yi Chen)、(Jeffery J.P. Tsai)、蔡輔仁(Fuu-Jen Tsai),Interleukin-10 gene –627 allele variants, not interleukin-1 beta gene and receptor antagonist gene polymorphisms, are associated with atopic bronchial asthma.,JOURNAL OF CLINICAL LABORATORY ANALYSIS,2003 May,(00):168-173
SCI論文 夏德椿(Te-Chun Hsia)、鍾景光*,Paclitaxel affects the amounts of the N-acetylation of 2-aminofluorene and DNA-2-aminofluorene adduct formation in Sprague-Dawley rats.,IN VIVO,2003 Mar,2(17):137-144
SCI論文 夏德椿(Te-Chun Hsia)、江宏志、蔣明晃(Chiang C)、杭良文(Liang-Wen Hang)、蔡輔仁(Fuu-Jen Tsai)、陳汶吉(Chen Wen-Chi)*,Prediction of survival in surgical unresectable lung cancer by artificial neural networks including genetic polymorphisms and clinical parameters.,JOURNAL OF CLINICAL LABORATORY ANALYSIS,2003 ,(17):229-234
MT論文 黃懷緒(Huai-Hsu Huang)、許南榮(Nan-Yung Hsu)*、施志勳(Chih-Shium Shih)、陳品儒(Ping-Ru Chen)、夏德椿(Te-Chun Hsia)、杭良文(Liang-Wen Hang),Video-assisted thoracoscopic surgery for spontaneous pneumothorax in emphysematous patients,Mid-Taiwan Journal of Medicine,2003 ,8(2):78-84
Other論文 洪崇文(Chung-Wen Hung)、夏德椿(Te-Chun Hsia)*,Hyperbaric oxygen therapy is safe-Mid-Taiwan Experience,胸腔醫學,2003 ,18(2):97-102
SCI論文 夏德椿(Hsia,Te-Chun)、鍾景光(Chung, Jing-Gung)*、(Lu, H.F.)、何恒堅、(Yang, C.C.)、(Lu, K.H.)、洪啟賦,The effect of paclitaxel on 2-aminofluorene-DNA adducts formation and arylamine N-acetyltransferase activity and gene expression in human lung tumor cells (A549).,FOOD AND CHEMICAL TOXICOLOGY,2002 May,40(5):697-703
SCI論文 (Lu, K.H.)、(Lin, K.L.)、(Yang, C.C.)、夏德椿(Hsia,Te-Chun)、(Hsiao, Y.M.)、(Chou, M.C.)、何恒堅(Heng-Chien Ho)、鍾景光*,The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells.,FOOD AND CHEMICAL TOXICOLOGY,2002 May,40(5):705-713
Other論文 涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)*、林智一(Tze-Yi Lin),Ultrasound-guided transthoracic core biopsy for the diagnosis of mucosa-associated lymphoid tissue lymphoma (MAL toma) of the lung- a case report,胸腔醫學,2002 Apr,17(2):172-177
MT論文 (Yung-Hao Yu)、夏德椿(Te-Chun Hsia)、杭良文(Liang-Wen Hang)、林智一(Tze-Yi Lin)、許南榮(Nan-Yung Hsu)、(Der-Yuan Wang),Localized pulmonary hemorrhage associated with massive hemoptysis:report of a case.,Mid-Taiwan Journal of Medicine,2002 ,(7):113-117
Other論文 (Chien-Ming Liu)、(Liang-Wen Hang)、夏德椿(Te-Chun Hsia),Tracheal stenosis Demonstrated by computerized tomography with 2-Dimensional and 3-Dimensional reconstruction,胸腔醫學,2002 ,4(4):380-386
Other論文 梁文敏(Liang,Wen-Miin)、陳建仲(Chen JJ)、張郁瑩(Chang YY)、王昶弼(Wang CB)、夏德椿(Te-Chun Hsia)、杭良文(Liang-Wen Hang)、(Yen CC)、李長興(Lee CH)、陳怡文(Chen IW)、施富金(Shih FJ),Application of Qualitative Focus Group Method in Measuring Health Related Quality of Life in Persons with Chronic Obstructive Pulmonary Disease,台灣醫學,2002 ,6(2):201-208
SCI論文 鍾景光、夏德椿(Te-Chun Hsia)、(Hsiu-Man Kuo)、(Yu-Ching Li)、(Yin-Min Lee)、(Song-Shei Lin)、(Chi-Fu Hung),Inhibitory actions of luteolin on the growth and arylamine N-acetyltransferase activity in strains of Helicobacter pylori from ulcer patients,TOXICOLOGY IN VITRO,2001 Jul,15(3):191-198
Other論文 (Ko-Hsiu Lu)、(Keh-Liang Lin)、夏德椿(Te-Chun Hsia)、(Jing-Gung Chung),Tamoxifen inhibits arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human leukemia HL-60 cells,Research Communications in Molecular Pathology and Pharmacology,2001 Jan,109(109):319-331
Other論文 (張堯欽)、夏德椿(Hsia,Te-Chun)、王子源(Tzu Yuan Wang)、許南榮(Hsu,Nan-Yung),Polysomnography as monitoring Management of obstructive sleep apnea in Madelung’ disease,胸腔醫學,2001 ,16(3):207-211
SCI論文 王德源、(楊泮池)、(余文良)、夏德椿(Hsia,Te-Chun)、郭憲文(Kuo,Hsien-Wen)、許南榮(Hsu,Nan-Yung),Comparison of Different Diagnostic Methods for Lupus Pleuritis and Pericarditis :A Prospective Three-year Study.,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2000 ,99():375-380
MT論文 夏德椿(Te-Chun Hsia)*、杭良文(Liang-Wen Hang)、王德源(Der-Yean Wang)、顏至慶(Chih- Chihng Ten)、Shwen Yang(Shwen Yang),Home Mechanical Ventilation in Central Taiwan:Experiences at china Medical College Hospital,Mid-Taiwan Journal of Medicine,2000 ,5(4):248-255
 
研討會論文/Conference Papers
(發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目)
1﹒ 第二代EGFR TKI與Osimertinib 在晚期表皮生長因子突變的非小細胞肺癌病人治療的比較:一項真實世界之觀察性研究,2023 台灣胸腔暨重症加護醫學會年會,台大醫院國際會議中心,2023.12.9 ~ 2023.12.10,
2﹒ Impact of smoking on the outcome of Immune Checkpoint Inhibitor Treatment in High PD-L1 Expression Non-squamous Non-small-cell Lung Cancer Patients: A Real-World Observational Study,2023台灣胸腔暨重症加護醫學會年會,台大國際會議中心,2023.12.9 ~ 2023.12.10,
3﹒ The clinical feature and optimal treatment strategy of bone metastasis in EGFR mutated NSCLC patients,European Respiratory Society (ERS) International Congress 2023,米蘭,2023.9.9 ~ 2023.9.13,
4﹒ Afatinib vs Dacomitinib as first line treatment in advanced EGFR mutated NSCLC patients : An observational study,2023 Lung Cancer Summer Summit,台北寒舍艾美酒店,2023.7.8 ~ 2023.7.9,
5﹒ 肺部鱗狀細胞癌,接受 Nivolumab 後併發乾癬,台灣內科醫學會111年會員大會暨學術演講會,台大醫院國際會議中心,2022.12.3 ~ 2022.12.4,
6﹒ Using business intelligence real-time visualization system for improving outcomes in chronic obstructive pulmonary disease patients.,台灣胸腔暨重症加護醫學會年會,高雄萬豪酒店8F,2022.12.10 ~ 2022.12.11,
7﹒ Endobronchial ultrasound-guided transbronchial mini forceps biopsy (TBMFB) from cytologic to histopathologic specimens,台灣胸腔暨重症加護醫學會年會,高雄萬豪酒店8F,2022.12.10 ~ 2022.12.11,
8﹒ Ergosta 7, 9 (11), 22 trien 3 ol Interferes with TLR4 Co Receptors and activates Nrf2 antioxidative signaling to attenuate the Inflammatory effects in vitro and Drosophila,21st International Congress of International Society for Ethnopharmacology (ISE),Taichung, Taiwan,2022.5.28 ~ 2022.5.31,
9﹒ L858R突變的轉移性肺腺癌患者使用dacomitinib加bevacizumab 聯合治療-病例報告,2021台灣胸腔暨重症加護醫學會年會暨第18屆第2次會員大會,台中榮民總醫院研究大樓、教學大樓,2021.12.11 ~ 2021.12.12,
10﹒ Cancer Exosomal Micrornas from Cisplatin-Erlotinib Double-resistant Lung Cancer Cells Contribute to Therapeutic Resistance for Parental Cells,14th Meeting of the Asia Pacific Federation of Pharmacologists,Taipei International Convention Center TICC,2021.11.26 ~ 2021.11.29,
11﹒ Ergosta 7,9(11),22 trien 3 β ol Attenuates Inflammatory Responses via Inhibiting TLR4/MAPK/AP 1 Induced IL 6/JAK/STAT Pathways and Activating Nrf2/HO 1 Signaling in LPS Stimulated Macrophage Like Cells,2021台灣國際創新生物醫學峰會,台灣 台中 中國醫藥大學水湳新校區,2021.11.19 ~ 2021.11.20,
12﹒ Role of genotype/phenotype of chitinase 3-like 1 in Taiwan allergic and non-allergic asthma,2020年中西醫整合系列學術研討會,中國醫藥大學,2020.12.20 ~ 2020.12.20,
13﹒ Significant association of MMP2 promoter genotypes to asthma susceptibility in Taiwan,2020年中西醫整合系列學術研討會,中國醫藥大學,2020.12.20 ~ 2020.12.20,
14﹒ Significant association of CCND1 promoter genotypes to asthma susceptibility in Taiwan,2020年中西醫整合系列學術研討會,中國醫藥大學,2020.12.20 ~ 2020.12.20,
15﹒ The significant interaction of excision repair cross-complementing group 1 genotypes and smoking to lung cancer risk,2020年中西醫整合系列學術研討會,中國醫藥大學,2020.12.20 ~ 2020.12.20,
16﹒ The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer,2019 International Research Forum on Biology and Medical Science,Kaohsiung,2019.8.22 ~ 2019.8.25,
17﹒ The Effects and Mechanisms of Prunella Vulgaris Extracts on Human Lung Cancer Cells,2019 International Research Forum on Biology and Medical Science,Kaohsiung,2019.8.22 ~ 2019.8.25,
18﹒ Interleukin-18 Promoter Genotype is Associated with The Risk of Nasopharyngeal Carcinoma in Taiwan,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
19﹒ Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
20﹒ Association of Polymorphisms in DNA Repair Gene XRCC3 with Asthma in Taiwan,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
21﹒ The Efficacies and Signaling Network of Phenethyl Isothiocyanate Plus Gefitinib to Induce Cell Apoptosis of NF-kB-Overexpression Human NSCLC Cells,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
22﹒ The Contribution of Interleukin-8 Genotypes and Expression to Nasopharyngeal Cancer Susceptibility in Taiwan,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
23﹒ The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
24﹒ The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
25﹒ The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Prostate Cancer in Taiwanese Patients,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
26﹒ The Contribution of Double Strand Break Repair Gene NBS1 Genotypes to Taiwan Adult Asthma,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
27﹒ Association of Matrix Metalloproteinase-7 Genotypes to the Risk of Oral Cancer in Taiwan,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
28﹒ The Contribution of MMP-7 Promoter Polymorphisms to Taiwan Lung Cancer Susceptibility,第34屆生物醫學聯合學術年會,國防醫學院,2019.3.23 ~ 2019.3.24,
29﹒ The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Breast Cancer,第34屆生物醫學聯合學術年會,國防醫學院,2019.2.23 ~ 2019.3.24,
30﹒ The Effects and Mechanisms of Prunella Vulgaris Extracts on Human Lung Cancer Cells,Fifteenth International Symposium on Recent Advances in Environmental Health Research,Marriott Hotel, Jackson, MS,2019.2.17 ~ 2019.2.20,
31﹒ Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect: A single-Center, Pilot, Prosepctive, Double-Blinded, Randomized Controlled TCM Reserarch,2018年成果發表暨國際研討會-癌症預防與治療發展之國際趨勢,台灣台北,2018.12.1 ~ 2018.12.1,
32﹒ Conventional treatment integrated with Chinese herbal medicine improves the survival of patients with advanced non-small cell lung cancer,第19屆國際東洋醫學學術大會,National Taiwan University Hospital International Convention Center,2018.11.24 ~ 2018.11.26,
33﹒ The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes to Taiwan Lung Cancer Risk,33屆生物醫學聯合學術年會,國防醫學院,2018.3.24 ~ 2018.3.25,
34﹒ Dithiothreitol Enhanced Arsenic-Trioxide-Induced Cell Apoptosis in Cultured Oral Cancer Cells via Mitochondrial Dysfunction and Endoplasmic Reticulum Stress,33屆生物醫學聯合學術年會,國防醫學院,2018.3.24 ~ 2018.3.25,
35﹒ Novel Association of MMP-8 Promoter Polymorphisms with Lung Cancer Risk,33屆生物醫學聯合學術年會,國防醫學院,2018.3.24 ~ 2018.3.25,
36﹒ Overall Evaluation of the Interleukin-12 Genotypes Association to Asthma risk in Taiwan,33屆生物醫學聯合學術年會,國防醫學院,2018.3.24 ~ 2018.3.25,
37﹒ Contribution of Matrix Metalloproteinase-7 Genotypes to the Risk of Non-solid Tumor, Childhood Leukemia,33屆生物醫學聯合學術年會,國防醫學院,2018.3.24 ~ 2018.3.25,
38﹒ Association of Asthma Risk in Patients with Primary Sjögren's Syndrome: a retrospective cohort study,33屆生物醫學聯合學術年會,國防醫學院,2018.3.24 ~ 2018.3.25,
39﹒ A Novel Association that Uterine Leiomyoma Patients Exhibited High Incidence but Low Mortality Rate for Breast Cancer in Taiwan,33屆生物醫學聯合學術年會,國防醫學院,2018.3.24 ~ 2018.3.25,
40﹒ Is the subjective assessment of the objective clinical test of respiratory therapy consistent with the prediction scale?,The 11th intercostal respiratory therapy and critical care assembly (IRTCCA),中國陝西省西安市,2017.8.11 ~ 2017.8.12,
41﹒ Risk of Chronic Obstructive Pulmonary Disease in Women of Reproductive Age with Pelvic Inflammatory Disease: A Nationwide Population-Based Cohort Study,American Thoracic Society International Conference (ATS 2017),Walter E. Washington Convention Center, Washington, DC,2017.5.19 ~ 2017.5.24,
42﹒ Contribution of DNA Double-strand Break Repair XRCC3 Genotypes, Gender, and Smoking Behavior to Lung Cancer Risk in Taiwan,第32屆生物醫學聯合學術年會,國防醫學院,2017.3.25 ~ 2017.3.26,
43﹒ Association of Tissue Inhibitor of Metalloproteinase-1 Genotypes with Lung Cancer Risk in Taiwan,第32屆生物醫學聯合學術年會,國防醫學院,2017.3.25 ~ 2017.3.26,
44﹒ Interleukin-10 Promoter Genotypes as Novel Early Detective Biomarkers for Asthma in Taiwan,第32屆生物醫學聯合學術年會,國防醫學院,2017.3.25 ~ 2017.3.26,
45﹒ Organizational Tenure and OSCE Performance in Two-year Trainees of Respiratory Therapist,第十屆海峽兩岸呼吸治療論壇暨武漢市醫師協會重症醫師分會(1+8城市圈)學術年會,中國湖北省武漢市,2016.9.9 ~ 2016.9.11,
46﹒ The contribution of Interleukin-10 promoter genotypes to adult asthma susceptibility,第31屆生物醫學聯合學術研討會,國防醫學院,2016.3.26 ~ 2016.3.27,
47﹒ Contribution of genotype of DNA double-strand break repair gene XRCC3, gender, and smoking behavior to lung cancer risk in Taiwan,第31屆生物醫學聯合學術研討會,國防醫學院,2016.3.26 ~ 2016.3.27,
48﹒ ,內科醫學會中部地區二月份地方會,中國醫藥大學立夫教學大樓102教室,2016.2.20 ~ 2016.2.20,A Case of Adrenal Insufficiency
49﹒ Cryoextraction: A Feasible Approach to Remove Aspirated Tooth in A Traumatic Patient with Respiratory Failure,American Thoracic Society 2015 International Conference,Denver Colorado Convention Center,2015.5.15 ~ 2015.5.20,
50﹒ A Novel Promoter Polymorphism on Interleukin-10 was Associated with Taiwan Lung Cancer Risk, especially among Males and Smokers,第30屆生物醫學聯合學術研討會,國防醫學院,2015.3.21 ~ 2015.3.22,
51﹒ DNA Repair Gene XRCC7 Genotypes were associated with Lung Cancer Risk Among Males and Smokers in Taiwan,第30屆生物醫學聯合學術研討會,國防醫學院,2015.3.21 ~ 2015.3.22,
52﹒ TrichostatinA Suppresses EGFR Expression through Induction of MicroRNA-7 in an HDAC-Independent Manner in Lapatinib-Treated Cells,50th EMBO conference-cellular signalling and cancer therapy,Cavtat, Croatia,2014.5.23 ~ 2014.5.27,
53﹒ Interaction of Ataxia Telangiectasia Mutated (ATM) Genotypes and Smoking Habits and Their Contribution to Lung Cancer Risk,第29屆生物醫學聯合學術研討會,國防醫學院,2014.3.15 ~ 2014.3.16,
54﹒ Synergistic Effects of DNA Apurinic/apyrimidinic Endonuclease Genotype and Smoking Habit on Lung Cancer Risk,第29屆生物醫學聯合學術研討會,國防醫學院,2014.3.15 ~ 2014.3.16,
55﹒ Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells,2013 International Symposium on Clinical and Translational Cancer Research,台北榮總,2013.9.28 ~ 2013.9.28,
56﹒ Interaction of cyclin D1 genotype and smoking habit in lung cancer,台灣調適科學會第三屆會員大會暨2012傳統中藥與環境壓力調適國際研討會,中國醫藥大學,2012.4.21 ~ 2012.4.22,
57﹒ Interaction of CCND1 Genotype and Smoking Habit in Taiwan Lung Cancer Patients.,第27屆生物醫學聯合學術年會,國防醫學院,2012.3.17 ~ 2012.3.13,
58﹒ Kinase-inactive EGFR stabilizes COX-2 mRNA to mediate lapatinib-promoted aggressiveness of triple-negative breast cancer cells,國際癌症轉譯醫學研究學術研討會暨第十五屆台灣癌症臨床研究合作組織年會,中央研究院人文社會科學館國際會議廳,2011.11.20 ~ 2011.11.21,
59﹒ The genetic role of cyclooxygenase 2 in Taiwan lung cancer patients,第二屆調適醫學聯合學術年會,臺北市立體育學院,2011.4.9 ~ 2011.4.10,
60﹒ Interaction of Cyclooxygenase 2 Genotype and Smoking Habit in Taiwanese Lung Cancer Patients,第 26 屆生物醫學聯合學術年會,國防醫學院致德廳一樓,2011.3.19 ~ 2011.3.20,
61﹒ Validity of the Chinese version of the EORTC QLQ-C30 and QLQ-LC13 in predicting mortality in patients with lung cancer,19th World Conference of Family Doctors,Cancun, Mexico,2010.5.19 ~ 2010.5.23,
62﹒ ,2009中華民國高壓暨海底醫學會秋季會,中國醫藥大學附設醫院癌症大樓1樓階梯教室,2009.9.12 ~ 2009.9.12,高壓氧治療之罕見併發症-病例報告及文獻回顧
63﹒ 急性一氧化碳中毒後的皮質視盲與視覺辦物不能-病例報告,高壓暨海底醫學會98年會員大會,國軍左營總醫院醫療大樓一樓大廳,2009.6.7 ~ 2009.6.7,
64﹒ 高壓氧治療與口腔癌再發生之關連性-臨床回顧研究,Internation conference of geriatric emergency & critical care,台北,2008.12.13 ~ 2008.12.14,
65﹒ 高壓氧治療後天竺鼠耳膜形態與耳蝸一氧化氮合成酶的改變,台灣耳鼻喉科醫學會第85屆學術演講會,台大醫院國際會議中心,2008.11.8 ~ 2008.11.9,
66﹒ 高壓氧治療與口腔顎性腫瘤再發的關聯性-回顧性臨床研究,中華民國口腔顎面外科學會第二十次學術研討會,中國醫藥大學立夫教學大樓,2008.3.15 ~ 2008.3.16,
67﹒ Induction of apoptosis by rhein via reactive oxygen species production, GADD153 expression, and caspase-3 activation in human lung cancer A-549 cells,12th World Conference on lung cancer,Seoul, Korea,2007.9.2 ~ 2007.9.6,
68﹒ Dose-Finding and Phase II Study of Weekly Docetaxel and Cisplatin as First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC),12th World Conference on lung cancer,Seoul, Korea,2007.9.2 ~ 2007.9.6,
69﹒ Cause of Patients with Acute Carbon Monoxide Intoxication in Mid-Taiwan,中華民國高壓氧暨海底醫學會第五屆第二次會員大會,三軍總醫院,2007.6.17 ~ 2007.6.17,
70﹒ Sleep disorders in the children with prader-willi syndrome: the polysomnographic findings,胸腔暨重症加護醫學會九十四年度會員大會季學術研討會,台灣台北市,2006.12 ~ ,
71﹒ Interventional pulmonology with airway stent for tracheobronchial stenosis,95年胸腔重症加護年會,台灣台北市,2006.12 ~ ,
72﹒ Clinical outcome of pig-tail catheter drainage for primary and secondary spontaneous pneumothorax,2006年胸腔病年會,台灣台北市,2006.12 ~ ,
73﹒ C-reactive protein and outcome of cirrhotic patients with infective pleural effusions in child-turcotte-pugh b and c,2006年胸腔病年會,台灣台北市,2006.12 ~ ,
74﹒ Association of p53 codon 72 polymorphism with risk of lung cancer in taiwan,11th congress of the asian pacific society of respirology(APSR),日本京都,2006.11 ~ ,
75﹒ Bacteriology and outcome analysis of cirrhotic patients with infective pleural effusions,11th congress of the asian pacific society of respirology(APSR),日本京都,2006.11 ~ ,
76﹒ The role of Ca2+ on the rhein-induced apoptosis via caspase-3 activation in human lung cancer A-549 cells.,APSR 2006,京都,2006.11.19 ~ 2006.11.22,The role of Ca2+ on the rhein-induced apoptosis via caspase-3 activation in human lung cancer A-549 cells
77﹒ A retrospective analysis of the bacteriology of complicated parapneumonic effusions or empyemas in a tertiary hospital: emphasis on the increasing incidence of aerobic gram-negative pathogens,歐洲胸腔年會,德國慕尼黑,2006.9 ~ ,
78﹒ A retrospective analysis of the bacteriology of complicated parapneumonic effusions or empyemas in a tertiary teaching hospital: emphasis on the increasing incidence of aerobic gram-negative pathogen.,16th ERS Annual Congress,Munich, Germany,2006.9.3 ~ 2006.12.6,
79﹒ Month experience thoracic empyema in a tertiary hospital: emphasis on different bacteriology and outcome between medical ICU and general ward,American thoracic society 2006 international conference,美國聖地牙哥,2006.5 ~ ,
80﹒ Urinary 8-hydroxydeoxyguanosine excretion relates to outcome of septic patients in medical intensive care unit,American Thoracic Society international Conference,美國聖地牙哥,2006.5 ~ ,
81﹒ CLINICAL SIGNIFICANCY OF URINARY 8-HYDROXY-2’-DEOXYGU-ANOSINE RELATED TO NON-ALCOHOLIC FATTY LIVER DISEASE IN TAIWAN-PRELIMINARY REPORT ,中華民國九十五年消化系聯合學術演講年會,台灣台南,2006.3 ~ ,
82﹒ Urinary 8-hydroxy-2’-deoxyguanosine related to the prognosis of septic patients in intensive care unit,台灣胸腔暨重症加護醫學會94年度會員大會暨學術研討會,台灣台北,2005.12 ~ ,
83﹒ Cause of death in acute carbon monoxide intoxication patients in mid-taiwan,台灣胸腔暨重症加護醫學會94年度會員大會暨學術研討會,台灣台北市,2005.12 ~ ,
84﹒ Sonographic septation: a useful diagnostic predictor in lymphocyte-rich exudative pleural effusions-- tuberculosis or lung cancer,九十四年度會員大會季學術研討會,台灣台北市,2005.12 ~ ,
85﹒ Analysis of the factors associated with clinical outcomes for ventilator-dependent patients in RCW,胸腔暨重症加護醫學會九十四年度會員大會季學術研討會,台灣台北市,2005.12 ~ ,
86﹒ Pig-tail drainage for primary spontaneous pneumothorax: dose the position influence the treatment result,Eur Respir J,丹麥哥本哈根,2005.9 ~ ,
87﹒ Polymorphism in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer(NSCLC),Eur Respir J,丹麥哥本哈根,2005.9 ~ ,
88﹒ Combined pleural CRP and chest ultrosonography for discrimination between tuberculous and malignant pleural effusion,Eur Respir J,丹麥哥本哈根,2005.9 ~ ,
89﹒ Aloe-emodin inhibit N-Acetyltransferase activity and gene expression in Human lung cancer cell line(NCI-H209),11th World Conference on Lung Cancer,西班牙巴塞隆納,2005.7 ~ ,
90﹒ N-Acetyltransferase activity and gene expression in Human lung cancer cell line(NCI-H209),11th World Conference on lung cancer,Barcelona, Spain,2005.7.3 ~ 2005.7.6,
91﹒ Down-regulation of Membrane Potential of Mitochondria by Chrysophanic Acid Promotes Human Breast Cancer CellEntry into the Apoptosis透過大黃酚(chrysophan01)對粒線體膜電位的抑制來刺激人類乳癌細胞產生細胞凋亡,20屆天然藥物研討會,國立中國醫藥研究所,2005.6.24 ~ 2005.6.25,
92﹒ Change of urinary excretion of 8-hydroxydeoxyguanosine inservere OSAS afterover night CPAP treatment,3rd SLEEP RESPIRATION FORUM第三屆亞東睡眠論壇,台灣台北,2005.3 ~ ,
93﹒ Application of 201tl chest spect to differentate thoracic malignancies from benign lesions: comparison with ct results,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
94﹒ Power ultasound"noise sign": comparable with ultrasound"gliding sign"for diagnosing pneumothorax,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
95﹒ Salmeterol/fluticasone(250inhalation therapy dose improve symptom scores in moderate to very severe chronic obstructive pulmonary disease patients- the experience in china medical university hospital,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
96﹒ Tissue harmonic imaging in 272 pleural effusion: conventional gray-scale sonography,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
97﹒ Computer-aided detection/diagnosis of ling lesions by dual phase tl-201 spect images,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
98﹒ Successful treatment of delayed neuropsy chiatric sequelae in carbon monoxide intoxication patient with hyperbaric oxygen-a case report,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
99﹒ vessel signals in thoracic lesions abutting pulsatile organs: imaging comparison between dynamic flow us, color dopp;er us and power us,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
100﹒ Pig-tail drainage for primary spontaneous pneumothorax: does the position influence the treatment result?,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
101﹒ Assessment of clinical guidelines for severe community-acquired pneumonia in young adults,台灣胸腔暨重症加護醫學會93年度會員大會暨學術研討會,台灣台北,2004.12 ~ ,
102﹒ Salmeterol/fluticasone (250) inhalation therapy dose improve symptom scores in moderate to very severe chronic obstructive pulmonary disease patients- the experience in China Medical University Hospital,台灣胸腔暨重症加護醫學會93年度第12屆第3次會員大會暨學術研討會,台灣台北,2004.12 ~ ,
103﹒ Salmeterol/fluticasone (250) inhalation therapy dose improve symptom scores in moderate to very severe chronic obstructive pulmonary disease patients- the experience in China Medical University Hospital,台灣胸腔暨重症加護醫學會93年度第12屆第3次會員大會暨學術研討會,台灣台南,2004.12 ~ ,
104﹒ Berberine induced in vitro G2/M arrest of cell cycle and apoptosis in human gastric cancer SNU-5 cells.,Seventh international Conference of Anticancer Research,希臘,科孚(Corfu,Greece),2004.10.25 ~ 2004.10.30,
105﹒ The relationships among characteristics of tongue diagnosis in TCM and quality of life in COPD patients, Quality of Life Research 2004,13(9),1569~1569,The 11th Annual Conference of ISOQOL,Hong Kong,2004.10.16 ~ 2004.10.19,
106﹒ 以項目反應理論探討COPD患者WHOQOL-BREF,2004生活品質研討會生活品質之觀念與測量,台灣台中市,2004.7 ~ ,
107﹒ 以項目反應理論探討COPD患者WHOQOL-BREF題目之心理計量特質, 2004生活品質研討會, 55~55,2004生活品質研討會,Taichung, Taiwan,2004.7.17 ~ 2004.7.17,
108﹒ Sleep Quality in chronic ventilator dependent patient,台灣睡眠醫學學會九十三年度會員大會,中華民國台 北,2004.3 ~ ,
109﹒ Application of 201T1 cheat SPECT to differentiate thoracic malignancies from benign lesions:comparison,胸腔醫學會年會,台灣台南,2003.12 ~ ,
110﹒ Luteolin induce apoptosis in human lung cancer cell line (A-549) through activation of caspase-3 and p53,10th world conference on lung cancer,Vancouver, Canada,2003.8.10 ~ 2003.8.14,
111﹒ ,Oncology Regional Medical Conference,Hanoi, Vienam,2002.11.23 ~ 2002.11.24,Treatment of advanced NSCLC with Gemcitabine – The experience in Middle Taiwan
 
研究計畫/Research Grant
(研究類型,研究計畫代號,主持人,補助或委託單位名稱,計畫名稱,研究經費,計畫期間)
1﹒ 個別型,CMU112-ASIA-03,夏德椿(Te-Chun Hsia),夏寧憶(Ning-Yi Hsia)、蒙美津,本校(含附醫),中醫藥研究與新穎藥物開發平台,$600000,2023.8.1 ~ 2024.7.31
2﹒ 個別型,CMU111-ASIA-02,夏德椿(Te-Chun Hsia),夏寧憶(Ning-Yi Hsia)、蒙美津,本校(含附醫),中醫藥研究與新穎藥物開發平台,$600000,2022.8.1 ~ 2023.7.31
3﹒ 個別型,DMR-112-026,夏德椿(Te-Chun Hsia),包大靝(Da-Tian Bau),附醫院內計畫,a-紅沒藥醇毒殺非小細胞肺癌之機制探究,$200000,2022.8.1 ~ 2023.7.31
4﹒ 個別型,CMU110-ASIA-05,夏德椿(Te-Chun Hsia),夏寧憶(Ning-Yi Hsia)、蒙美津,本校(含附醫),中醫藥研究與新穎藥物開發平台,$550000,2021.8.1 ~ 2022.7.31
5﹒ 個別型,DMR-111-036,夏德椿(Te-Chun Hsia),附醫院內計畫,蔓荊子黃素奈米微粒於CD44高量表現之非小細胞肺癌細胞中之凋亡與自噬之交互作用,$300000,2021.8.1 ~ 2022.7.31
6﹒ 個別型,無,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、楊啟瑞(Chi-Rei Yang)、楊美都(Mei-Due Yang)、謝明家、方信元(Hsin-Yuan Fang)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、張維君(Wei-Chun Chang)、葉士芃(Shih-Peng Yeh)、劉良智(Liang-Chih Liu)、柯道維(Tao-Wei Ke)、林振源(Lin, Chen-Yuan)、陳自諒(Tzu-Liang Chen)、張兆祥(Chao-Hsiang Chang)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、林文元(Wen-Yuan lin)、花俊宏(Chun-Hung Hua)、孟乃欣(Nai-Hsin Meng)、王約翰(John Wang)、徐華穗(Hua-Shai Hsu)、蔡伯邦(Po-Pang Tsai)、陳育傑(Yu-Chieh Chen)、王帝皓(Ti-Hao Wang)、吳博倫(Po-Lun Wu)、謝清昀(Ching-Yun Hsieh)、陳芮筠(Rui-Yun Chen)、林昭君(Chao-Chun Lin)、莊素蓉(Su-Jung Chuang),衛福部,110年全方位癌症防治策進計畫,$9754280,2021.1.1 ~ 2021.12.31
7﹒ 個別型,CMU109-MF-40,林香汶(Hsiang-Wen Lin),林志學(Chih-Hsueh Lin)、葉士芃(Shih-Peng Yeh)、簡君儒(Chun-Ru Chien)、葉子裴(Tzu-Pei Yeh)、李采娟(Tsai-Chung Li)、夏德椿(Te-Chun Hsia)、李佳霙(Chia-Ing Li)、謝右文(Yow-Wen Hsieh)、林振源(Lin, Chen-Yuan)、陳育傑(Yu-Chieh Chen)、劉良智(Liang-Chih Liu)、郭錦輯(Kuo, Chin-Chi),國科會,於臨床執業中納入病人自述成效測量-癌症病人使用新科技藥品為例,$300000,2020.9.8 ~ 2021.7.31
8﹒ 個別型,CMU109-ASIA-05,余建志,夏德椿(Te-Chun Hsia)、蒙美津,本校(含附醫),肺癌抗藥研究與新穎藥物開發平台,$500000,2020.8.1 ~ 2021.7.31
9﹒ 個別型,MOST 109-2320-B-039-023,林香汶(Hsiang-Wen Lin),林志學(Chih-Hsueh Lin)、葉士芃(Shih-Peng Yeh)、簡君儒(Chun-Ru Chien)、葉子裴(Tzu-Pei Yeh)、李采娟(Tsai-Chung Li)、夏德椿(Te-Chun Hsia)、李佳霙(Chia-Ing Li)、謝右文(Yow-Wen Hsieh)、林振源(Lin, Chen-Yuan)、陳育傑(Yu-Chieh Chen)、劉良智(Liang-Chih Liu)、郭錦輯(Kuo, Chin-Chi),國科會,於臨床執業中納入病人自述成效測量-癌症病人使用新科技藥品為例,$1300000,2020.8.1 ~ 2021.7.31
10﹒ 個別型,DMR-110-029,夏德椿(Te-Chun Hsia),附醫院內計畫,外泌體內微小分子核糖核酸轉介順鉑與得舒緩雙抗藥性徵予肺癌無抗性母細胞之分子機制,$400000,2020.8.1 ~ 2021.7.31
11﹒ 個別型,無,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、楊啟瑞(Chi-Rei Yang)、楊美都(Mei-Due Yang)、謝明家、方信元(Hsin-Yuan Fang)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、洪耀欽(Yao-Ching Hung)、葉士芃(Shih-Peng Yeh)、劉良智(Liang-Chih Liu)、柯道維(Tao-Wei Ke)、林振源(Lin, Chen-Yuan)、陳自諒(Tzu-Liang Chen)、張兆祥(Chao-Hsiang Chang)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、林文元(Wen-Yuan lin)、花俊宏(Chun-Hung Hua)、孟乃欣(Nai-Hsin Meng)、王約翰(John Wang)、徐華穗(Hua-Shai Hsu)、蔡伯邦(Po-Pang Tsai)、陳育傑(Yu-Chieh Chen)、王帝皓(Ti-Hao Wang)、吳博倫(Po-Lun Wu)、謝清昀(Ching-Yun Hsieh)、陳芮筠(Rui-Yun Chen)、林昭君(Chao-Chun Lin)、莊素蓉(Su-Jung Chuang),衛福部,109年全方位癌症防治策進計畫,$10358000,2020.1.1 ~ 2020.12.31
12﹒ 個別型,MOST 106-2320-B-039-013-MY3,高尚德(Kao, Shung-Te),林麗娟(Lin, Li-Jen)、夏德椿(Hsia, Te-Chun),國科會,補腎陽方劑右歸丸與補腎陰方劑七味都氣丸對支氣管氣喘臨床療效與調 控機轉之研究,$1600000,2019.8.1 ~ 2020.7.31
13﹒ 個別型,無,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、楊啟瑞(Chi-Rei Yang)、楊美都(Mei-Due Yang)、方信元(Hsin-Yuan Fang)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、洪耀欽(Yao-Ching Hung)、葉士芃(Shih-Peng Yeh)、劉良智(Liang-Chih Liu)、柯道維(Tao-Wei Ke)、林振源(Lin, Chen-Yuan)、陳自諒(Tzu-Liang Chen)、張兆祥(Chao-Hsiang Chang)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、林文元(Wen-Yuan lin)、花俊宏(Chun-Hung Hua)、孟乃欣(Nai-Hsin Meng)、王約翰(John Wang)、徐華穗(Hua-Shai Hsu)、蔡伯邦(Po-Pang Tsai)、陳育傑(Yu-Chieh Chen)、王帝皓(Ti-Hao Wang)、吳博倫(Po-Lun Wu)、謝清昀(Ching-Yun Hsieh)、陳芮筠(Rui-Yun Chen)、林昭君(Chao-Chun Lin)、張麗銀(Li-Yin Chang)、莊素蓉(Su-Jung Chuang),衛福部,108年全方位癌症防治策進計畫,$9500000,2019.1.1 ~ 2019.12.31
14﹒ 個別型,A1051222-107,趙坤山(Kun-San Chao),邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、陳自諒(Tzu-Liang Chen)、柯道維(Tao-Wei Ke)、王輝明(Hwei-Ming Wang)、陳宏彰(Hung-Chang Chen)、黃郁純(Yu-Chuen Huang)、花俊宏(Chun-Hung Hua)、張兆祥(Chao-Hsiang Chang)、楊啟瑞(Chi-Rei Yang)、吳錫金(Hsi-Chin Wu)、黃志平(Chi-Ping Huang)、蔡宗欣(Tzong-Shin Tzai)、張議徽(Yi-Huei Chang)、梁基安(Ji-An Liang)、簡君儒(Chun-Ru Chien)、吳建廷(Chen-Teng Wu)、劉良智(Liang-Chih Liu)、吳曜充(Yao-Chung Wu)、陳芝蓉(Chih-Jung Chen)、鄭書(Yu-Shu Cheng)、方信元(Hsin-Yuan Fang)、夏德椿(Te-Chun Hsia)、李嘉翔(Chia-Hsiang Li)、陳鴻仁(Hung-Jen Chen)、劉秋松(Chiu-Shong Liu)、陳毓隆(Yu-Lung Chen)、王中儀(JONG-YI WANG),衛福部,全方位癌症照護醫病共享決策輔助工具介入及其效益評估(106-107年) 107年後續擴充,$1803511,2018.10.5 ~ 2019.10.4
15﹒ 個別型,MOST 106-2320-B-039-013-MY3,高尚德(Kao, Shung-Te),林麗娟(Lin, Li-Jen)、夏德椿(Hsia, Te-Chun),國科會,補腎陽方劑右歸丸與補腎陰方劑七味都氣丸對支氣管氣喘臨床療效與調 控機轉之研究,$1500000,2018.8.1 ~ 2019.7.31
16﹒ 個別型,MOST 107-2314-B-039-026-,簡君儒(Chun-Ru Chien),夏德椿(Te-Chun Hsia)、梁基安(Ji-An Liang),國科會,放射治療與標靶治療於體能良好之臨床IIIB期具表皮生長因子受體突變的肺腺癌病人:成本與有效性之評估,$930000,2018.8.1 ~ 2019.7.31
17﹒ 個別型,DMR-108-022,陳偉峻(Chen, Wei-Chun),夏德椿(Hsia, Te-Chun)、招明威,附醫院內計畫,桑白皮萃取物與具潛力之化療藥物協同抑制肺癌細胞效應,$300000,2018.8.1 ~ 2019.7.31
18﹒ 個別型,DMR-108-020,陳致宇(Chih-Yu Chen),林季千、夏德椿(Te-Chun Hsia)、陳偉峻(Wei-Chun chen)、林裕超(Yu-Chao Lin),附醫院內計畫,探討高良薑活性成分1,7-二(4-羥基苯基)-1,4,6-庚三烯-3-酮抗人類鱗狀細胞肺癌的功效及機轉,$500000,2018.8.1 ~ 2019.7.31
19﹒ 個別型,DMR-108-019,沈德群(Shen, Te-Chun),夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau),附醫院內計畫,研究SERPIN D1活化野生型間變性淋巴瘤激酶受體以促進非小細胞肺癌轉移的角色,$500000,2018.8.1 ~ 2019.7.31
20﹒ 個別型,A1061223,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、楊美都(Mei-Due Yang)、陳自諒(Tzu-Liang Chen)、方信元(Hsin-Yuan Fang)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、洪耀欽(Yao-Ching Hung)、葉士芃(Shih-Peng Yeh)、劉良智(Liang-Chih Liu)、張兆祥(Chao-Hsiang Chang)、柯道維(Tao-Wei Ke)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、林文元(Wen-Yuan lin)、王約翰(John Wang)、陳育傑(Yu-Chieh Chen)、張麗銀(Li-Yin Chang)、莊素蓉(Su-Jung Chuang)、孟乃欣(Nai-Hsin Meng)、花俊宏(Chun-Hung Hua)、楊啟瑞(Chi-Rei Yang)、徐華穗(Hua-Shai Hsu)、陳芮筠(Rui-Yun Chen)、蔡伯邦(Po-Pang Tsai)、林昭君(Chao-Chun Lin)、王帝皓(Ti-Hao Wang)、吳博倫(Po-Lun Wu)、謝清昀(Ching-Yun Hsieh),衛福部,107年癌症防治品質精進計畫,$11850000,2018.1.1 ~ 2018.12.31
21﹒ 個別型,MOST 106-2320-B-039-013-MY3,高尚德(Kao, Shung-Te),林麗娟(Lin, Li-Jen)、夏德椿(Hsia, Te-Chun),國科會,補腎陽方劑右歸丸與補腎陰方劑七味都氣丸對支氣管氣喘臨床療效與調 控機轉之研究,$1700000,2017.8.1 ~ 2018.7.31
22﹒ 個別型,MOST 106-2314-B-039-011-,沈德群(Te-Chun Shen),夏德椿(Hsia, Te-Chun)、包大靝(Bau, Da-Tian),國科會,介白素-33基因之單核苷酸多型性與過敏型及非過敏型氣喘發生之相關性,$766000,2017.8.1 ~ 2018.7.31
23﹒ 個別型,MOST 106-2314-B-039-022-,夏德椿(Hsia, Te-Chun),包大靝(Bau, Da-Tian),國科會,細胞激素誘發之殺手細胞療法於尖端肺癌治療之應用,$1300000,2017.8.1 ~ 2018.7.31
24﹒ 個別型,DMR-107-024,林裕超(Yu-Chao Lin),夏德椿(Te-Chun Hsia)、陳偉峻(Wei-Chun chen)、林季千(Chi-Chen Lin),附醫院內計畫,探討紫檀芪抗人類鱗狀細胞肺癌的功效及機轉,$300000,2017.8.1 ~ 2018.7.31
25﹒ 國家型,A1051222,趙坤山(Kun-San Chao),邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、陳自諒(William Tzu-Liang Chen)、柯道維(TAO-WEI KE)、花俊宏(Chun-Hung Hua)、張兆祥(Chang,Chao-Hsiang)、張議徽(Yi-Huei Chang)、梁基安(Ji-An Liang)、簡君儒(Chun-Ru Chien)、劉良智(Liu, Liang-Chih)、吳曜充(Yao-Chung Wu)、方信元(Hsin-Yuan Fang)、夏德椿(Te-Chun Hsia)、李嘉翔(Chia-Hsiang Li)、黃郁純(YU-CHUEN HUANG)、王中儀(JONG-YI WANG),衛福部,全方位癌症照護醫病共享決策輔助工具介入及其效益評估(106-107年),$1241289,2017.2.16 ~ 2018.2.15
26﹒ 國家型,A1051121,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、洪耀欽(Yao-Ching Hung)、方信元(Hsin-Yuan Fang)、楊美都(Mei-Due Yang)、葉士芃(Su-Peng Yeh)、劉良智(Liu, Liang-Chih)、張兆祥(Chang,Chao-Hsiang)、柯道維(TAO-WEI KE)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、林文元(Wen-Yuan Lin)、王約翰(John Wang)、謝右文(Yow-Wen Hsieh)、蔡麗雲(Li-Yun Tsai)、謝淑惠(Shwn-Huey Shieh)、廖惠娟(Hui-Chuan Liao)、孟乃欣(Nai-Hsin Meng)、花俊宏(Chun-Hung Hua)、楊啟瑞(Che-Rei Yang)、徐華穗(Hua-Shai Hsu)、詹佳穎(Chia-Ing Jan)、蔡伯邦(Po-Pang Tsai)、林昭君(Chao-Chun Lin)、吳博倫(Po-Lun Wu)、謝清昀(Ching-Yun Hsieh)、簡君儒(Chun-Ru Chien)、楊世能(Shih-Neng Yang)、白禮源(Li-Yuan Bai),衛福部,106醫院癌症診療品質精進計畫,$11540000,2017.1.1 ~ 2017.12.31
27﹒ 個別型,106-2-N003,黃升騰(Huang, Sheng-Teng),夏德椿(Te-Chun Hsia)、林宏任(Lin Hung-jen)、何文照(Wen-Chao Ho)、王禎佑(WANG,CHEN-YU),衛福部,106年度「常見疾病之中醫證型研究」科技委託研幾究計畫,$1150000,2017.1.19 ~ 2018.1.18
28﹒ 臨床試驗與研究計畫,CMUH104-REC1-080,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,對於曾接受含鉑化療之第4期鱗狀非小細胞肺癌患者,使用Abemaciclib (LY2835219) 相較於Docetaxel治療的一項隨機分配第2期試驗,$1012270,2017.1.1 ~ 2017.12.31
29﹒ 臨床試驗與研究計畫,CMUH105-REC3-108,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,針對上皮細胞生長因子受體 (EGFR) 突變、T790M 陰性且第一線(1L) EGFR 酪胺酸激酶抑制劑治療失敗的第四期或復發性非小細胞肺癌 (NSCLC) 受試者,給予Nivolumab (BMS-936558) 加 Pemetrexed/鉑 (platinum) 或 Nivolumab 加 Ipilimumab (BMS-734016),相較於 Pemetrexed 加鉑之開放性、隨機分配試驗,$18914008,2017.1.1 ~ 2017.12.31
30﹒ 臨床試驗與研究計畫,CMUH105-REC2-076,夏德椿(Hsia, Te-Chun),附醫廠商計畫,RealGiDo:使用Gi(1)otrif®作為未接受過酪氨酸激酶抑製劑(TKI)且伴隨EGFR活化性突變的晚期非小細胞肺癌患者之第一線治療劑量調整之現實生活數據,$114131,2017.1.1 ~ 2017.12.31
31﹒ 臨床試驗與研究計畫,CMUH106-REC2-057,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,一項比較 REGN2810(抗 PD 1 抗體)和含鉑化療作為第一線療法治療晚期或轉移性 PD-L1陽性之非小細胞肺癌患者的全球性、隨機分配、第三期開放性試驗,$5281002,2017.1.1 ~ 2017.12.31
32﹒ 臨床試驗與研究計畫,CMUH106-REC2-074,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih)、陳致宇(Chih-Yu Chen),附醫廠商計畫,一項隨機分配、雙盲、安慰劑對照、第3期試驗,在罹患廣泛期小細胞肺癌的受試者中,研究rovalpituzumab tesirine作為第一線含鉑化療後之維持療法 (MERU),$7032356,2017.1.1 ~ 2017.12.31
33﹒ 臨床試驗與研究計畫,CMUH106-REC2-096,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、林裕超(Lin, Yu-Chao)、李嘉翔(Li, Chia-Hsiang),附醫廠商計畫,一項第三期、隨機分配、雙盲、安慰劑對照試驗,以Pembrolizumab(MK-3475/SCH900475)合併Etoposide/ 鉑類藥物 (Cisplatin或Carboplatin)作為擴散期小細胞肺癌受試者的第一線治療(KEYNOTE-604),$2444661,2017.1.1 ~ 2017.12.31
34﹒ 臨床試驗與研究計畫,CMUH106-REC2-037,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、林裕超(Lin, Yu-Chao)、李嘉翔(Li, Chia-Hsiang)、陳致宇(Chih-Yu Chen),附醫廠商計畫,一項第一/二期、開放標示、多中心試驗,在先前接受表皮生長因子受體酪胺酸激酶抑制劑治療後惡化的局部晚期或轉移性非小細胞肺癌患者中,評估每日口服一次HS-10296的安全性、耐受性、藥物動力學及療效,$7373888,2017.1.1 ~ 2017.12.31
35﹒ 臨床試驗與研究計畫,CMUH106-REC2-098,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,一項第三期、隨機分配、多中心、開放標示、對照試驗,目的為評估Durvalumab 或 Durvalumab 加上 Tremelimumab 併用含鉑化療,做為擴散期 (第四期) 小細胞肺癌 (SCLC) 患者第一線治療的療效,$3563327,2017.1.1 ~ 2017.12.31
36﹒ 臨床試驗與研究計畫,CMUH106-REC3-122,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,全球性第三期、隨機分配、多中心、開放標記、含對照的臨床試驗,評估 Durvalumab 或 Durvalumab 加上 Tremelimumab 併用含鉑化療,做為轉移性非小細胞肺癌 (NSCLC) 患者的第一線治療 (POSEIDON),$6051308,2017.1.1 ~ 2017.12.31
37﹒ 臨床試驗與研究計畫,CMUH106-REC3-121,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、林裕超(Lin, Yu-Chao)、李嘉翔(Li, Chia-Hsiang)、陳韋成(Chen Wei-cheng),附醫廠商計畫,一項針對先前未接受過治療且腫瘤為PD-L1陽性(TPS ≥ 50%)之第四期轉移性非小細胞肺癌受試者,比較Pembrolizumab加上Ipilimumab與Pembrolizumab加上安慰劑的第三期、隨機分配、雙盲試驗(KEYNOTE-598),$2817827,2017.1.1 ~ 2017.12.31
38﹒ 臨床試驗與研究計畫,CMUH106-REC2-132,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、林裕超(Lin, Yu-Chao)、陳家弘(Chen, Chia-Hung)、李嘉翔(Li, Chia-Hsiang),附醫廠商計畫,對轉移性非小細胞肺癌患者以pembrolizumab (MK-3475)加上epacadostat (INCB024360)單獨使用或併用含鉑化療作為第一線療法,並與pembrolizumab加上含鉑化療搭配安慰劑進行比較的隨機分配第三期試驗,$3512131,2017.1.1 ~ 2017.12.31
39﹒ 臨床試驗與研究計畫,CMUH105-REC2-113,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,一項針對 ALK 陽性晚期肺癌病患使用 Brigatinib (AP26113) 對比 Crizotinib 的第 3 期、多中心、開放標示試驗,$1485033,2017.1.1 ~ 2017.12.31
40﹒ 臨床試驗與研究計畫,DMR100-IRB-207,夏德椿(Hsia, Te-Chun),附醫廠商計畫,針對具有上皮生長因子接受器活化性突變的第四期非鱗狀非小細胞肺癌病患,比較Pemetrexed併用Gefitinib相對於單獨使用Gefitinib作為第一線治療藥物之第二期隨機臨床試驗。,$2386633,2017.1.1 ~ 2017.12.31
41﹒ 臨床試驗與研究計畫,DMR101-IRB1-245,夏德椿(Hsia, Te-Chun),附醫廠商計畫,合併TS-1 與Cisplatin 用以治療進展性(第三期b 或四期)非小細胞肺癌(NSCLC)病患之臨床試驗,$641584,2017.1.1 ~ 2017.12.31
42﹒ 臨床試驗與研究計畫,CMUH102-REC2-060,夏德椿(Hsia, Te-Chun),附醫廠商計畫,一項隨機分配、對照、第二期試驗,評估 LY2875358 加上 Erlotinib,相較於 Erlotinib,做為第一線治療,用於帶有活化EGFR突變,經過8週Erlotinib導入治療後,病情獲得控制之轉移非小細胞肺癌患者的療效,$1917596,2017.1.1 ~ 2017.12.31
43﹒ 臨床試驗與研究計畫,CMUH104-REC1-126,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,晚期非小細胞肺癌的多中心、開放性、單一組別第二期試驗 副標題:一項多中心、開放性、單一組別第二期試驗,於不適合根除性放射療法且對含鉑化療療程產生抗藥性之第IIIB/IV期或復發性非小細胞肺癌患者,評估ONO-4538的安全性及療效,$6322758,2017.1.1 ~ 2017.12.31
44﹒ 臨床試驗與研究計畫,CMUH102-REC2-068,夏德椿(Hsia, Te-Chun),附醫廠商計畫,一項針對先前未接受治療的第IIIB或IV期ALK重組(ALK陽性)之非鱗狀非小細胞肺癌成年病患,比較口服LDK378與標準化學治療的第III期多中心、隨機分配試驗,$5702372,2017.1.1 ~ 2017.12.31
45﹒ 臨床試驗與研究計畫,CMUH104-REC3-102,夏德椿(Hsia, Te-Chun),陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih)、涂智彥(Tu, Chih-Yen),附醫廠商計畫,一項多中心、隨機分配、開放標記試驗,對於 ALK 重組 (ALK 陽性) 轉移非小細胞肺癌 (NSCLC) 成年患者,評估隨低脂肪餐點服用 450 毫克 ceritinib,和隨低脂肪餐點服用 600 毫克 ceritinib,相較於空腹狀態服用 750 毫克 ceritinib 之全身曝藥量、療效和安全性,$1391227,2017.1.1 ~ 2017.12.31
46﹒ 臨床試驗與研究計畫,CMUH104-REC2-069,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,針對先前不曾接受治療、患有轉移性、表皮生長因子受體(EGFR)突變之非小細胞肺癌(NSCLC)且具有BDX004陽性標記(Positive Label)的受試者,比較ficlatuzumab加上erlotinib與安慰劑加上erlotinib所進行的ㄧ項第2期、多中心、隨機分配、雙盲的研究,$3739287,2017.1.1 ~ 2017.12.31
47﹒ 臨床試驗與研究計畫,CMUH103-REC1-155,夏德椿(Hsia, Te-Chun),陳家弘(Chen, Chia-Hung)、陳鴻仁(Chen, Hung-Jen)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,一項隨機分配、開放性、多中心第二期試驗,在首次接受細胞毒性化療且目前或曾經吸菸的轉移性或晚期非鱗狀型非小細胞肺癌(NSCLC)受試者,對Veliparib與Carboplatin和paclitaxel的合併治療以及試驗主持人選擇的標準化療進行比較。,$19364378,2017.1.1 ~ 2017.12.31
48﹒ 臨床試驗與研究計畫,CMUH105-REC3-029,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih)、李嘉翔(Li, Chia-Hsiang),附醫廠商計畫,一項第三期、隨機分配、雙盲、多中心試驗,比較SB8 (提倡為bevacizumab生物相似性藥品)與Avastin®使用於轉移性或復發性之非鱗狀細胞非小細胞肺癌的療效、安全性、藥動學與免疫原性,$2237007,2017.1.1 ~ 2017.12.31
49﹒ 臨床試驗與研究計畫,CMUH104-REC2-116,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,一項多中心、隨機分配的雙盲試驗,探討Erlotinib與Ramucirumab或安慰劑併用,對於未曾接受治療、EGFR突變陽性之轉移性非小細胞肺癌患者的效果。,$2104962,2017.1.1 ~ 2017.12.31
50﹒ 臨床試驗與研究計畫,CMUH105-REC2-062,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,PT-112合併Docetaxel使用於第I期劑量漸增試驗之晚期實質腫瘤受試者以及第II期劑量確認試驗之非小細胞肺癌(NSCLC)受試者的一項開放性第I/II期臨床試驗,$13198873,2017.1.1 ~ 2017.12.31
51﹒ 臨床試驗與研究計畫,CMUH103-REC2-125,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、陳偉峻(Chen, Wei-Chun),附醫廠商計畫,一項第三期隨機試驗,針對可測得KRAS突變且接受含鉑化學治療後疾病惡化的第四期NSCLC患者,評估LY2835219併用最佳支持性照護相較於erlotinib併用最佳支持性照護的療效,$696265,2017.1.1 ~ 2017.12.31
52﹒ 臨床試驗與研究計畫,CMUH105-REC2-044,夏德椿(Hsia, Te-Chun),陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih)、涂智彥(Tu, Chih-Yen),附醫廠商計畫,一項以口服 cMET 抑制劑 INC280 治療帶有野生型 (wild-type,wt) EGFR 基因,且先前曾接受一次或二次全身性療法治療晚期/轉移性疾病的晚期非小細胞肺癌 (NSCLC) 成人患者之第II期、多中心、四個群體的試驗,$1776258,2017.1.1 ~ 2017.12.31
53﹒ 臨床試驗與研究計畫,CMUH103-REC1-123,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、林裕超(Lin, Yu-Chao)、陳家弘(Chen, Chia-Hung),附醫廠商計畫,於未曾接受過治療且PD-L1陽性的晚期或轉移性非小細胞肺癌患者,使用Pembrolizumab (MK-3475)相較於含鉑藥物化學療法治療後的整體存活期之隨機分組、開放標示的第三期臨床試驗 (Keynote042),$2418560,2017.1.1 ~ 2017.12.31
54﹒ 臨床試驗與研究計畫,CMUH103-REC2-113,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、陳偉峻(Chen, Wei-Chun),附醫廠商計畫,一項第 III 期、隨機分配、雙盲、安慰劑對照、多國多中心試驗,研究以MEDI4736作為局部晚期、不可切除之非小細胞肺癌 (第 III 期)、且接受確定性含鉑同步化學放射治療後未惡化的患者之序列性治療 (PACIFIC),$2646537,2017.1.1 ~ 2017.12.31
55﹒ 臨床試驗與研究計畫,CMUH104-REC2-065,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih),附醫廠商計畫,一項針對完全切除的非小細胞肺癌以MEDI4736輔助性治療的第三期、前瞻性、雙盲、安慰劑對照、隨機分配試驗,$3660000,2017.1.1 ~ 2017.12.31
56﹒ 臨床試驗與研究計畫,CMUH103-REC1-110,夏德椿(Hsia, Te-Chun),涂智彥(Tu, Chih-Yen)、陳鴻仁(Chen, Hung-Jen)、陳家弘(Chen, Chia-Hung)、陳偉峻(Chen, Wei-Chun),附醫廠商計畫,第二期、非比較性、開放標示、多國多中心試驗,研究MEDI4736 用於患有局部晚期或轉移性非小細胞肺癌 (第 IIIB-IV 期)且曾接受過包含一項含鉑化療在內之至少兩種全身性療法的患者(ATLANTIC),$2628801,2017.1.1 ~ 2017.12.31
57﹒ 臨床試驗與研究計畫,DMR99-IRB-292,夏德椿(Hsia, Te-Chun),附醫廠商計畫,一隨機、雙盲、安慰劑對照之臨床試驗,以評估對接受多週期化學治療之患有晚期非小細胞肺癌貧血患者,每三週一次施用Darbepoetin Alfa 500微克之長期安全性和療效,$37911370,2017.1.1 ~ 2017.12.31
58﹒ 個別型,CMU105-ASIA-17,包大靝(Da-Tian Bau),夏德椿(Te-Chun Hsia)、趙哲毅(Che-Yi Chao),本校(含附醫),由基因型表現型探究台灣肺癌之癌化與抗藥機制,$500000,2016.8.1 ~ 2017.7.31
59﹒ 個別型,A1041016,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、洪耀欽(Yao-Ching Hung)、楊美都(Mei-Due Yang)、葉士芃(Su-Peng Yeh)、劉良智(Liu, Liang-Chih)、楊啟瑞(Che-Rei Yang)、柯道維(TAO-WEI KE)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、詹佳穎(Chia-Ing Jan)、林文元(Wen-Yuan Lin)、林昭君(Chao-Chun Lin)、蔡伯邦(Po-Pang Tsai)、花俊宏(Chun-Hung Hua)、吳博倫(Po-Lun Wu)、謝清昀(Ching-Yun Hsieh)、簡君儒(Chun-Ru Chien)、楊世能(Shih-Neng Yang)、白禮源(Li-Yuan Bai)、謝右文(Yow-Wen Hsieh)、謝淑惠(Shwn-Huey Shieh)、蔡麗雲(Li-Yun Tsai)、廖惠娟(Hui-Chuan Liao),衛福部,105年度醫院癌症診療品質提升計畫-分項2,$11480000,2016.1.1 ~ 2016.12.31
60﹒ 臨床試驗與研究計畫,DMR97-IRB-240,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項開放性、隨機分配、多國之第Ⅲb期試驗,評估睌期非小細胞肺癌(NSCLC)受試者以含金白類藥物化學治療併用cetuximab作為第一線治療後,以cetuximab作為第一線治療後,以cetuximab每週一次 250 mg/m²及每周一次500 mg/m²作為治療之活性及安全性,$1834175,2016.1.1 ~ 2016.12.31
61﹒ 臨床試驗與研究計畫,DMR98-IRB-117,夏德椿(Te-Chun Hsia),附醫廠商計畫,探討局部惡化或轉移復發非小細胞肺癌腺癌且曾接受第一線化學治療的男性病患,使用表皮生長因子接受器抑制劑臨床療效與吸菸型態之相關性,多中心、觀察性研究。,$28500,2016.1.1 ~ 2016.12.31
62﹒ 臨床試驗與研究計畫,DMR98-IRB-096,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項第三階段、多中心、安慰劑對照試驗,評估Sorafenib (BAY 43-9006) 用於先前曾接受2或3次治療、患有復發型或頑固型晚期、非鱗狀非小細胞肺癌 (NSCLC)的病患,$955908,2016.1.1 ~ 2016.12.31
63﹒ 臨床試驗與研究計畫,DMR98-IRB-124,夏德椿(Te-Chun Hsia),附醫廠商計畫,第三期隨機分組、開放標示比較BIBW 2992與化療作為第一線療法治療有EGFR活化基因突變的第期肺腺癌患者之臨床試驗(簡稱LUX-Lung 3),$4133276,2016.1.1 ~ 2016.12.31
64﹒ 臨床試驗與研究計畫,DMR98-IRB-156,夏德椿(Te-Chun Hsia),附醫廠商計畫,INSPIRE-針對亞洲非小細胞肺癌病人的Stimuvax試驗:刺激免疫反應 針對接受主要化學放射線治療後,已證實為穩定疾病或有客觀療效之第Ⅲ期、無法手術切除、非小細胞肺癌(NSCLC) 亞洲受試者的癌症疫苗Stimuvax® (L-BLP25 或 BLP25 微脂體疫苗)的 一項多國、雙盲、安慰劑對照隨機分配第Ⅲ期臨床試驗。,$1166765,2016.1.1 ~ 2016.12.31
65﹒ 臨床試驗與研究計畫,DMR98-IRB-199,夏德椿(Te-Chun Hsia),附醫廠商計畫,比較第一線Pemetrexed併用Cisplatin(其後使用Genfitinib作為維持性治療)和Gefitinib單一療法於局部晚期轉移性非麟狀非小細胞肺癌(未曾吸煙者或過去吸煙量為輕度的已戒煙者)東亞病患之隨機分配、第三期臨床試驗。,$2647988,2016.1.1 ~ 2016.12.31
66﹒ 臨床試驗與研究計畫,DMR98-IRB-224,夏德椿(Te-Chun Hsia),附醫廠商計畫,評估惡化或轉移性非小細胞肺癌患者施用LY2603618合併使用Pemetrexed的二期試驗,$197860,2016.1.1 ~ 2016.12.31
67﹒ 臨床試驗與研究計畫,DMR98-IRB-272,夏德椿(Te-Chun Hsia),附醫廠商計畫,研究口服Vinorelbine併用Cisplatin或Pemetrexed併用Cisplatin之合併療法做為第一線治療轉移或局部晚期之非鱗狀組織學類型非小細胞肺癌患者之前瞻性、隨機分配之第二期臨床試驗.,$1132119,2016.1.1 ~ 2016.12.31
68﹒ 臨床試驗與研究計畫,DMR99-IRB-025,夏德椿(Te-Chun Hsia),附醫廠商計畫,對於erlotinib 或 gefitinib治療無效之非小細胞肺癌病人, 以BIBW 2992單一治療結束後,給予BIBW 2992併用每週 1 次 paclitaxel 相較於使用試驗醫師選擇之化學治療藥物之第 III 期隨機性試驗,$1211985,2016.1.1 ~ 2016.12.31
69﹒ 臨床試驗與研究計畫,DMR99-IRB-038,夏德椿(Te-Chun Hsia),附醫廠商計畫,針對患有無法治癒之第ⅢB/Ⅳ其非小細胞肺癌患者,再以標準療法治療晚期或轉移性疾病無效後,進行的一項雙盲、安慰劑對照、隨機分配試驗,試驗藥物為PF-804,$1044634,2016.1.1 ~ 2016.12.31
70﹒ 臨床試驗與研究計畫,DMR98-IRB-123,夏德椿(Te-Chun Hsia),附醫廠商計畫,第1b/2 期試驗,以AMG479或AMG102併用含鉑化學治療,作為擴散期小細胞肺癌的第一線治療,$1074300,2016.1.1 ~ 2016.12.31
71﹒ 臨床試驗與研究計畫,DMR99-IRB-055,夏德椿(Te-Chun Hsia),附醫廠商計畫,對曾治療晚期非小細胞肺癌的患者,以兩種不同Eribulin Mesyla 給藥方案,併用間歇性Erlotinib的一項第二期、多中心、隨機分配之研究。,$1509765,2016.1.1 ~ 2016.12.31
72﹒ 臨床試驗與研究計畫,DMR99-IRB-028,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項比較結合使用 Gemcitabine-Cisplatin 化學治療和 IMC-11F8 與單獨使用 Gemcitabine-Cisplatin 化學治療對於第 IIIb 期或第 IV 期鱗狀細胞非小細胞肺癌 (NSCLC) 患者的第一線治療之隨機分配、多中心、開放性、第 3 期試驗,$247341,2016.1.1 ~ 2016.12.31
73﹒ 臨床試驗與研究計畫,DMR99-IRB-173,夏德椿(Te-Chun Hsia),附醫廠商計畫,一個評估於亞洲非小細胞肺腺癌晚期(第三期B/第四期)患者之上皮生長因子受體(EGFR)突變狀態之分子流行病學研究,$169560,2016.1.1 ~ 2016.12.31
74﹒ 臨床試驗與研究計畫,DMR99-IRB-210,夏德椿(Te-Chun Hsia),附醫廠商計畫,在間變性淋巴瘤激酶(ALK)基因座受到錯位或倒置事件影響且先前未接受治療的肺部非鱗狀細胞癌病患中,比較crizotinib與pemetrexed/cisplatin或pemetrexed/carboplatin療效和安全性的第3期、隨機分配、開放性試驗。,$1103960,2016.1.1 ~ 2016.12.31
75﹒ 臨床試驗與研究計畫,DMR99-IRB-245,夏德椿(Te-Chun Hsia),附醫廠商計畫,比較Docetaxel倂用Ramucirumab與Docetaxel倂用安慰劑用於治療接受過一次含鉑化療後疾病惡化的第四期非小細胞肺癌之隨機、雙盲、第三期臨床試驗,$3377200,2016.1.1 ~ 2016.12.31
76﹒ 臨床試驗與研究計畫,DMR99-IRB-292,夏德椿(Te-Chun Hsia),附醫廠商計畫,一隨機、雙盲、安慰劑對照之臨床試驗,以評估對接受多週期化學治療之患有晚期非小細胞肺癌貧血患者,每三週一次施用Darbepoetin Alfa 500微克之長期安全性和療效,$3226979,2016.1.1 ~ 2016.12.31
77﹒ 臨床試驗與研究計畫,DMR99-IRB-328,夏德椿(Te-Chun Hsia),附醫廠商計畫,比較愛斯萬(S-1)與歐洲紫杉醇(Docetaxel)用於曾接受過鉑金類治療的非小細胞肺癌病患之隨機分配對照試驗,$2546916,2016.1.1 ~ 2016.12.31
78﹒ 臨床試驗與研究計畫,DMR100-IRB-009,夏德椿(Te-Chun Hsia),附醫廠商計畫,以Erlotinib (Tarceva®)作為EGFR突變的非小細胞肺癌(NSCLC)病患之第一線治療的開放性、多中心臨床試驗,$801261,2016.1.1 ~ 2016.12.31
79﹒ 臨床試驗與研究計畫,DMR100-IRB-102,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項第二階段、雙盲、安慰劑對照,對於曾接受治療之第 IIIB 或第 IV 期非小細胞型肺癌患者之 IPI-504 及多西紫杉醇試驗。,$387148,2016.1.1 ~ 2016.12.31
80﹒ 臨床試驗與研究計畫,DMR100-IRB-126,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項隨機分配、雙盲、安慰劑對照第Ⅲ期試驗,針對接受4週期含鉑藥物化療後病情未惡化的晚期非小細胞肺癌(NSCLC)病患,比較第一線維持性治療時使用Tarceva®與病情惡化時使用Tarceva®之療效。,$3337139,2016.1.1 ~ 2016.12.31
81﹒ 臨床試驗與研究計畫,DMR100-IRB-182,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項隨機分配、開放性、多中心、第3期試驗,比較以Eribuli或是醫師選擇之治療方式,治療晚期非小細胞肺癌受試者的療效與安全性。,$2561675,2016.1.1 ~ 2016.12.31
82﹒ 臨床試驗與研究計畫,DMR100-IRB-171,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項第三期、隨機分組、雙盲、安慰劑對照試驗,比較ARQ197搭配Erlotinib,或安慰劑搭配Erlotinib用於先前接受治療、具野生型上皮生長因子受體、患有局部晚期或轉移性非鱗狀非小細胞肺癌之受試者,$3476705,2016.1.1 ~ 2016.12.31
83﹒ 臨床試驗與研究計畫,DMR100-IRB-082,夏德椿(Te-Chun Hsia),附醫廠商計畫,比較其Ipilimumab加Paclitaxel/Carboplatin與安慰劑Paclitaxel/Carboplatin,使用於患有第4期/復發型非小細胞肺癌(NSCLC)受試者之療效的隨機分配、多中心、雙盲、第3期試驗,$852959,2016.1.1 ~ 2016.12.31
84﹒ 臨床試驗與研究計畫,DMR100-IRB-022,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項多中心、隨機、雙盲、第三期臨床試驗,與ceftriaxone比較,評估靜脈輸注ceftaroline fosamil於治療社區感染細菌性肺炎亞洲成人住院病患之療效與安全性。(D3720C00002),$399632,2016.1.1 ~ 2016.12.31
85﹒ 臨床試驗與研究計畫,DMR100-IRB-097,夏德椿(Te-Chun Hsia),附醫廠商計畫,比較艾瑞莎/愛寧達及單獨使用愛寧達作為維持治療在轉移性、表皮生長因子接受器變異為陰性、非小細胞肺癌(第ⅢB或Ⅳ期)肺腺癌,並且接受四個週期愛寧達/順鉑作為第一線治療有反應的患者的療效及安全性之開放性、隨機分配、多中心、第Ⅱ期臨床試驗,$2600,2016.1.1 ~ 2016.12.31
86﹒ 臨床試驗與研究計畫,DMR100-IRB-207,夏德椿(Te-Chun Hsia),附醫廠商計畫,針對具有上皮生長因子接受器活化性突變的第四期非鱗狀非小細胞肺癌病患,比較Pemetrexed併用Gefitinib相對於單獨使用Gefitinib作為第一線治療藥物之第二期隨機臨床試驗。,$2594123,2016.1.1 ~ 2016.12.31
87﹒ 臨床試驗與研究計畫,DMR100-IRB-241,夏德椿(Te-Chun Hsia),附醫廠商計畫,比較Ipilimumab加上Etoposide/Platinum與Etoposide/Platinum之間,使用在治療新診斷擴散期疾病小細胞肺癌(ED-SCLC)的病患有效性之隨機分配、多中心、雙盲、第三期試驗。,$360524,2016.1.1 ~ 2016.12.31
88﹒ 臨床試驗與研究計畫,DMR100-IRB-226,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項隨機、開放性、第IIb期臨床試驗,評估afatinib對照gefitinib用於第一線治療有表皮生長因子受體突變的晚期肺腺癌患者之研究。,$855644,2016.1.1 ~ 2016.12.31
89﹒ 臨床試驗與研究計畫,DMR100-IRB-245,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項針對三組非小細胞肺癌患者進行 MM-121 與 Erlotinib 合併治療的第1-2 期臨床試驗,$617545,2016.1.1 ~ 2016.12.31
90﹒ 臨床試驗與研究計畫,DMR101-IRB1-164,夏德椿(Te-Chun Hsia),附醫廠商計畫,一個採多中心、開放、適應性、隨機分配的臨床試驗,比較將Palifosfamide-tris(一種全新的DNA交聯劑)與Carboplatin及Etoposide (PaCE)化學療法合併使用與單獨使用Carboplatin及Etoposide (CE)化學療法用於治療未曾接受過化學療法的擴散期小細胞肺癌患者。MATISSE試驗。,$577833,2016.1.1 ~ 2016.12.31
91﹒ 臨床試驗與研究計畫,DMR101-IRB1-026,夏德椿(Te-Chun Hsia),附醫廠商計畫,LUX-肺癌 8:於第一線含鉑化療後的末期鱗狀細胞肺癌患者,比較afatinib與erlotinib第二線治療效果之開放標示、隨機分組的第三期臨床試驗。,$3083687,2016.1.1 ~ 2016.12.31
92﹒ 臨床試驗與研究計畫,DMR101-IRB1-245,夏德椿(Te-Chun Hsia),附醫廠商計畫,合併TS-1 與Cisplatin 用以治療進展性(第三期b 或四期)非小細胞肺癌(NSCLC)病患之臨床試驗,$641584,2016.1.1 ~ 2016.12.31
93﹒ 臨床試驗與研究計畫,DMR101-IRB1-207,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項評估非小細胞肺癌腦轉移受試者搭配使用全腦放射線治療與Veliparib或安慰劑之安全性與療效之隨機、雙盲、第二期之劑量範圍探查研究,$3880006,2016.1.1 ~ 2016.12.31
94﹒ 臨床試驗與研究計畫,DMR101-IRB1-206,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項全球性第三期、隨機分配、安慰劑對照雙盲試驗,評估AMG 706與Paclitaxel及Carboplatin併用,以治療晚期非鱗狀細胞、非小細胞肺癌之功效(亞洲第三期試驗),$457159,2016.1.1 ~ 2016.12.31
95﹒ 臨床試驗與研究計畫,DMR101-IRB1-209,夏德椿(Te-Chun Hsia),附醫廠商計畫,一個採二階段、安慰劑對照的試驗,評估以 Sativex 口腔黏膜噴劑(Sativex®,主要成分為Nabiximols)做為輔助療法,用於緩解接受鴉片類藥物長期治療仍無法止痛的晚期癌症患者控制不良的持續性長期疼痛之安全性與療效。,$308991,2016.1.1 ~ 2016.12.31
96﹒ 臨床試驗與研究計畫,DMR101-IRB1-208,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項多中心、非對照之開放式延伸試驗,評估以Sativex口腔黏膜噴劑(Sativex®;Nabiximols)作為癌症患者控制不良的持續性長期疼痛輔助療法之長期安全性。,$112692,2016.1.1 ~ 2016.12.31
97﹒ 臨床試驗與研究計畫,DMR101-IRB1-283,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項單組、多中心、開放性、第二期試驗,使用Gemcitabine-Cispatin化學療法併用Necitumumab (IMC-11F8),做為第IV期鱗狀非小細胞肺癌(NSCLC)之第一線治療,$1194826,2016.1.1 ~ 2016.12.31
98﹒ 臨床試驗與研究計畫,CMUH102-REC2-035,夏德椿(Te-Chun Hsia),附醫廠商計畫,AZ- 亞太回溯性EGFR基因研究案,$44022,2016.1.1 ~ 2016.12.31
99﹒ 臨床試驗與研究計畫,DMR101-IRB2-274,夏德椿(Te-Chun Hsia),附醫廠商計畫,評估Custirsen (TV-1011/OGX-011)併用Docetaxel相較於Docetaxel在晚期或轉移性(第IV期)非小細胞肺癌病患中作為第二線治療的一項多國、隨機分配、開放式第III期試驗,$248358,2016.1.1 ~ 2016.12.31
100﹒ 臨床試驗與研究計畫,CMUH102-REC2-060,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項隨機分配、對照、第二期試驗,評估 LY2875358 加上 Erlotinib,相較於 Erlotinib,做為第一線治療,用於帶有活化EGFR突變,經過8週Erlotinib導入治療後,病情獲得控制之轉移非小細胞肺癌患者的療效,$2866230,2016.1.1 ~ 2016.12.31
101﹒ 臨床試驗與研究計畫,CMUH102-REC2-055,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項多中心、開放性的第 2 期試驗,以評估肺腺癌 KIF5B-RET 陽性病患使用 Lenvatinib (E7080) 的安全性和療效。,$62600,2016.1.1 ~ 2016.12.31
102﹒ 臨床試驗與研究計畫,CMUH102-REC2-093,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項隨機分配、雙盲、第3 期研究,評估 ABP 215 相對於Bevacizumab治療晚期非小細胞肺癌受試者的療效和安全性,$908740,2016.1.1 ~ 2016.12.31
103﹒ 臨床試驗與研究計畫,CMUH102-REC2-080,夏德椿(Te-Chun Hsia),附醫廠商計畫,DCA114273: 一項比較亞裔罹患實體腫瘤之骨轉移受試者使用 denosumab 與 zoledronic acid 效果之試驗。,$2661881,2016.1.1 ~ 2016.12.31
104﹒ 臨床試驗與研究計畫,CMUH102-REC2-068,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項針對先前未接受治療的第IIIB或IV期ALK重組(ALK陽性)之非鱗狀非小細胞肺癌成年病患,比較口服LDK378與標準化學治療的第III期多中心、隨機分配試驗,$5171198,2016.1.1 ~ 2016.12.31
105﹒ 臨床試驗與研究計畫,CMUH102-REC2-107,夏德椿(Te-Chun Hsia),附醫廠商計畫,回溯性、非介入性研究,評估先前曾接受表皮生長因子接受體酪胺酸激酶抑制劑(EGFR-TKI)作為一線治療與化學治療作為二線治療後之局部惡化或表皮生長因子接受體突變(EGFR mutated)轉移的非小細胞肺癌病患,再次接受表皮生長因子接受體酪胺酸激酶抑制劑(EGFR-TKI)治療之研究。,$144566,2016.1.1 ~ 2016.12.31
106﹒ 臨床試驗與研究計畫,CMUH102-REC2-106,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項前瞻性、非介入性之臨床研究,以EGFR (表皮生長因子受體)Tyrosine Kinase Inhibitor (TKI,酪胺酸激酶抑制劑)作為治療晚期非小細胞肺癌且帶有表皮生長因子受體變異陽性之病患的第一線用藥,評估其症狀之改善。,$267827,2016.1.1 ~ 2016.12.31
107﹒ 臨床試驗與研究計畫,CMUH102-REC2-111,夏德椿(Te-Chun Hsia),附醫廠商計畫,一項隨機分配、第3期、多中心、雙盲、安慰劑對照試驗,評估Onartuzumab與Erlotinib併用,作為MET陽性無法手術切除第3B期或第4期非小細胞肺癌(NSCLC)伴有活化EGFR突變病患的第一線治療的療效和安全性。,$114600,2016.1.1 ~ 2016.12.31
108﹒ 臨床試驗與研究計畫,CMUH103-REC1-004,夏德椿(Te-Chun Hsia),附醫廠商計畫,第三期、開放性、多中心、隨機分配的臨床試驗,於曾接受含鉑療法但治療失敗之非小細胞肺癌患者中,探討MPDL3280A(抗PD-L1抗體)相較於Docetaxel的療效與安全性,$862471,2016.1.1 ~ 2016.12.31
109﹒ 臨床試驗與研究計畫,CMUH103-REC2-007,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、林裕超(Yu-Chao Lin)、廖偉志(Wei-Chih Liao)、葉士芃(Su-Peng Yeh)、白禮源(Li-Yuan Bai)、廖裕民,附醫廠商計畫,一項針對晚期固態瘤(solid tumor)病患使用單株抗體ABT-700之多中心,開放型,第1/1b期之劑量遞增試驗,$426070,2016.1.1 ~ 2016.12.31
110﹒ 臨床試驗與研究計畫,CMUH102-REC2-132,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項開放性、多中心、單組試驗,評估afatinib用於帶有表皮生長因子受體(EGFR)突變之局部晚期或轉移性非小細胞肺癌(NSCLC)患者之安全性研究,$106075,2016.1.1 ~ 2016.12.31
111﹒ 臨床試驗與研究計畫,CMUH103-REC2-063,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、林裕超(Yu-Chao Lin)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項針對先前使用表皮生長因子受體 (EGFR) 酪胺酸激脢抑制劑 (TKI) 治療後惡化的局部晚期或轉移性非小細胞肺癌病患,且其腫瘤具有表皮生長因子受體基因帶有 T790M 突變,使用 AZD9291 相較於含鉑雙重化療之第三期、開放標示、隨機分配試驗 (AURA3),$5835616,2016.1.1 ~ 2016.12.31
112﹒ 臨床試驗與研究計畫,CMUH103-REC2-064,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳偉峻(Wei-Chun chen)、陳家弘(Chia-Hung Chen),附醫廠商計畫,比較兩種vinorelbine tartrate (20 mg/capsule)軟膠囊由癌症病患在進食情況下口服單劑量之隨機、多中心、雙向交叉之生體相等性試驗。,$212952,2016.1.1 ~ 2016.12.31
113﹒ 臨床試驗與研究計畫,CMUH103-REC2-125,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、陳偉峻(Wei-Chun chen),附醫廠商計畫,一項第三期隨機試驗,針對可測得KRAS突變且接受含鉑化學治療後疾病惡化的第四期NSCLC患者,評估LY2835219併用最佳支持性照護相較於erlotinib併用最佳支持性照護的療效,$300683,2016.1.1 ~ 2016.12.31
114﹒ 臨床試驗與研究計畫,CMUH103-REC1-110,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、陳偉峻(Wei-Chun chen),附醫廠商計畫,第二期、非比較性、開放標示、多國多中心試驗,研究MEDI4736 用於患有局部晚期或轉移性非小細胞肺癌 (第 IIIB-IV 期)且曾接受過包含一項含鉑化療在內之至少兩種全身性療法的患者(ATLANTIC),$1034682,2016.1.1 ~ 2016.12.31
115﹒ 臨床試驗與研究計畫,CMUH103-REC1-123,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、林裕超(Yu-Chao Lin)、陳家弘(Chia-Hung Chen),附醫廠商計畫,於未曾接受過治療且PD-L1陽性的晚期或轉移性非小細胞肺癌患者,使用Pembrolizumab (MK-3475)相較於含鉑藥物化學療法治療後的整體存活期之隨機分組、開放標示的第三期臨床試驗 (Keynote042),$284506,2016.1.1 ~ 2016.12.31
116﹒ 臨床試驗與研究計畫,CMUH103-REC2-113,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、陳偉峻(Wei-Chun chen),附醫廠商計畫,一項第 III 期、隨機分配、雙盲、安慰劑對照、多國多中心試驗,研究以MEDI4736作為局部晚期、不可切除之非小細胞肺癌 (第 III 期)、且接受確定性含鉑同步化學放射治療後未惡化的患者之序列性治療 (PACIFIC),$846107,2016.1.1 ~ 2016.12.31
117﹒ 臨床試驗與研究計畫,CMUH104-REC2-029,夏德椿(Te-Chun Hsia),附醫廠商計畫,對患有特定分子變異的晚期非小細胞肺癌患者使用 PF‑06463922(ALK/ROS1 酪氨酸激酶抑制劑)之第 1 期/第 2 期研究,$839642,2016.1.1 ~ 2016.12.31
118﹒ 臨床試驗與研究計畫,CMUH103-REC1-155,夏德椿(Te-Chun Hsia),陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項隨機分配、開放性、多中心第二期試驗,在首次接受細胞毒性化療且目前或曾經吸菸的轉移性或晚期非鱗狀型非小細胞肺癌(NSCLC)受試者,對Veliparib與Carboplatin和paclitaxel的合併治療以及試驗主持人選擇的標準化療進行比較。,$783289,2016.1.1 ~ 2016.12.31
119﹒ 臨床試驗與研究計畫,CMUH103-REC2-117,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、陳偉峻(Wei-Chun chen),附醫廠商計畫,TIGER-2:口服 CO-1686 作為第二線表皮細胞生長因子受體 (epidermal growth factor receptor, EGFR) 導向酪胺酸激酶抑制劑 (tyrosine-kinase inhibitor, TKI),用於出現 T790M 抗性突變之 EGFR 突變非小細胞肺癌 (Non-Small Cell Lung Cancer, NSCLC) 病人的一項第二期、開放性、多中心、安全性與療效研究,$1828329,2016.1.1 ~ 2016.12.31
120﹒ 臨床試驗與研究計畫,CMUH104-REC2-017,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、林裕超(Yu-Chao Lin)、李嘉翔(Chia-Hsiang Li),附醫廠商計畫,在未曾接受治療、間變性淋巴瘤激酶陽性的晚期非小細胞肺癌患者中,比較alectinib和crizotinib的隨機分組、多中心、第三期、開放標示試驗,$559459,2016.1.1 ~ 2016.12.31
121﹒ 臨床試驗與研究計畫,CMUH104-REC1-009,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao)、李嘉翔(Chia-Hsiang Li),附醫廠商計畫,TIGER-3:一項開放標記、多中心、隨機分配的第三期試驗,針對罹患 EGFR 突變之非小細胞肺癌 (NSCLC) 且先前接受至少一項 EGFR 酪胺酸激酶抑制劑 (TKI) 和含鉑雙藥化療而治療失敗的患者,評估口服 Rociletinib (CO 1686) 單一療法相較於單一藥物細胞毒性化療之療效,$1763990,2016.1.1 ~ 2016.12.31
122﹒ 臨床試驗與研究計畫,CMUH104-REC2-038,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項評估口服EGFRmut-TKI EGF816使用於帶有EGFRmut實體惡性腫瘤成年患者之第I/ II期、多中心、開放標記試驗,$448302,2016.1.1 ~ 2016.12.31
123﹒ 臨床試驗與研究計畫,CMUH104-REC2-074,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項多中心、隨機、開放性之第Ib/II期試驗,比較以MSC2156119J併用Gefitinib相對於化學治療作為MET陽性、帶有EGFR突變且對Gefitinib第一線治療產生抗藥性之局部晚期或轉移性非小細胞肺癌(NSCLC)患者之第二線治療,$792275,2016.1.1 ~ 2016.12.31
124﹒ 臨床試驗與研究計畫,CMUH104-REC2-069,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,針對先前不曾接受治療、患有轉移性、表皮生長因子受體(EGFR)突變之非小細胞肺癌(NSCLC)且具有BDX004陽性標記(Positive Label)的受試者,比較ficlatuzumab加上erlotinib與安慰劑加上erlotinib所進行的ㄧ項第2期、多中心、隨機分配、雙盲的研究 (FOCAL),$1627947,2016.1.1 ~ 2016.12.31
125﹒ 臨床試驗與研究計畫,CMUH104-REC2-071,夏德椿(Te-Chun Hsia),林裕超(Yu-Chao Lin)、廖偉志(Wei-Chih Liao)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu),附醫廠商計畫,TAURAS-T790M AURA篩選失敗標準照護登錄庫,$50217,2016.1.1 ~ 2016.12.31
126﹒ 臨床試驗與研究計畫,CMUH104-REC2-065,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項針對完全切除的非小細胞肺癌以MEDI4736輔助性治療的第三期、前瞻性、雙盲、安慰劑對照、隨機分配試驗,$192000,2016.1.1 ~ 2016.12.31
127﹒ 臨床試驗與研究計畫,CMUH104-REC1-038,夏德椿(Te-Chun Hsia),附醫廠商計畫,晚期非小細胞肺癌全球治療模式、資源利用與生物標記測試,$495257,2016.1.1 ~ 2016.12.31
128﹒ 臨床試驗與研究計畫,CMUH104-REC2-116,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項多中心、隨機分配的雙盲試驗,探討Erlotinib與Ramucirumab或安慰劑併用,對於未曾接受治療、EGFR突變陽性之轉移性非小細胞肺癌患者的效果。,$346836,2016.1.1 ~ 2016.12.31
129﹒ 臨床試驗與研究計畫,CMUH104-REC2-098,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項第三期、開放性、多中心、隨機分配的試驗,以初次接受化學治療的第四期鱗狀非小細胞肺癌患者為對象,評估 MPDL3280A(抗PD-L1)搭配CARBOPLATIN  PACLITAXEL 或 MPDL3280A 搭配CARBOPLATIN  NAB-PACLITAXEL 之療效與安全性,相較於CARBOPLATIN  NAB-PACLITAXEL,$663781,2016.1.1 ~ 2016.12.31
130﹒ 臨床試驗與研究計畫,CMUH104-REC2-076,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、林裕超(Yu-Chao Lin)、李嘉翔(Chia-Hsiang Li),附醫廠商計畫,一項第 3 期隨機、雙盲試驗在晚期非鱗狀非小細胞肺癌的患者將PF 06439535 併用 PACLITAXEL-CARBOPLATIN 與 BEVACIZUMAB 併用 PACLITAXEL-CARBOPLATIN作為第一線療法,$504985,2016.1.1 ~ 2016.12.31
131﹒ 臨床試驗與研究計畫,CMUH104-REC1-075,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、陳偉峻(Wei-Chun chen),附醫廠商計畫,第三期、開放標示、隨機分配、多國多中心試驗,研究 MEDI4736根據 PD-L1 表現而採單一療法或與 Tremelimumab 併用,相對於標準照護,用於患有局部晚期或轉移性非小細胞肺癌 (第 IIIB-IV 期)、曾接受過包含一項含鉑化療在內之至少兩種全身性療法且已知無EGFR TK活化突變或 ALK重組的患者 (ARCTIC),$573348,2016.1.1 ~ 2016.12.31
132﹒ 臨床試驗與研究計畫,CMUH104-REC1-080,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,對於曾接受含鉑化療之第4期鱗狀非小細胞肺癌患者,使用Abemaciclib (LY2835219) 相較於Docetaxel治療的一項隨機分配第2期試驗,$249466,2016.1.1 ~ 2016.12.31
133﹒ 臨床試驗與研究計畫,CMUH104-REC1-081,夏德椿(Te-Chun Hsia),林裕超(Yu-Chao Lin)、陳偉峻(Wei-Chun chen),附醫廠商計畫,前瞻性探討引藻精對非小細胞肺癌患者接受鉑金類化療藥產生之副作用的改善效果,$800000,2016.1.1 ~ 2016.12.31
134﹒ 臨床試驗與研究計畫,CMUH104-REC2-145,夏德椿(Te-Chun Hsia),陳鴻仁(Hung-Jen Chen),附醫廠商計畫,針對EGFR 突變活化之第 IIIB/IV 期非小細胞肺癌腫瘤病患,以ASP8273 對照 Erlotinib 或 Gefitinib 作為第一線治療的開放式隨機分配第 3 期療效試驗。,$175410,2016.1.1 ~ 2016.12.31
135﹒ 臨床試驗與研究計畫,CMUH104-REC1-126,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,晚期非小細胞肺癌的多中心、開放性、單一組別第二期試驗 副標題:一項多中心、開放性、單一組別第二期試驗,於不適合根除性放射療法且對含鉑化療療程產生抗藥性之第IIIB/IV期或復發性非小細胞肺癌患者,評估ONO-4538的安全性及療效,$934158,2016.1.1 ~ 2016.12.31
136﹒ 臨床試驗與研究計畫,CMUH105-REC1-060,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、林裕超(Yu-Chao Lin)、李嘉翔(Chia-Hsiang Li),附醫廠商計畫,比較 MM-121 併用歐洲紫杉醇 (Docetaxel) 或愛寧達 (Pemetrexed) 與歐洲紫杉醇 (Docetaxel) 單方或愛寧達 (Pemetrexed) 單方用於治療生長因子 (Heregulin) 陽性的局部晚期或轉移性非小細胞肺癌之病患的一項第 2 期試驗,$836056,2016.1.1 ~ 2016.12.31
137﹒ 臨床試驗與研究計畫,CMUH104-REC2-172,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項針對先前接受含鉑第一線化療的復發小細胞肺癌受試者使用Nivolumab 或化療的開放性、隨機分配、第三期的試驗,$137800,2016.1.1 ~ 2016.12.31
138﹒ 臨床試驗與研究計畫,CMUH104-REC3-102,夏德椿(Te-Chun Hsia),陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao)、涂智彥(Chih-Yen Tu),附醫廠商計畫,一項多中心、隨機分配、開放標記試驗,對於 ALK 重組 (ALK 陽性) 轉移非小細胞肺癌 (NSCLC) 成年患者,評估隨低脂肪餐點服用 450 毫克 ceritinib,和隨低脂肪餐點服用 600 毫克 ceritinib,相較於空腹狀態服用 750 毫克 ceritinib 之全身曝藥量、療效和安全性,$276639,2016.1.1 ~ 2016.12.31
139﹒ 臨床試驗與研究計畫,CMUH105-REC2-044,夏德椿(Te-Chun Hsia),陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao)、涂智彥(Chih-Yen Tu),附醫廠商計畫,一項以口服 cMET 抑制劑 INC280 治療帶有野生型 (wild-type,wt) EGFR 基因,且先前曾接受一次或二次全身性療法治療晚期/轉移性疾病的晚期非小細胞肺癌 (NSCLC) 成人患者之第II期、多中心、四個群體的試驗,$371490,2016.1.1 ~ 2016.12.31
140﹒ 臨床試驗與研究計畫,CMUH105-REC3-029,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao)、李嘉翔(Chia-Hsiang Li),附醫廠商計畫,一項第三期、隨機分配、雙盲、多中心試驗,比較SB8 (提倡為bevacizumab生物相似性藥品)與Avastin®使用於轉移性或復發性之非鱗狀細胞非小細胞肺癌的療效、安全性、藥動學與免疫原性,$134564,2016.1.1 ~ 2016.12.31
141﹒ 臨床試驗與研究計畫,CMUH105-REC2-050,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項第三期、開放標示、多中心試驗,以avelumab(MSB0010718C)或含鉑雙藥療法作為復發性或第四期PD-L1陽性非小細胞肺癌的第一線治療,$361398,2016.1.1 ~ 2016.12.31
142﹒ 臨床試驗與研究計畫,CMUH105-REC1-076,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項第三期、開放性、隨機分配的試驗,針對初次接受化學治療的第四期非鱗狀非小細胞肺癌患者,探討 ATEZOLIZUMAB (MPDL3280A , 抗PD-L1)搭配 CARBOPLATIN+PACLITAXEL且伴隨或未伴隨BEVACIZUMAB之治療,並相較於CARBOPLATIN+PACLITAXEL+ BEVACIZUMAB,$966474,2016.1.1 ~ 2016.12.31
143﹒ 臨床試驗與研究計畫,CMUH105-REC2-062,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,PT-112合併Docetaxel使用於第I期劑量漸增試驗之晚期實質腫瘤受試者以及第II期劑量確認試驗之非小細胞肺癌(NSCLC)受試者的一項開放性第I/II期臨床試驗,$240758,2016.1.1 ~ 2016.12.31
144﹒ 臨床試驗與研究計畫,CMUH105-REC2-113,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao),附醫廠商計畫,一項針對 ALK 陽性晚期肺癌病患使用 Brigatinib (AP26113) 對比 Crizotinib 的第 3 期、多中心、開放標示試驗,$462071,2016.1.1 ~ 2016.12.31
145﹒ 臨床試驗與研究計畫,CMUH105-REC3-065,夏德椿(Te-Chun Hsia),涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、林裕超(Yu-Chao Lin)、李嘉翔(Chia-Hsiang Li),附醫廠商計畫,一項國際、隨機分配、多中心、活性對照、開放標記第三期試驗評估接受表皮生長因子受體-酪胺酸激酶抑制劑(EGFR-TKI)治療時疾病惡化之T790M突變陽性局部晚期或轉移的非小細胞肺癌(NSCLC)病患相較於標準含鉑雙效化學治療使用BI 1482694的療效,$22200,2016.1.1 ~ 2016.12.31
146﹒ 個別型,CMU103-ASIA-05,殷梅津(YIN, MEI-CHIN),夏德椿(Te-Chun Hsia)、蒙美津,本校(含附醫),呼吸系統之保健食品研發,$500000,2015.8.1 ~ 2016.7.31
147﹒ 個別型,DMR-105-046,簡君儒(Chun-Ru Chien),夏德椿(Te-Chun Hsia)、方信元(Hsin-Yuan Fang)、梁基安(Ji-An Liang)、涂智彥(Chih-Yen Tu)、楊仕哲(Su-Tso Yang or YANG Shi-zhe),附醫院內計畫,癌症治療的效用與成本效益:台灣經驗, 以身體立體定位放射治療為例,$200000,2015.8.1 ~ 2016.7.31
148﹒ 整合型(召集人、總主持人),A1031024,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、洪耀欽(Yao-Ching Hung)、方信元(Hsin-Yuan Fang)、楊美都(Mei-Due Yang)、葉士芃(Su-Peng Yeh)、劉良智(Liu, Liang-Chih)、柯道維(TAO-WEI KE)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、林智一(Tze-Yi Lin)、林文元(Wen-Yuan Lin)、蔡伯邦(Po-Pang Tsai)、謝清昀(Ching-Yun Hsieh)、花俊宏(Chun-Hung Hua)、楊世能(Shih-Neng Yang)、簡君儒(Chun-Ru Chien)、白禮源(Li-Yuan Bai)、謝右文(Yow-Wen Hsieh)、蔡麗雲(Li-Yun Tsai)、廖惠娟(Hui-Chuan Liao),衛福部,104年度醫院癌症診療品質提升計畫,$13860000,2015.1.1 ~ 2015.12.31
149﹒ 整合型(召集人、總主持人),A1021236,周德陽(Der-Yang Cho),蔡銘修(Ming-Hsui Tsai)、蔡伯邦(Po-Pang Tsai)、彭成元(Cheng-Yuan Peng)、邱昌芳(Chang-Fang Chiu)、謝清昀(Ching-Yun Hsieh)、謝右文(Yow-Wen Hsieh)、葉士芃(Su-Peng Yeh)、花俊宏(Chun-Hung Hua)、楊世能(Shih-Neng Yang)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、許玲女(Ling-Nu Hsu)、葉聯舜(Lian-Shung Yeh)、林維卿(Wei-Ching Lin)、劉秋松(Chiu-Shong Liu)、梁基安(Ji-An Liang)、陳志毅(Chih-Yi Chen)、洪耀欽(Yao-Ching Hung)、吳錫金(Wu,Hsi-Chin)、謝淑惠(Shwn-Huey Shieh)、柯道維(TAO-WEI KE)、方信元(Hsin-Yuan Fang)、楊美都(Mei-Due Yang)、林文元(Wen-Yuan Lin)、白禮源(Li-Yuan Bai)、范淑貞(Shu-Chen Fan)、劉良智(Liu, Liang-Chih)、簡君儒(Chun-Ru Chien)、林智一(Tze-Yi Lin)、廖惠娟(Hui-Chuan Liao),衛福部,103年醫院癌症診療品質提升計畫,$14400000,2014.1.22 ~ 2014.12.31
150﹒ 個別型,DMR-103-124,吳秉儒(Biing-Ru Wu),涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、陳偉峻(Wei-Chun chen),附醫院內計畫,上皮生長因子接受器酪胺酸激霉抑制劑在具有不常見但有敏感性突變的晚期非小細胞肺癌病患的治療效果,$279000,2013.8.1 ~ 2014.6.30
151﹒ 個別型,DMR-103-012,程味兒(Wei-Erh Cheng),夏德椿(Te-Chun Hsia),附醫院內計畫,以雙相式正子斷層合併電腦造影之術前腫瘤代謝體積(MTV)預測初期之非小細胞肺癌病患的存活率,$300000,2013.8.1 ~ 2014.7.31
152﹒ 整合型(召集人、總主持人),102CANCER,周德陽(Der-Yang Cho),陳志毅(Chih-Yi Chen)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、彭成元(Cheng-Yuan Peng)、蔡伯邦(Po-Pang Tsai)、謝清昀(Ching-Yun Hsieh)、謝右文(Yow-Wen Hsieh)、葉士芃(Su-Peng Yeh)、花俊宏(Chun-Hung Hua)、楊世能(Shih-Neng Yang)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、許玲女(Ling-Nu Hsu)、葉聯舜(Lian-Shung Yeh)、何永仁(Yung-Jen Ho)、劉秋松(Chiu-Shong Liu)、梁基安(Ji-An Liang)、洪耀欽(Yao-Ching Hung)、吳錫金(Wu,Hsi-Chin)、謝淑惠(Shwn-Huey Shieh)、柯道維(TAO-WEI KE)、方信元(Hsin-Yuan Fang)、楊美都(Mei-Due Yang)、林文元(Wen-Yuan Lin)、白禮源(Li-Yuan Bai)、葉名焮(Ming-Hsin, Alex, Yeh)、簡君儒(Chun-Ru Chien)、林智一(Tze-Yi Lin)、范淑貞(Shu-Chen Fan),衛福部,102年醫院癌症醫療品質提升計畫,$13132010,2013.1.1 ~ 2013.12.31
153﹒ 個別型,DMR-102-014,程味兒(Wei-Erh Cheng),夏德椿(Te-Chun Hsia),附醫院內計畫,使用正子-電腦斷層造影於肺癌以評估合併使用EGFR與VEGF抑制劑之標靶治療效益之研究,$300000,2012.8.1 ~ 2013.7.31
154﹒ 國家型,DOH101-TD-C-111-005,陳志毅(Chih-Yi Chen),邱昌芳(Chang-Fang Chiu)、洪明奇(Mien-Chie Hung)、蔡銘修(Ming-Hsui Tsai)、周德陽(Der-Yang Cho)、陳偉德(Walter Chen)、蔡輔仁(Fuu-Jen Tsai)、邱俊誠(Jin-Chern Chiou)、劉秋松(Chiu-Shong Liu)、鍾景光(Jing-Gung Chung)、夏德椿(Te-Chun Hsia)、郭盛助(Sheng-Chu Kuo)、吳天賞(Tian-Shung Wu)、何承懋(Cheng-Mao Ho)、郭悅雄(Yueh-Hsiung Kuo),衛福部,建置癌症卓越研究體系計畫,$42250000,2012.1.1 ~ 2012.12.31
155﹒ 個別型,NSC 100-2320-B-039-021-,夏德椿(Te-Chun Hsia),黃偉謙(Wei-Chien Huang),國科會,BCRP表現影響EGFR抑制劑治療效果之探討,$710000,2011.8.1 ~ 2012.7.31
156﹒ 個別型,DMR-101-080,楊世能(Shih-Neng Yang),夏德椿(Te-Chun Hsia),附醫院內計畫,正子斷層造影標準攝入量與肺癌使用EGFR抑制劑之化學治療的相關性研究,$300000,2011.8.1 ~ 2012.7.31
157﹒ 國家型,DOH100-TD-C-111-005,陳志毅(Chih-Yi Chen),邱昌芳(Chang-Fang Chiu)、洪明奇(Mien-Chie Hung)、蔡銘修(Ming-Hsui Tsai)、周德陽(Der-Yang Cho)、陳偉德(Walter Chen)、蔡輔仁(Fuu-Jen Tsai)、邱俊誠(Jin-Chern Chiou)、林璨(Tsann Lin)、鍾景光(Jing-Gung Chung)、王惠暢(Hwei-Chung Wang)、郭盛助(Sheng-Chu Kuo)、盧章智(Jang-Jih Lu)、吳天賞(Tian-Shung Wu)、夏德椿(Te-Chun Hsia)、李龍緣(Long-Yuan Li),衛福部,建置癌症卓越研究體系計畫,$48500000,2011.1.1 ~ 2011.12.31
158﹒ 個別型,DMR-100-110,楊世能(Shih-Neng Yang),夏德椿(Te-Chun Hsia),附醫院內計畫,葡萄糖正子斷層造影之標準攝入量與肺癌上TKI表現及KRAS變異的相關性研究,$300000,2010.8.1 ~ 2011.7.31
159﹒ 產學合作,09842782,劉秋松(Chiu-Shong Liu),林正介(Cheng-Chieh Lin)、林文元(Wen-Yuan Lin)、林志學(Chih-Hsueh Lin)、張淳堆(Chwen-Tzuei Chang)、陳清助(Ching-Chu Chen)、劉崇祥(Chung-Hsiang Liu)、賴學洲(Hsueh-Chou Lai)、白培英(Pei-Ying Pai)、夏德椿(Te-Chun Hsia)、周仁偉(Jen-Wei Chou),荷商葛蘭素史克藥廠台灣分公司,一項隨機分配、觀察者遮盲、有安慰劑對照組、多中心之第三期臨床疫苗接種試驗,評估葛蘭素史克藥廠 gE/AS01B疫苗,於第0、第2個月以肌肉注射方式施打於50歲以上成人之預防效力、安全性以及免疫生成性,$4319650,2010.6.20 ~ 2014.12.31
160﹒ 國家型,DOH99-TD-C-111-005,陳志毅(Chih-Yi Chen),邱昌芳(Chang-Fang Chiu)、洪明奇(Mien-Chie Hung)、蔡銘修(Ming-Hsui Tsai)、周德陽(Der-Yang Cho)、陳偉德(Walter Chen)、蔡輔仁(Fuu-Jen Tsai)、邱俊誠(Jin-Chern Chiou)、林璨(Tsann Lin)、鍾景光(Jing-Gung Chung)、王惠暢(Hwei-Chung Wang)、郭盛助(Sheng-Chu Kuo)、盧章智(Jang-Jih Lu)、吳天賞(Tian-Shung Wu)、夏德椿(Te-Chun Hsia)、李龍緣(Long-Yuan Li),衛福部,建置癌症卓越研究體系計畫,$48500000,2010.2.9 ~ 2010.12.31
161﹒ 個別型,DMR-99-139,謝右文(Yow-Wen Hsieh),邱昌芳(Chang-Fang Chiu)、王惠暢(Hwei-Chung Wang)、夏德椿(Te-Chun Hsia)、陳素靜(Su-Jing Chen)、林妍如(Blossom Yen-Ju Lin)、謝清昀(Ching-Yun Hsieh)、黃靖雅(Ching-Ya Huang)、廖裕民(Yu-Min Liao)、羅偉忠、林振源(Chen-Yuan Lin),附醫院內計畫,影響癌症患者於化療期間生活品質之相關因素探討—以化療引起噁心嘔吐之止吐藥選擇為例,$100000,2009.8.1 ~ 2010.7.31
162﹒ 國家型,CCMP98-CT-202,蔡長海(Chang-Hai Tsai),林正介(Cheng-Chieh Lin)、謝慶良(Ching-Liang Hsieh)、李正淳(Cheng-Chun Lee)、邱昌芳(Chang-Fang Chiu)、劉崇祥(Chung-Hsiang Liu)、陳春忠(CHUN-CHUNG CHEN)、夏德椿(Te-Chun Hsia)、李采娟(Tsai-Chung Li),衛福部,98年度教學醫院成立中藥臨床試驗中心,$1200000,2009.1.1 ~ 2009.12.31
163﹒ 整合型(召集人、總主持人),CCMP97-CT-202,蔡長海(Chang-Hai Tsai),林正介(Cheng-Chieh Lin)、謝慶良(Ching-Liang Hsieh)、李正淳(Cheng-Chun Lee)、邱昌芳(Chang-Fang Chiu)、劉崇祥(Chung-Hsiang Liu)、陳春忠(CHUN-CHUNG CHEN)、夏德椿(Te-Chun Hsia)、李采娟(Tsai-Chung Li),衛福部,97年教學醫院成立中藥臨床試驗中心,$1850000,2008.1.1 ~ 2008.12.31
164﹒ 個別型,DOH-BHP-95-01,林正介(Lin,Cheng-Chieh),彭慶添(Peng,Ching-Tien)、鄭隆賓(Jeng,Long-Bin)、吳錫金(Wu,His-Chin)、邱昌芳(Chiu,Chang-Fang)、許南榮(Hsu,Nan-Yung)、蔡銘修(Tsai,Ming-Hsui)、張兆祥(Chang,Chao-Hsian)、周德陽(Cho,Der-Yang)、夏德椿(Hsia,Te-Chun)、洪耀欽,衛福部,95-96年度安寧共同照護計畫,$2100000,2006.1.1 ~ 2007.12.31
165﹒ 個別型,DMR-95-031,涂智彥(Chih-Yen Tu),徐武輝(Wu-Huei Hsu)、陳鴻仁(Hung-Jen Chen)、夏德椿(Te-Chun Hsia)、施純明(Chuen-Ming Shih),附醫院內計畫,內科加護病房病人之膿胸致病菌及其預後,$100000,2005.7.1 ~ 2006.6.30
166﹒ 個別型,DOH-BHP-94-03,林正介(Lin,Cheng-Chieh),彭慶添(Peng,Ching-Tien)、鄭隆賓(Jeng,Long-Bin)、陳志毅、吳錫金(Wu,His-Chin)、邱昌芳(Chiu,Chang-Fang)、許南榮(Hsu,Nan-Yung)、蔡銘修(Tsai,Ming-Hsui)、張兆祥(Chang,Chao-Hsian)、周德陽(Cho,Der-Yang)、夏德椿(Hsia,Te-Chun),衛福部,九十四年度安寧共同照護計畫,$1100000,2005.1.1 ~ 2005.12.31
167﹒ 整合型(召集人、總主持人),NHRI-EX94-9204PP,陳建仲(Chen,Jian-Jung),梁文敏(Liang,Wen-Miin)、夏德椿(Te-Chun Hsia)、杭良文(Liang-Wen Hang),08,慢性阻塞性肺疾病患者接受中醫治療之生活品質及成本效性評估(3/5),$160000,2005.1.1 ~ 2005.12.31